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ABSTRACT
Non-small cell lung cancer (NSCLC) is the number one cause of cancer-related deaths
worldwide. Furthermore, it is predicted that the incidence and mortality will fur-
ther increase due to smoking, increasing pollution of the environment, and an aging
population. For patients unable to undergo surgery corresponding radiotherapy con-
cepts are necessary. However, due to the vicinity of critical organs like the heart,
esophagus, trachea, larger blood vessels, and the spinal cord a dose escalation is not
always easily achievable using photon-based radiotherapy. Proton therapy (PT) has
the potential to deposit a conformal dose in the target volume while better sparing
surrounding normal tissue and hence could be beneficial for lung cancer patients.
However, there are various challenges connected to proton therapy in general and
proton therapy of lung cancer patients in particular. One of these challenges arises
from the structure of the lung tissue itself: due to the microscopic density hetero-
geneity the proton dose distribution is degraded resulting in a broader Bragg peak
and a wider distal dose fall-off. This modulation effect can significantly influence the
dose distribution in patients resulting in a lower dose deposited in the target volume
and higher doses deposited in distal normal tissue and organs at risk (OAR). Since
the microscopic structure of the lung tissue is not fully resolved in clinical treatment-
planning CT-images, a consideration of the Bragg peak degradation is not possible
with current state-of-the-art treatment-planning systems (TPS).
In this dissertation, a mathematical model is used to describe the effects due to
the Bragg peak degradation. The strength of the degradation is quantified using
the material characteristic modulation power. Microscopic heterogeneous voxelized
geometries are used to generate degraded dose distributions with the help of Monte
Carlo (MC) simulations. Subsequently, these geometries representing human lung
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tissue are replaced by clinical voxels with an edge length of 2 mm. Hence, the
transition from the microscopic lung tissue as it is present in the patient to coarser
clinical CT-structures that cannot resolve the fine lung structure is performed. By
modulating the density of each clinical voxel the Bragg peak degradation can be
reproduced. Hence, a solution is found to reproduce the lung modulation effects on
clinical CT-images.
Using this technique, a CT-based phantom study was designed to estimate the ef-
fects of the Bragg peak degradation for realistic patient anatomies. Different tumor
volumes located at different depths in the lung were investigated. It was shown
that, if the lung modulation effects are not accounted for during the treatment-
planning process, the dose deposited in the target volume is overestimated and the
dose deposited in distal normal tissue is underestimated. This effect increases with
an increasing depth of the tumor in lung and a decreasing extent of the tumor in
beam direction.
At last, the effects were investigated for clinical treatment plans for lung cancer pa-
tients. The overestimation of the mean dose in the CTV was 5% at maximum and
in the order of 2% on average. The effect on OARs distal to the target volume was
negligible for all cases investigated. The investigation of treatment plans confirms
that the lung modulation effects are clinically tolerable to a certain degree in the
current clinical context considering the various more critical dose uncertainties due
to motion and range uncertainties in proton therapy.
Nevertheless, PTV concepts were presented that could compensate for the lung
modulation effects.
XI
ZUSAMMENFASSUNG
Nicht-kleinzelliger Lungenkrebs ist weltweit die häufigste krebsbedingte Todesur-
sache. Darüber hinaus ist anzunehmen, dass die Inzidenz und Mortalität auf-
grund von Rauchen, der zunehmenden Umweltverschmutzung und der alternden
Bevölkerung zunehmen wird. Für Patienten, die sich keiner Operation unterziehen
können, sind entsprechende Strahlentherapiekonzepte notwendig. Aufgrund der
Nähe von Risikoorganen wie dem Herzen, der Speiseröhre, der Luftröhre, größerer
Blutgefäße und dem Rückenmark, ist eine Dosiseskalation im Tumor mit der photo-
nenbasierten Strahlentherapie nicht immer möglich. Die Bestrahlung mit Protonen
hat das Potenzial, eine konformale Dosis im Zielvolumen zu applizieren und gleich-
zeitig umliegendes Normalgewebe besser zu schonen. Es ergeben sich jedoch einige
Herausforderungen im Zusammenhang mit der Protonentherapie im Allgemeinen
und der Protonentherapie von Lungenkrebs im Besonderen. Eine dieser Heraus-
forderungen ergibt sich aus der Struktur des Lungengewebes selbst: Aufgrund der
mikroskopischen Dichteheterogenität kommt es zu einer Modulation der Tiefendo-
siskurve was einen verbreiterten Bragg Peak und einen größeren distalen Dosisabfall
zur Folge hat. Dieser Modulationseffekt kann die Dosisverteilung bei Patienten
signifikant beeinflussen, was potentiell zu einer niedrigeren Dosis im Zielvolumen
und einer höheren Dosis im distalen Normalgewebe und Risikoorganen führen kann.
Da die mikroskopische Struktur des Lungengewebes nicht vollständig in klinischen
CT-Bildern aufgelöst wird, ist eine Berücksichtigung der Lungemodulationseffekte
mit derzeitigen Bestrahlungsplanungssystemen nicht möglich.
In dieser Dissertation wird ein mathematisches Modell verwendet, um die
Auswirkungen der Bragg-Peak-Verbreiterung zu beschreiben. Die Materialeigen-
schaft Modulationsstärke wird verwendet, um die Stärke der Lungenmodulation zu
XII
quantifizieren. Eine heterogene, mikroskopisch voxelierte Geometrie wird verwendet,
um mit Hilfe von Monte Carlo (MC) Simulationen modulierte Dosisverteilungen zu
erzeugen. Anschließend werden diese voxelierten Geometrien, die menschliches Lun-
gengewebe repräsentieren, durch gröbere Voxel klinischen Maßstabes ersetzt. Dies
entspricht dem Übergang vom mikroskopischen Lungengewebe im Patienten zu den
gröberen, klinischen CT-Strukturen, die das feine Lungengewebe nicht ausreichend
auflösen. Durch Modulation der Dichte dieser klinischen Voxel kann die Bragg-
Peak-Verbreiterung reproduziert werden. Es wurde also eine Lösung gefunden, die
Lungenmodulationseffekte auf der Basis klinischer CT-Bilder zu reproduzieren.
Mit dieser Technik wurde eine CT-basierte Phantomstudie entwickelt, um die
Auswirkungen der Bragg-Peak-Verbreiterung für realistische Patientenanatomien
zu analysieren. Unterschiedliche Tumorvolumina in unterschiedlichen Tiefen in der
Lunge wurden untersucht. Es wurde gezeigt, dass wenn die Lungenmodulation
während der Bestrahlungsplanung nicht berücksichtigt wird, die Dosis im Zielvolu-
men überschätzt und die Dosis in distalem Normalgewebe unterschätzt wird. Dieser
Effekt nimmt mit zunehmender Tiefe des Tumors in der Lunge und abnehmender
Ausdehnung des Tumors in Strahlrichtung zu.
Außerdem wurden die Auswirkungen der Lungenmodulation auf klinischen Be-
strahlungsplänen für Lungenkrebspatienten untersucht. Die Überschätzung der
mittleren Dosis im CTV betrug maximal 5% und im Mittel ca. 2%. Für alle
untersuchten Fälle war keine klinisch relevante Erhöhung der Dosis in distalen
Risikoorganen zu erkennen. Die Ergebnisse zeigen, dass die Lungenmodulations-
effekte im gegenwärtigen klinischen Kontext bis zu einem gewissen Grad tolerierbar
sind. Insbesondere in Anbetracht der unter anderem kritischeren Dosisunsicher-
heiten aufgrund von Bewegung und allgemeinen Reichweiteunsicherheiten in der
Protonentherapie.
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Nichtsdestotrotz wurden PTV-Konzepte vorgestellt, die grundsätzlich im Stande
sind, die Lungenmodulationseffekte während der Bestrahlungsplanung zu kompen-
sieren.
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Chapter 1
Introduction
1.1 Cancer and cancer treatment
Cancer is a serious cause of morbidity and mortality worldwide. In 2012 roughly
8.2 million cancer-related deaths were observed while in the same year approximately
12 million incidences were reported (IARC 2014). What is more, the number of in-
cidences is expected to rise by about 70% until 2035 (IARC 2014), making cancer
an increasing health issue. For men the three most common sites of cancer in 2012
were the lung (16.7% of the total), prostate (15.0%), and colorectum (10.0%). For
women the three most common sites of cancer were the breast (25.2%), colorectum
(9.2%), and lung (8.7%) (IARC 2014).
Cancer is commonly treated with either surgery, chemotherapy, radiotherapy or a
combination of these three modalities while the therapy scheme depends individu-
ally on each patient case and tumor site. The aim of the treatment can either be
curative or palliative. For the curative treatment the aim is to cure the patient while
a successful curative treatment requires the removal of all tumor tissue or at least
a completion of the tumor's growth and ability to spread. If that is not possible, a
palliative approach is used to improve the life quality of the patient by relieving the
patient of some pain and symptoms related to the disease.
Radiotherapy plays and important role in the treatment of cancer-related diseases.
After surgery it is the most frequently used modality. Over 50% of all patients with
localized tumors are treated with radiation (Schardt et al. 2010). The goal of radi-
ation therapy is to damage the DNA in the cell nucleus by using ionizing radiation
and hence making the tumor cell non-survivable (Lomax et al. 2013). The number
of DNA damages is proportional to the energy deposited. Hence, the chance of
killing the tumor cell increases with an increase in dose deposited in the tumor cells.
However, cell damages in the surrounding healthy tissue must be kept low enough to
avoid severe side effects. The challenge of radiotherapy is to optimize the treatment
in order to deposit enough dose in the tumor region to cure the patient (for the cu-
rative treatment approach) while side effects are kept reasonable low. The ionizing
radiation can be applied in two different ways: in teletherapy the ionizing radiation
is applied from outside the patient's body (tele, meaning "at a distance"') while
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in brachytherapy a radioactive source is inserted inside the tumor region (brachy,
meaning "short distance").
Several different radiation types are clinically used for teletherapy: in the "conven-
tional" radiotherapy ("conventional" since it was the first to be clinically applied)
high-energy photons in the MeV energy range are used. For the treatment of shallow
regions like skin high-energy electrons in the same energy range can be deployed due
to the short range of electrons in tissue. At last, in particle therapy heavy charged
particles in the ∼100 MeV/u range such as protons or heavier ions (He4+ or C12+)
are used. This work focuses on the external irradiation with protons only.
1.2 Proton therapy
Since the radiological use of fast protons has been proposed in 1946 (Wilson 1946),
the significance of proton therapy (PT) as a treatment modality is continuously
growing worldwide. Over 200 000 patients are treated per year (PTCOG 2019a) in
almost 100 facilities (PTCOG 2019b) while many more facilities are under construc-
tion (PTCOG 2019c).
The most important advantage of PT compared to conventional radiotherapy is
the more beneficial dose deposition in the patient: as shown in figure 1.1, photons
develop an initial dose build-up in matter followed by an exponential decrease in
dose1 leading to a theoretically infinite range of the radiation. In contrast, the dose
profile of protons consists of a low-dose plateau at small depths followed by a dose
maximum, the so-called Bragg peak (Bragg and Kleeman 1905), where most of the
energy is deposited. The Bragg peak is followed by a sharp dose fall-off. Distal to
that fall-off almost no dose is deposited in the case of protons and only small doses
for heavier ions (Kraft 2000; Schardt et al. 2010). The background for these different
dose shapes lies in the kind of interactions of the particles with matter: photons are
indirectly ionizing which means that in a first step, the photon's energy has to be
transferred to secondary particles like electrons via collisions. Subsequently, these
secondary particles in turn transfer the gained energy to the medium mostly by
coulomb interactions. The initial dose build-up in photon beams is a result of the
production of secondary particles. The depth of the dose maximum is approximately
equal to the range of the secondary particles which is in the order of ∼1.5-3.5 cm for
clinical energies (Podgorsak 2003). The exponential decrease in dose is due to the
attenuation of the photon's fluence since photons are absorbed or scattered during
the collisions with secondary particles.
In contrast to photons, protons are directly ionizing. On their way through matter
they constantly loose energy via coulomb scattering, mostly with shell electrons of
the penetrated material. Hence, the mean energy of protons decreases with depth
1Note that the decrease in dose is not exactly exponential but is also depending on 1/r2 with
r being the distance to the source. However, for clinical setups the exponential part is dominant.
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Figure 1.1: Depth-dose curves for clinical photon and proton beams in water.
in medium until they stop. The energy loss of protons is characterized by the so-
called stopping power which consists of the nuclear stopping power (due to nuclear
interactions) and the electronic stopping power (due to coulomb interactions with
charged particles - mostly electrons). For protons with clinical energies the electronic
stopping power dominates. This electronic stopping power theory is well-described
by Bethe and Bloch (Bethe 1930; Bloch 1933) and several corrections for this for-
mula exist (Ziegler 1999; Kraft 2000). The electronic stopping power dE/dx can be
calculated as follows:
dE
dx
= κ
Z2P
β2
ZT
AT
ρ
[
1
2
ln
(
2mec
2β2γ2Tmax
I
)
− β2 − δ(βγ)
2
]
κ =
4pi
mec2
(
e2
4pi0
)2
NA
(1.1)
me is the electron mass, c the velocity of light in vacuum, 0 is the vacuum permit-
tivity and NA is the Avogadro constant. ZP is the charge of the projectile while ZT
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and AT are the atomic number and mass of the target material. β = v/c is the rela-
tive velocity of the projectile and γ = 1/
√
1− β2 is the Lorentz factor. The energy
Tmax is the maximum energy that can be transferred to an electron in a coulomb
interaction and I is the mean ionization potential of the target material. δ(βγ)/2
is the density effect correction term which becomes relevant at relativistic energies
and accounts for the deformation of the electric field of the projectile.
The stopping power is proportional to 1/β2 and hence, at the end of a proton's
range (where the proton's energy is smallest) the energy deposit is largest resulting
in the Bragg peak. Due to the 1/β2 dependency the range of protons and thereby
the position of the Bragg peak is defined by the initial energy E0. Furthermore, the
electronic stopping power depends on the target material's characteristics (namely
atomic number, mass, and (electron) density). As a result, the range of protons
highly depends on the patient's anatomy which leads to challenges in PT as de-
scribed in section 1.4.
Since the coulomb scattering is a statistical process, fluctuations occur in the energy
deposition of a proton traversing a material. Hence, the net energy loss per traveled
distance has to be described by a probability distribution (Bohr 1915; Vavilov 1957;
Ahlen 1980; Bichsel et al. 2000). Due to this energy loss straggling the ranges of
protons of the same energy are different and their stopping positions are shifted
against each other. As a result, the Bragg peak is enlarged. The width of the Bragg
peak increases with an increasing depth in medium and hence an increasing initial
energy.
To deliver proton beams two approaches are clinically used: passive scattering and
active scanning. The passive scattering technique uses passive beam elements to
model the beam in order to meet clinical requirements. Scattering foils are used
to spread the beam laterally while compensators and collimators shape the beam
according to the patient-specific tumor geometry. A modulator wheel is used to
create a spread-out Bragg peak (SOBP) covering the tumor's extension in beam
direction. Hence, a conformal dose distribution is achieved in the complete tumor
volume using only one proton beam with a specific energy. Although historically
motivated, the passive beam scattering technique has been replaced by the active
scanning technique in most facilities. In active beam scanning systems, the dose
is delivered to the tumor volume step by step using a pencil beam. The tumor is
scanned laterally using dipole magnets and in depth by changing the initial energy.
In general, the integral dose is lower when using the active scanning technique com-
pared to the passive scattering technique (Schippers and Lomax 2011; Kase et al.
2011). Furthermore, with active scanning systems an intensity-modulated proton
therapy (IMPT) is possible (Schippers and Lomax 2011). Additionally, except for
the beam monitor system no further beam elements are used and thus, the produc-
tion of undesired secondary particles, such as neutrons, is significantly lower. For
passive scattering systems the dose contribution due to secondary particles is up
to ten times higher compared to active scanning systems (Agosteo et al. 1998; Yan
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et al. 2002).
Active scanning is more time consuming compared to the passive scattering tech-
nique. It depends on the tumor volume, the spot scan size, the Bragg peak width,
and the time the accelerator needs to switch the proton energy. Using fast degraders,
the energy can be switched in milliseconds at modern cyclotrons (Lomax et al. 2004;
Pedroni et al. 2011). Still, this longer irradiation times make pencil beam scanning
vulnerable to intrafractional motion effects as described in section 1.4.
1.3 Rationale for proton therapy of lung cancer pa-
tients
In a review by Chang et al. (Chang et al. 2016) the potential benefits and prob-
lems related to PT of early stage and locally advanced non-small cell lung cancer
(NSCLC) patients as well as an overview of important clinical studies are presented.
This chapter is in parts a summary of the most important and relevant aspects of
this review. Additionally, various other relevant clinical studies and research results
are being presented as well.
NSCLC is worldwide the number one cause of cancer-related deaths (Chang et al.
2016). Furthermore, it is predicted that the incidence and mortality will further
increase due to smoking, increasing pollution of the environment, and an aging pop-
ulation (Chang et al. 2016).
For early stage lung cancer patients, anatomical resection is the standard procedure
(Timmerman et al. 2010). However, patients might not be able to undergo surgery
due to restrictions like emphysema, heart disease or age. For these medically inop-
erable lung cancer patients, conventional radiotherapy is an alternative.
Studies have shown that a dose escalation with >100 Gy (BED) delivered with
photon-based radiotherapy leads to local control rates greater than 95% and in-
creases the overall survival compared to surgery for early stage I NSCLC patients
(Timmerman et al. 2010; Shirvani et al. 2014; Chang et al. 2015, 2016). However,
in locally advanced NSCLC this dose escalation with photons is limited due to the
vicinity of organs at risk (OAR) like the heart, trachea, and esophagus, with po-
tential rates of severe toxicities of grade >3 of 76-79% (Chang et al. 2016). Hence,
PT might be an interesting alternative for the treatment of NSCLC patients. In the
clinical routine mainly two approaches for the use of PT have evolved (Chang et al.
2016): the first approach is to escalate the dose in the target volume while allowing
the same dose to normal tissue and OARs compared to conventional therapy. The
second possibility is to spare the normal tissue and OARs compared to conventional
therapy while the same dose is applied to the target volume. The first approach is
most applicable for NSCLC patients with poor local control when using conventional
radiotherapy (Chang et al. 2016). In a virtual clinical study by Zhang et al (Zhang
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et al. 2010) it was shown that it is possible to safely deliver higher doses to locally ad-
vanced NSCLC with PT than with photon-based intensity-modulated radiotherapy
(IMRT), under the condition that the dose-volume constraints for normal tissues are
the same for both modalities. Since the sparing of normal tissue like lung, esophagus,
heart, and spinal cord is easier achieved in PT compared to IMRT, it was possible
to escalate the dose from 63 Gy (RBE) to 74 Gy (Zhang et al. 2010; Chang et al.
2016).
The second approach is most applicable in difficult anatomical situations where the
tumor is near to sensitive structures like heart, esophagus, trachea, large blood ves-
sels, and the spinal cord. Several studies showed that the integral dose to normal
tissue can be reduced in PT compared to conventional radiotherapy, even when com-
pared to modern IMRT (Lomax et al. 1999; Nill et al. 2004; Macdonald et al. 2009;
Hoppe et al. 2010; Register et al. 2011; Loeer and Durante 2013). Although the
integral dose to normal tissue can be reduced in PT, it was noted that the dose
delivered to the skin and chest wall is slightly higher for cases where less than three
proton beams were used (Macdonald et al. 2009; Chang et al. 2016). However, by
using more proton beams (∼4 different beam directions) (Welsh et al. 2013) or for
example arc proton therapy (Seco et al. 2013), the dose to the skin and chest wall
could be reduced if clinically demanded (Chang et al. 2016).
Although it can be shown in dosimetric studies that patients potentially benefit
from PT in terms of improved dose-volume histograms (DVH), this does not mean
that this dosimetric benefit automatically translates into an approved clinical benefit
(Chang et al. 2016).
For early stage NSCLC several studies showed that 2-years local control rates of
80-100% can be achieved with PT (Shioyama et al. 2003; Nihei et al. 2006; Hata
et al. 2007; Nakayama et al. 2010; Chang et al. 2016). However, since techniques like
image-guidance systems increase the robustness of photon-based SBRT, similar rates
can be achieved with SBRT (Sonke et al. 2009; Grutters et al. 2010; Timmerman
et al. 2010; Shirvani et al. 2014; Chang et al. 2015; Harada and Murayama 2017).
Additionally, most of the early stage NSCLC are small peripheral lesions that are
not located in the vicinity of critical structures, hence, dose escalation is often also
possible with photon-based SBRT (Chang et al. 2016).
Locally advanced (stage III) NSCLC are usually large primary tumors that are
in the vicinity of critical structures (Chang et al. 2016). Additionally, locally ad-
vanced NSCLC occur together with mediastinal nodes resulting in a bad prognosis
due to high local failure and metastasis (Chang et al. 2016). The current standard
treatment is concurrent chemotherapy with thoracic radiotherapy (Harada and Mu-
rayama 2017). PT can spare more healthy tissue, especially OARs like the heart,
compared to photon-based radiotherapy(Chang et al. 2006; Nichols et al. 2011; Ohno
et al. 2015), while it is possible to deliver a comparable dose to the target volume
(Chang et al. 2011; Oshiro et al. 2014; Nguyen et al. 2015; Hoppe et al. 2016; Chang
et al. 2016). However, it was shown, that esophageal toxicities in high-dose PT occur
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(Oshiro et al. 2014; Chang et al. 2011). Thus, the dose escalation with the use of
PT stays a demanding task (Harada and Murayama 2017). In a phase II study by
Chang et al (Chang et al. 2011), 44 patients with stage III NSCLC were treated
with protons in combination with chemotherapy. A 74 Gy (radiobiologic equivalent)
was applied in 37 fractions. No grade 4 or 5 toxicities were observed while some
grade 3 toxicities (dermatitis, esophagitis and pneumonitis) occurred. The median
survival was 29.4 months compared to 20.3 months for the regime treated with 74 Gy
photons (RTOG 0617).
In conclusion, dosimetric studies show that PT can spare healthy tissue compared
to photon-based radiotherapy, which is important due to the anatomical challenges
in thoracic cancers, especially the vicinity of OARs. However, these dosimetric ad-
vantages do not automatically translate into clinical benefits inducing a demand for
clinical studies (Chang et al. 2016).
1.4 Challenges related to proton therapy
In this section general as well as lung-specific challenges related to PT are described.
The main challenge is due to the proton's finite range that strongly depends on the
irradiated material. Thus, changes in the patient's anatomy that are not accounted
for can affect the dose deposition and hence the treatment outcome severely. These
changes can be due to weight loss, motion during irradiation, a shift in the posi-
tioning of the patient or a shrinkage of the tumor (Unkelbach et al. 2007; Hui et al.
2008; Paganetti 2012; Szeto et al. 2016). In particular, the interfractional anatom-
ical change demands for plan adaption strategies in PT (Hoffmann et al. 2017).
Szeto et al (Szeto et al. 2016) showed that an undercoverage of the target volume
of up to 14 GyE can occur when the treatment plan is not adapted to the daily
anatomy of the patient. Additional, a maximum increase of 4.7 GyE in the D1 (dose
that is received by 1% of the volume) in OARs was observed.
Furthermore, the range of protons and the dose deposition is calculated on CT-
images in the current clinical practice (Arbor et al. 2015). These CT-images provide
tissue attenuation coefficients that are converted to stopping powers for the calcula-
tion of proton ranges and energy loss using a stoichiometric calibration (Schneider
et al. 1996). Several studies have investigated range uncertainties of protons due to
such a conversion, while predicted range uncertainties ranged from 0.8% (Matsufuji
et al. 1998; Chvetsov and Paige 2010) to 3% (Schaffner and Pedroni 1998; Yang et al.
2012; Arbor et al. 2015). As a result of these range uncertainties, safety margins are
used to account for these range uncertainties. Different margin concepts are used
clinically that enlarge the target volume by between 2.5%(of the range)+1.5 mm
and 3.5%+3 mm depending on the center (Paganetti 2012). It is obvious that these
margins decrease the potential of sparing normal tissue which is one of the main
advantages in PT. In order to reduce the extent of the safety margins, several range
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verification techniques like prompt gamma imaging (Smeets et al. 2012; Richter et al.
2016), PET imaging (Parodi and Enghardt 2000; Enghardt et al. 2004; Parodi et al.
2007; Knopf et al. 2008) or ionoacoustic detection (Assmann et al. 2015; Lehrack
et al. 2017) are being developed and partly clinically implemented at the time.
Range uncertainties are also due to uncertainties in biological effectiveness models
(Paganetti 2012; Carabe et al. 2012). The relative biological effectiveness (RBE)
is defined as the ratio of the photon dose (as reference) and the proton dose that
is necessary to cause the same effect in terms of the same clinical end point. The
RBE depends on the delivered dose, end point, particle type, dose-averaged linear
energy transfer (LETd) and tissue type (characterized by the α/β coefficient) (Pa-
ganetti 2012; Carabe et al. 2012). A constant RBE of 1.1 for protons is usually
used clinically due to a lack of data that would be necessary to model the biological
effectiveness more accurately (Paganetti 2012). However, it is known that the RBE
strongly correlates with LETd. Since the LETd increases at the distal end of the
Bragg peak, the biological effective range reaches farther compared to the physical
dose range, causing a shift of about 1-2 mm (Paganetti 2012).
Especially for the irradiation of lungs, motion plays an important role for scanned
proton beams, since the motion of the lung interferes with the pencil beam (Bert
et al. 2008). The resulting interplay effects lead to an inhomogeneous dose in the
target and to a reduced target coverage (Bert and Durante 2011; Grassberger et al.
2013; Dowdell et al. 2013). Due to interplay effects the volume receiving 95% of the
prescribed dose can decrease to 70% for one fraction (Bert et al. 2008). When apply-
ing more fractions the interplay effects might be compensated partially. However,
especially for small fraction numbers motion mitigation techniques are demanded
when treating moving targets with scanned proton beams (Bert et al. 2008). Cur-
rent solutions include robust planning, gating, rescanning or tracking (Stuschke et al.
2012; Bert et al. 2007; Engwall et al. 2018; Lu et al. 2007; Kanehira et al. 2017).
1.5 Modulation effects of lung tissue
Another challenge in PT of lung cancer patients arises from the lung tissue itself.
The lung is structured in tubular branches, the bronchi, which transport the inhaled
air into the lung. These bronchi divide into smaller and smaller branches, the so-
called bronchioles, which end in microscopic clusters of air sacs, the alveoli (Webpage
2019). These clusters of air sacs are surrounded by the interstitium, a layer of cells,
that contains blood vessels and supports the alveoli (Webpage 2019). While the alve-
oli are filled with air with a low physical density of ∼1 mg/cm3, the density of the
interstitium is roughly 1 g/cm3. This microscopic density heterogeneity of the lung
tissue has an effect on the range of the protons traversing the lung: depending on
the path of the protons through the lung, different compositions of low-density and
high-density regions will lead to different energy losses resulting in variable ranges
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of the protons and thus a broadened Bragg peak and a larger distal dose fall-off.
This modulation of the dose distribution due to heterogeneous structures like the
lung is also called degradation of the Bragg peak and has already been described
in 1986 (Urie et al. 1986): dose distributions in a water phantom were measured
for different heterogeneous geometries that were placed in the particle beam. The
full-width-half-maximum (FWHM) of the Bragg peak as well as the distal fall-off
width (DFW) were investigated demonstrating the Bragg peak degradation. In an-
other study by Sawakuchi et al. (Sawakuchi et al. 2008) the Bragg peak degradation
was investigated with the help of Monte Carlo (MC) studies and virtual, voxelized
geometries where the voxels were either bone or air. They analyzed the change in
the energy spectrum of the protons due to the different energy losses and developed
a model to predict the change in the DFW in dependence of the energy spectrum.
Clinically, the degradation of the Bragg peak can significantly influence the dose
distribution in lung cancer patients (España and Paganetti 2011) and lead to an un-
derdosage of the target volume and an overdosage of distal normal tissue (Sawakuchi
et al. 2008; Sell et al. 2012; Titt et al. 2015). Hence, the Bragg peak degradation
should be considered during the treatment-planning process of lung cancer patients
(Titt et al. 2015). However, typical CT-scanners do not fully resolve the heteroge-
neous structure of the lung tissue due to the restricted resolution and hence merge
the microscopic structures of the lung into larger voxels (España and Paganetti 2011;
Titt et al. 2015). As a result of that, a more homogeneous density distribution is
predicted. Hence, it is hardly possible to consider the Bragg peak degradation based
on typical CT-images. The fact that the density is averaged in CT-images can lead
to differences in the Bragg peak dose of up to 11% while the distal edge degradation
can be as large as 1.1 mm in water for clinical proton beams (Perles et al. 2011).
In a study by Titt et al. (Titt et al. 2015) the modulation effects of lung tissue were
investigated using a high-resolution 3d-printed phantom as a lung substitute. The
phantom was built up of microscopic voxels that consisted of plastic or air. Depth
dose distributions in water downstream from that phantom were measured as well as
MC simulated for a 150 MeV and 200 MeV proton beam. Additionally, proton beams
penetrating CT-images of the 3d-printed phantom were simulated and compared to
the measurements and simulations of the true geometry. For the simulations based
on the CT-images of the phantom the distal dose fall-off was underestimated by up
to 2 mm in water (corresponding to ∼10 mm in lung tissue), and the dose in the
Bragg peak was overestimated by up to ∼35% (Titt et al. 2015). Additionally, a
plastinated human lung was irradiated to demonstrate the Bragg peak degradation.
The DFW was increased by up to 60% compared to an unperturbed pristine dose
distribution. At last, the authors proposed a mathematical model to describe the
degraded dose distributions: the degraded dose distribution can be estimated by
shifting an unperturbed pristine dose distribution by the water-equivalent thickness
of the phantom and by applying a convolution with a normal distribution.
This mathematical model was also described and further evaluated in other stud-
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ies (Witt 2014; Witt et al. 2015; Ringbæk et al. 2017). By including the shift due
to the water-equivalent thickness of the heterogeneous material directly into the
normal distribution, the degraded dose distribution can be estimated immediately
by convolving the unperturbed pristine dose distribution with that adapted nor-
mal distribution (without the need of additionally shifting the unperturbed dose
distribution). From the mean value µ and standard deviation σ of the normal dis-
tribution, the material characteristic modulation power (Pmod) can be derived as
Pmod = σ
2/µ. The modulation power has the unit length in water and is indepen-
dent on the geometrical thickness of the heterogeneous material. Additionally, it
can easily be determined experimentally in proton beams by measuring depth dose
distributions with and without lung tissue probes in the beam. Subsequently, the
parameters µ and σ of the normal distribution have to be optimized in order to
minimize the difference between the degraded dose distribution and the convolution
of the unperturbed dose distribution with the normal distribution.
Witt (Witt 2014) determined experimentally the modulation power of an ex-vivo
porcine lung. For each measurement the position at which the lung was irradiated
as well as the respiratory state of the lung were varied. The modulation powers
were in the range of 300 µm to 750 µm. Since complete lungs were positioned in the
beam, the so-measured modulation power corresponds to an integrated modulation
power. However, the modulation power might depend on the position within the
lung due to differences in the structure size of the alveoli and bronchioles. For most
measurements the modulation power was in the range from 300 µm to 500 µm with
an average of 450 µm. For one measurement the modulation power was 750 µm,
since due to the lung's positioning a large bronchial structure was in the beam.
Additionally, high-resolution CT-images of human lung samples with a resolution of
4 µm were investigated in order to verify whether the measured modulation powers
for porcine lungs are applicable for human lung tissue. The so-gained modulation
powers for human lung tissue were in the range of 50 µm to 250 µm. However, the
human lung tissue samples were prepared using a "critical point drying" method
(Litzlbauer et al. 2006), resulting in loss of water and hence mass of up to 37%. As
a consequence, the size of the structures of the lung tissue was reduced resulting in
a smaller modulation power.
In conclusion, several studies have observed and described the modulation effect of
lung tissue in PT and the resulting Bragg peak degradation. A mathematical model
has been developed to estimate the degraded dose distribution starting from an un-
perturbed pristine dose distribution. The quantity modulation power Pmod has been
introduced that quantifies the Bragg peak degradation. First measurements with ex-
vivo porcine lungs and high-resolution CT-images of human lung samples suggest
that the modulation power is in the range of some hundred µm water-equivalent.
The main problem is that the fine structure of the lung tissue is not fully resolved in
typical treatment-planning CT-images. Hence, the geometrical information is lost
and it is, until now, not possible to estimate the potential effects due to the Bragg
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peak degradation clinically. Especially, the potential underdosage of the target vol-
ume and overdosage of distal normal tissue cannot be approximated, yet.
1.6 The Monte Carlo code topas/geant4
The Monte Carlo (MC) method is a technique that is widely used in the field of med-
ical physics and is an important tool for scientific research questions connected to
radiation transport. It was originally presented by Metropolis and Ulman (Metropo-
lis and Ulam 1949) and is used to solve problems by repeating a random experiment
multiple times. Following the law of large numbers (LLN), the average of the results
that are obtained from a large number of randomly sampled, independent trials
converges to the expected value (Dekking 2005). Concerning radiation transport
applications connected to medical physics, the MC method provides a numerical
solution of the Boltzmann transport equation (Bielajew 2001), while all underlying
physical parameters like absorption and scattering cross-sections must be provided
using corresponding formulas or data tables. Over the time many different MC codes
have been developed that were designed and optimized to satisfy the specific needs
of a certain research field.
One example is the multipurpose MC code geant4 (GEometry And Tracking)
(Agostinelli et al. 2003) that was primarily designed for high-energy physics appli-
cations. It was shown that by adjusting the transport parameters, it can be used for
medical physics applications and especially for dosimetric calculations in PT (Bau-
mann et al. 2019c). For the studies in this dissertation the toolkit topas (TOol
for PArticle Simulation) (Perl et al. 2012) was used that is based on the MC code
geant4. Previous studies have extensively validated topas against experimental
data (Perl et al. 2012; Testa et al. 2013). Since topas is based on geant4, it
uses the same physics models, processes, and interaction cross sections as geant4.
It is capable of transporting a large variety of particles including photons, electrons,
positrons, neutrons, protons, and heavy ions over a large energy range including the
clinically relevant energies.
Since computing time is an important issue when using MC codes, different ap-
proaches are used to reduce the computing time. However, in general, these ap-
proaches come at the expense of the accuracy and the user has to adjust the cor-
responding parameters depending on the research question. In order to reduce
computing time, in geant4 electromagnetic (EM) interactions of charged par-
ticles are grouped in the condensed history (CH) approach. The deflection at the
end of a CH step is calculated using a multiple scattering (MSC) algorithm. The
user can choose between various MSC theories including the Urban model (Urban
2002), the Goudsmit-Saunderson model (Goudsmit and Saunderson 1940a,b) and
the WentzelVI model (Ivanchenko et al. 2010). The length of a CH step is limited
by tracking limits, such as geometric boundaries and physics-related parameters such
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as the parameter dRoverR. It determines the maximum length of one single step in
relation to the residual range of the particle. Due to collisions, particles loose energy
on their way through a medium and hence, the CH step length decreases until it
is smaller than the finalRange. As soon as the CH step length gets smaller than
the finalRange, the particle is ranged out in a single step and its residual energy is
deposited locally.
The parameter controlling the production of secondary particles is given in units of
length in geant4. Only particles with an energy high enough that the correspond-
ing continuous slowing down approximation range (RCSDA) is greater than or equal
to the production cut range are produced. All other particles are absorbed on the
spot and their energy is deposited locally.
To verify the accuracy of the CH transport algorithms implemented in a MC code,
the so-called Fano cavity test can be performed, which is the most stringent test
(Rogers 2006; Sterpin et al. 2014). The Fano theorem states that, as long as a
medium is in charged particle equilibrium (CPE), the electron fluence is indepen-
dent of the physical density as long as the cross sections (/(g cm−2)) are independent
of the physical density (Rogers 2006). For geant4 it was shown that the Fano
cavity test is violated by less than 0.2% for clinical photon (O'Brien et al. 2016) and
proton beams (Wulff et al. 2018).
Since topas is developed for the clinical use in PT, it includes various features
like modeling beam monitor systems or passive scattering facilities as well as per-
forming dose calculations on patient-specific data (Perl et al. 2012). It is capable of
importing CT-images via the dicom standard (Digital Imaging and COmmunication
in Medicine). To convert HU values into stopping powers the conversion table by
Schneider et al. (Schneider et al. 1996) is implemented by default - however, any
desired conversion table can be used. Since topas has a time feature, the dicom
position and orientation as well as the beam quality can be changed within a simu-
lation and after any amount of simulated primaries. Additionally, various physical
quantities like dose, fluence or energy deposition can be scored within the dicom.
Hence, the calculation of complete treatment plans is possible in topas.
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Chapter 2
Aim of this dissertation
The ultimate aim of this dissertation was to clinically quantify the effects of the
Bragg peak degradation due to lung tissue in PT. Additionally, these effects shall be
discussed in a clinical context considering the various range and dose uncertainties
connected to PT of lung cancer patients as described in chapter 1.4.
The main problem remains that the fine structure of the lung tissue is not fully re-
solved in typical treatment-planning CT-images. Hence, the geometrical information
is lost and it is hardly possible to estimate the potential effects due to the Bragg
peak degradation clinically. However, with the help of measurements of ex-vivo
lungs or high-resolution CT-images of human lung samples, the modulation power
Pmod of lung tissue can be determined experimentally which quantifies the Bragg
peak degradation. Based on this modulation power, a solution must be found to
reproduce the Bragg peak degradation on typical treatment-planning CT-images.
In a next step, this solution shall be used to investigate the dependencies of the
effects of the Bragg peak degradation on different anatomical scenarios. With the
help of CT-based phantoms, the dependencies on tumor volume, tumor shape and
depth of the tumor in the lung can be characterized.
At last, the effects have to be investigated for clinical treatment plans. By calcu-
lating treatment plans with and without including the Bragg peak degradation, the
potential underdosage of the target volume and overdosage of distal normal tissue as
well as OARs can be evaluated for different treatment scenarios for patient-specific
cases.
Since MC codes provide various features and can be adjusted individually, all studies
from this dissertation are MC based using the toolkit topas that is based on the
MC code geant4.
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Chapter 3
Summary of the results and
contributions
In this chapter the results of each published article are presented. At the end of the
chapter the contributions of each author are being constituted.
3.1 Summary of results
3.1.1 Article 1
In the first article (Baumann et al. 2017), a voxelized geometry was used as
a representative of human lung tissue to produce degraded dose distributions
in a water phantom. The voxels consisted of either air with a physical den-
sity of ρa = 0.0012 g/cm−3 or solid lung material with a physical density of
ρl = 1.05 g/cm−3. The average density ρmean of the geometry is controlled by the
fraction pl of solid lung material voxels. For this study pl was set to 0.25 in order
to achieve an average density of 0.26 g/cm3, which is the density of an inflated lung
(Schneider et al. 1996). The probability F that the water-equivalent thickness of
a random path through this voxelized geometry equals t′ is described by a normal
distribution:
F (t′|t, σt) = 1√
2piσ2t
· exp
(
− (t
′ − t)2
2σ2t
)
(3.1)
where t is the average water-equivalent thickness of the voxelized geometry and σ
describes the strength of the degradation due to this heterogeneous geometry. The
parameters are calculated as follows:
t =
ρmean
ρH2O
·D with ρmean = pl · ρl + (1− pl) · ρa ≈ ρl · pl (3.2)
where D is the geometrical thickness of the voxelized geometry in beam direction,
ρH2O := 1 g/cm
3, and ρmean is the average water-equivalent density of the geometry.
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The approximation takes into account that ρa  ρl.
σ2t is calculated as follows:
σ2t =
D
d
· pl · (1− pl) · d2 ·
(
ρl − ρa
ρH2O
)2
≈ t · d · (1− pl) · ρl
ρH2O
(3.3)
where d is the size of each voxel in beam direction. Note that the thickness D of
the complete geometry is n · d while n is the number of voxels in beam direction.
Furthermore, it is assumed that the water-equivalent density of the solid lung ma-
terial is equal to its physical density, since the solid lung material consists of over
85% water.
The function F (t′|t, σt) describing the voxelized geometry can also be used to esti-
mate the degraded dose distribution due to this heterogeneous geometry as shown
in figure 3.1 (this figure corresponds to figure 1 in article 1): when convolving an
unperturbed pristine dose distribution b0(z) with F (t′|t, σt), the result equals the
degraded dose distribution b∗(z):
b∗(z) =
(
F ∗ b0
)
(z) =
∫ ∞
−∞
F (t′|t, σt)b0(z + t′)dt′ (3.4)
The mean value t describes the shift of the dose distribution and σt describes the
broadening. This concept is in agreement with other studies (Witt 2014; Witt et al.
2015; Titt et al. 2015; Ringbæk et al. 2017). Note that t describes the shift of the
depth zp82 at which the dose of the distal fall-off is 82% of the maximum dose. The
background is the energy loss straggling theory as described in chapter 1.2: the
energy loss is a statistical effect that is described by a probability distribution. The
maximum of this distribution corresponds to an energy loss that results in a range
equal to zp82 (Bichsel et al. 2000).
The modulation power Pmod describing the modulation strength of the voxelized
geometry can be derived from the normal distribution F (t′|t, σt) using t and σt:
Pmod ≡ σ
2
t
t
≈ d · (1− pl) · ρl
ρH2O
(3.5)
The modulation power Pmod is directly proportional to the size d of the voxels in
beam direction. This size of the voxels is the analogue to the size of the microscopic
structures in the lung. Hence, the larger the microscopic structure of the lung the
larger the modulation effect. Note that it is also possible to derive the normal dis-
tribution F (t′|t, σt) from the modulation power Pmod for a geometry of thickness D
via t = ρmean/ρH2O ·D and σ2t = Pmod · t. Hence, the mathematical model can be
used either way: for an arbitrary voxelized geometry the corresponding modulation
power can be derived using the normal distribution and from the measured mod-
ulation power of an heterogeneous material the corresponding normal distribution
can be derived. The mathematical model and the modulation power are a construct
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Figure 3.1: Schematic description of the mathematical model: the binary voxelized
geometry consists of air (black voxels) and solid lung material (white
voxels). An unperturbed reference curve b0(z) and a broadened dose
distribution b∗(z) are shown. The broadening and displacement of b∗(z)
can be described by the convolution of the reference curve with a normal
distribution F (t′|t, σt) giving the probability that the path a particle is
taking through the voxelized geometry has a water-equivalent thickness
t′. The displacement of b∗(z) is given by the mean value t. The broad-
ening is given by the value of σt. Figure taken from (Baumann et al.
2017). © Institute of Physics and Engineering in Medicine. Reproduced
with permission. All rights reserved.
that is based on dose distributions measured or calculated in water. Hence, t, σt
and Pmod and physical densities have to be understood in water-equivalent units.
To investigate the effects due to lung modulation, different microscopic voxelized
geometries with a thickness D in beam direction of D ≈ 50 mm were created. The
voxel size d was varied for each of these geometries. Values for d between ∼130 µm
and ∼1000 µm were chosen in order to achieve modulation powers between 100 µm
and 800 µm which is the range of determined modulation powers of human lung
tissue samples and porcine lungs (Witt 2014). Using these voxelized geometries, de-
graded dose distributions as well as an unperturbed pristine dose distribution were
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calculated in a water phantom downstream from the voxelized geometries with the
MC code topas/geant4. Subsequently, the modulation powers of the simulated
voxelized geometries were determined by optimizing the parameters t and σt of a
normal distribution in order to fulfill equation (3.4). From the parameters t and
σt the modulation power was calculated as Pmod = σ2t /t. In order to validate the
mathematical model, these modulation powers from the simulations were compared
to the theoretical modulation powers as calculated with equation (3.5). The max-
imum difference between simulated and theoretical modulation powers was 26 µm
(=ˆ 3.7%). Additionally, the distal fall-off widths (DFW) from 80% to 20% of the
maximum dose were investigated. For the unperturbed pristine dose distribution it
was 0.9 mm, while for the degraded dose distributions it varied between 1.9 mm (for
Pmod = 100 µm) and 4.2 mm (for Pmod = 800 µm), demonstrating the broadening
of the Bragg peak due to the modulation effect of heterogeneous materials. It was
shown that the depth zp82 was the same for all modulated dose distributions. It was
shifted by 13.2 mm towards zp82 of the unperturbed pristine dose distribution. This
shift corresponds to the prediction of the value t from the mathematical model.
Since clinical CT-scanners do not resolve the microscopic structures of the lung
tissue, a solution is needed to reproduce the modulation effects of lung tissue on
typical treatment-planning CTs. In order to reproduce the modulating effect, the
energy loss of the single protons has to be modulated resulting in a variation of the
proton's range. Following the electronic stopping power theory by Bethe and Bloch
(Bethe 1930; Bloch 1933) (compare equation (1.1)), the energy loss of a particle
is proportional to the geometrical thickness of the penetrated material as well as
its density. Since the size of the voxels in a CT-image can hardly be altered, the
solution lies in modulating the density of the voxels. A corresponding probability
distribution F (ρ′|D) describing the probability that a voxel of thickness D has the
water-equivalent density ρ′ can directly be derived from the normal distribution
F (t′|t, σt) by substituting the water-equivalent thickness t′ with ρ′ = t′/D · ρH2O.
However, for small values of D, especially when D equals the size of CT-voxels, the
normal distribution F (t′|t, σt) can be positive for negative values of t′ as shown in
figure 3.2 (this figure corresponds to figure 2 in article 1). In that case the nor-
mal distribution cannot be used. Thus, a different distribution F (t′|D) has to be
developed that has no negative contributions and describes the distribution of water-
equivalent thicknesses t′ for a thin target of thickness D, in this case a CT-voxel.
To do so, in a first step the normal distribution FT (t′|t, σt) from equation (3.1) with
t = ρmean/ρH2O · T and σ2t = Pmod · t is derived for a sufficiently thick target of
thickness T = n ·D with n ∈ N, assuring that FT (t′|t, σt) ≈ 0 for t′ < 0.
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Figure 3.2: Deriving the distribution of water-equivalent thicknesses for clinical vox-
els of size D. In solid line the normal distribution for a target of
size T = n · D with n = 20. In dashed line the normal distribution
for D = 2 mm having non-negligible contributions for negative water-
equivalent thicknesses. In circles the optimized discrete distribution con-
sisting of a Poisson distribution and a single weight w0 at t′ = 0 mm.
The weight w0 is scaled with a factor of 0.1 for better visibility. The
circles are connected to guide the eye. The result when convolving this
distribution 20 times with itself is shown in triangles. Figure taken
from (Baumann et al. 2017). © Institute of Physics and Engineering in
Medicine. Reproduced with permission. All rights reserved.
In order to construct F (t′|D), the following requirements have to be fulfilled:
 F (t′|D) consists of single weights wi based on fine steps of e.g. ∆ = 50 µm:
wi = F (t
′ = i ·∆|D) with ∑wi = 1
 F (t′|D) = 0 for t′ < 0
 F (t′|D) convolved n times with itself equals the normal distribution
FT (t
′|t, σt):
F (t′|D) ∗ F (t′|D) ... ∗ F (t′|D)︸ ︷︷ ︸
n times
≈ FT (t′|t, σt) (3.6)
The last requirement is the most important one: it assures that n thin targets of
thickness D have the same physical properties (such as average density and modu-
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lation effects) as the thick target of thickness T = n ·D.
To construct F (t′|D), a shifted Poisson distribution was used in combination with
a single weight w0 at t′ = 0. This weight accounts for the negative contribution of
the normal distribution for small targets of size D. The shifted Poisson distribution
is defined only for positive values and has a similar shape compared to a normal
distribution making it an optimal candidate. The Poisson distribution was gener-
alized for non-integers by replacing the factorial function by the Gamma function.
F (t′|D) was determined by optimizing w0 and the parameters of the shifted Poisson
distribution in order to best fulfill equation (3.6).
In figure 3.2 an exemplary distribution F (t′|D) is shown for a voxel size D of 2 mm
and a modulation power Pmod = 800 µm. Generalizing from this optimized function
F (t′|D) the density-probability function F (ρ′|D) can be derived by substituting the
water-equivalent thickness t′ with ρ′ = t′/D · ρH2O.
After optimizing the density-probability function F (ρ′|D), the microscopic voxelized
geometries with voxel sizes d between ∼130 µm and ∼1000 µm were replaced in the
MC code topas/geant4 by voxelized geometries consisting of clinical voxels with
an edge length ofD = 2 mm. This replacement represents the transition from the mi-
croscopic heterogeneous structure and hence the lung tissue as it is in the patient to
coarser structures and hence the clinical CT-image of the lung. Density probability
distributions F (ρ′|D) were derived for D = 2 mm and for each modulation power as
designed in the first simulations. Subsequently, dose distributions in a water phan-
tom downstream from the clinical voxels were calculated while the density of each
of the 2×2×2 mm3 voxles was modulated individually following F (ρ′|D). In order
to reduce the computing time, the voxels were not modulated for each simulated
particle. Instead, 500 different sets of individually modulated voxels were generated
and used for the simulation. The depth dose distributions that were created using
the clinical voxels and a modulated density (MD) are shown in figure 3.3 (this figure
corresponds to figure 6 in article 1) for two exemplary modulation powers. Ad-
ditionally, the depth dose distributions from the microscopic voxelized geometries
(BD for binary density since the voxels consist of either air or solid lung material)
are shown for comparison. By modulating the density of the clinical CT-voxels
the degraded dose distributions from the microscopic voxelized geometries can be
reproduced almost perfectly. Subsequently, modulation powers for the geometries
consisting of clinical voxels were derived and compared to the modulation powers
from the microscopic voxelized geometries. The maximum difference between both
modulation powers was 19 µm (=ˆ 2.7%). Again, the DFW from 80% to 20% of the
maximum dose were investigated. For all modulation powers the difference in DFW
between the microscopic voxelized geometry and the geometry consisting of clinical
voxels was 0.1 mm or even smaller. The difference in zp82 between both geometries
was 0.2 mm at maximum. Hence, the degraded dose distributions produced with the
microscopic voxelized geometries representing human lung tissue can be reproduced
on the basis of clinical voxels when the density of these voxels is being modulated
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Figure 3.3: Depth dose distributions created using the microscopic voxelized geome-
tries (BD) and the voxels of clinical sizes with a modulated density (MD)
for two exemplary modulation powers. Additionally, the dose distribu-
tion when the density of the voxels is not modulated but kept constant
at the average density. Figure taken from (Baumann et al. 2017). ©
Institute of Physics and Engineering in Medicine. Reproduced with per-
mission. All rights reserved.
correspondingly.
Furthermore, the dose distribution in a water phantom was calculated when the
density of the clinical voxels was not modulated but kept constant at the average
density. This represents the actual clinical case where the microscopic structure of
the lung tissue is not resolved in treatment-planning CT-images and hence an aver-
age density is assigned to each voxel. In that case, the Bragg peak degradation was
not being reproduced and the dose distribution was as narrow as the unperturbed
pristine dose distribution resulting in a DFW from 80% to 20% of the maximum
dose of 0.9 mm.
3.1.2 Article 2
In the second article (Flatten et al. 2019), this technique of modulating the density
in order to reproduce the Bragg peak degradation on the basis of clinical CT-images
was used to analyze the effects due to the lung modulation. Therefore, CT-based
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phantoms were created representing a human lung while artificial tumors of differ-
ent volumes were located at different positions within the lung. These phantoms
consisted of two slabs of water each 2 cm thick that were separated by 25 cm of
lung tissue. Hence, these phantoms represent the lung enclosed by the thorax wall
and the mediastinum or other distal tissue. The density of the lung tissue in each
voxel was set to 0.26 g/cm3 which is the density of an inflated lung (Schneider et al.
1996). The CT-voxels were 1.5×1.5×1.5 mm3 large. The artificial tumors that were
placed within the lung were represented by spheres or ellipsoids with a density of
1 g/cm3. These CT-based phantoms correspond to a clinical treatment-planning CT
where the microscopic structure of the lung tissue is not resolved and a homogeneous
density is predicted.
In order to extensively evaluate the effects of the Bragg peak degradation, the fol-
lowing parameters were investigated (compare figure 2 in article 2):
 Depth of tumor in lung: six different depths of the tumors in the lung
were investigated: 2 cm, 4 cm, 6 cm, 10 cm, 15 cm, and 20 cm. The depth dL
of the tumors corresponds to the distance between the entrance wall and the
center of the tumor.
 Volume of the tumor: six different spherical tumors with volumes of 1 cm3,
2 cm3, 6 cm3, 14 cm3, 25 cm3, and 43 cm3 were investigated.
 Shape of the tumor: the shape of lung tumors can be non-spherically which
might have an effect on the Bragg peak degradation. Hence, two different
elliptical tumor volumes were investigated with volumes of 9 cm3 and 19 cm3.
For each CT-based phantom a treatment plan was optimized using the commercially
available treatment-planning system (TPS) Eclipse version 13.7 (Varian). Each plan
consisted of one single beam perpendicular to the entrance wall of the CT-based
phantom. The lateral spot spacing was 60% of the FWHM of the beam spot. The
energy spacing was varied between 1 MeV for small tumor volumes and 3 MeV
for larger tumor volumes. No motion was considered. The planning target vol-
ume (PTV) was the gross tumor volume (GTV) -in this case all voxels identified as
tumor- plus an isotropic margin of 3 mm. The prescribed dose was 30 Gy RBE to
be applied in a single fraction.
All treatment plans were subsequently recalculated with topas/geant4. Both
in Eclipse and in topas/geant4 the same beam data were used. The beam data
were commissioned to match the beam delivery system at the Marburg Ion-Beam
Therapy Center (MIT). The ionization chambers and multi-wire chambers of the
beam monitor system were modeled in topas/geant4. The source parameters
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like initial proton energy, beam divergence and spot size were optimized so that
calculated depth dose curves, spot sizes, and dose cubes matched measurements
performed at MIT.
The calculation of treatment plans optimized with Eclipse were performed in two sce-
narios in topas/geant4: in a first scenario, the density of each voxel in the lung
was not modulated but set to a constant value of 0.26 g/cm3. This non-modulated
case corresponds to the prediction from the TPS that does not consider the hetero-
geneity of the lung tissue. In a second scenario, the density of each voxel in the lung
was modulated according to modulation powers of 250 µm, 450 µm, and 800 µm.
The dose distribution from this modulated case corresponds to the dose distribution
as it would occur in the patient due to the lung modulation. By comparing the dose
distributions from the non-modulated and the modulated case the effects due to the
Bragg peak degradation can be investigated. The modulation powers were chosen
in order to cover both the average and extreme modulation powers as measured by
Witt (Witt 2014). By using a modulation power of 800 µm a conservative estimation
of the effects due to the lung modulation is possible.
The general effects due to the Bragg peak degradation were investigated by means
of depth dose curves and dose-volume histograms (DVH) as shown in figure 3.4 (this
figure corresponds to figure 3 in article 2). The Bragg peak degradation leads to
a lower dose at both the proximal and especially the distal end of the target region
compared to the prediction from the TPS. Additionally, a higher dose is deposited in
distal normal tissue. Hence, the TPS overestimates the dose deposited in the PTV
and underestimates the dose deposited in distal normal tissue. The underdosage of
the GTV can clearly be seen in the DVH. The underdosage of the GTV increases
with an increasing modulation power.
In order to investigate the dependency of the Bragg peak degradation on the depth
of the tumor in lung and the tumor's volume, the difference in average dose Dmean
deposited in the PTV between the non-modulated and modulated case was deter-
mined for all CT-based phantoms. In figure 3.5 (this figure corresponds to figure 4
from article 2) the difference in Dmean is shown in dependency on the depth dL of
the tumor in lung for the different tumor volumes. The difference in Dmean increases
with an increasing dL. Additionally, it increases with a decreasing tumor volume.
The difference in Dmean is almost directly proportional to dL while the slope of the
line depends on the tumor volume. For the smallest dL = 2 cm and the largest
tumor volume (43 cm3) the Bragg peak degradation leads to a reduction of Dmean
by less than 1%. For the largest dL = 20 cm and the smallest tumor volume (1 cm3)
the difference in Dmean is ∼-8%. For the largest dL = 20 cm and the largest tumor
volume (43 cm3) the difference in Dmean is ∼-3%.
For the ellipsoid-shaped tumors it was found that the difference in Dmean depends
on the orientation of the tumor rather than on its volume: for the short axis be-
ing parallel to the beam axis the underdosage of the PTV was up to three times
larger compared to when the long axis was parallel to the beam axis. An empirical
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Figure 3.4: Depth-dose curve (a) and the corresponding dose-volume histogram
(DVH) (b) with and without simulation of the lung modulation effect for
two exemplary modulation powers. The modulating lung tissue starts at
a depth of 2 cm. The position of the tumor volume is indicated by black
lines. The depth dose curve in panel (a) and the corresponding dose-
volume histogram in panel (b) feature a small tumor volume. Figure
taken from (Flatten et al. 2019). © Institute of Physics and Engineer-
ing in Medicine. Reproduced with permission. All rights reserved.
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Figure 3.5: Difference in the mean dose due to the Bragg peak degradation for the
spherical tumor volumes in dependency on the depth of the tumor in
lung dL. In this case the results for a modulation power of 450 µm are
shown. Figure taken from (Flatten et al. 2019). © Institute of Physics
and Engineering in Medicine. Reproduced with permission. All rights
reserved.
parameter Ls was found to describe both the tumor volume and its shape:
Ls = 2 · a
2
√
b · c (3.7)
a denotes the axis of the ellipsoid parallel to the beam while b and c denote the
lateral axes perpendicular to the beam. Ls can be understood as the scaled length
of the tumor in beam direction. Using this scaled tumor length, the effect of the
Bragg peak degradation is directly proportional to the term dL/Ls combining the
parameters tumor volume, shape, and depth of the tumor in lung. Figure 3.6 (this
figure corresponds to figure 7 in article 2) shows the difference in Dmean for all
CT-based phantoms investigated in the study in dependence on dL/Ls. With an
increasing dL/Ls and hence a larger depth of the tumor in the lung and a smaller
scaled tumor length, the difference in Dmean increases linearly. The slope is larger
for larger modulation powers of the lung tissue. By using a linear fit for each
modulation power the effects due to the Bragg peak degradation can be estimated
for any clinically possible tumor scenario.
At last, the influence on the longitudinal spot spacing on the effects due to the
Bragg peak degradation was analyzed. The effects were smaller for a wider spot
spacing of 3 MeV compared to 1 MeV. The background is that plans with a wider
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Figure 3.6: Difference in the mean dose in % for all CT-based phantoms investi-
gated in dependency on the depth of the tumor in lung (dL) divided by
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tively. Figure taken from (Flatten et al. 2019). © Institute of Physics
and Engineering in Medicine. Reproduced with permission. All rights
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energy spacing often have a worse conformity compared to plans with a narrower
spot spacing. In that case, the Bragg peak degradation has a smoothing effect on
the dose distribution. Due to this smoothing effect the dose profile is flattened but
the reduction in the mean dose Dmean is not as large as when compared to plans
with a higher conformity where the smoothing effects more likely result in a larger
reduction of Dmean.
The lateral spot spacing has no significant influence on the effects of the Bragg peak
degradation.
3.1.3 Article 3
In the third article (Baumann et al. 2019b), clinical treatment plans of NSCLC pa-
tients were investigated to quantify the effects of the Bragg peak degradation for
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clinical cases and to give a conservative approximation of the lung modulation ef-
fects.
Five exemplary clinical cases with tumor volumes between 2.7 cm3 and 46.4 cm3
were investigated. The tumors were located either at the center of the lung or the
vicinity of soft tissue as well as organs at risk (OAR), especially the spinal cord. No
tumors were located near the chest wall in order to always have lung tissue between
the thorax wall and the tumor and hence in the beam path. Although small tumor
volumes might not benefit from PT compared to photon-based SBRT as described
in chapter 1.3, small tumor volumes were investigated anyway. The background is
that such small tumors have been treated at different centers (Hata et al. 2007; Bush
et al. 2004; Chen et al. 2019) and hence an investigation of these tumor volumes is
reasonable. Additionally, following the results from article 2 the effects of the Bragg
peak degradation increase with a decreasing tumor volume. Hence, by investigating
such small tumor volumes an upwards estimation of the lung modulation effects can
be made.
For all patients treatment plans were optimized with Eclipse v.13.7 (VARIAN). The
total prescribed dose was 30 Gy (RBE) and the only planning objective was to de-
liver at least 95% of that prescribed dose to at least 98% of the PTV. The PTV was
the CTV plus an isotropic margin of 3 mm. The treatment plans were optimized
on static CT data ignoring movements of the anatomy due to respiration. For each
patient three different treatment plans were optimized as shown in figure 3.7 (this
figure corresponds to figure 1 in article 3): each plan consisted of one single field
coming from either 0◦, 270◦ or 315◦. The plans were chosen to be simple in order
to highlight the effects due to the Bragg peak degradation. The use of different
beam directions enables scenarios with different depths of the tumor in the lung and
different relative positions of the PTV and OARs, especially cases where the OAR
is located distal to the PTV since the Bragg peak degradation leads to an enhanced
dose distal to the PTV. The depths of the tumors in lung were between 1.5 cm and
12.2 cm depending on the patient and beam direction as shown in table 1 in arti-
cle 3. The distal spot spacing was 3 mm and the lateral spot spacing was 0.45 times
the FWHM of the beam spot. At last, two exemplary IMPT plans were optimized
for the patients with the largest and smallest tumor volume to investigate the lung
modulation effects on more complex treatment plans. Multi-field optimization was
enabled to optimize three fields for each plan. The same PTV concept and planning
objectives were used as for the simple plans.
Analogue to article 2, all treatment plans were subsequently calculated in
topas/geant4 in two different scenarios: in the non-modulated case the density
of the voxels associated with the lung was not modulated but the average values
as predicted by the CT were taken. In the modulated case the density of the vox-
els associated with the lung were modulated according to modulation powers Pmod
of 100 µm, 250 µm, 450 µm, and 800 µm to cover the whole range of modulation
powers determined for human lung tissue samples and ex-vivo porcine lungs (Witt
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Figure 3.7: CT slices of one exemplary patient: for the beam directions 0◦, 270◦, and
315◦ plans were optimized individually consisting of one single field. On
the bottom right the sum of these plans is shown. The CTV is marked in
white, trachea in light green and spinal cord in red. On the right a color
bar is given indicating the relative dose. Figure taken from (Baumann
et al. 2019b).
2014) with some additional buffer. By comparing the dose distributions from both
scenarios, the effects due to the Bragg peak degradation can be analyzed.
As shown in article 2, the lung modulation leads to an underdosage of the PTV and
an overdosage of distal normal tissue if not accounted for in the treatment-planning
process. This effect is visualized in figure 3.8 (this figure corresponds to figure 6
in article 3): exemplary isodose lines (ICRU 1993, 1999) are shown for 95%, 80%,
and 20% of the prescribed dose for the non-modulated and modulated case for se-
lected treatment plans. For all cases the region of the 95% and 80% isodose lines
is smaller for the modulated case compared to the non-modulated case and hence
the prediction from the TPS demonstrating the underdosage of the target volume.
Additionally, the range of the 20% isodose lines is greater in the modulated cases.
This greater range of the 20% isodose lines demonstrates the potential overdosage of
distal normal tissue and OARs - especially for the cases, where the tumor is located
near to an OAR. However, the maximum additional range of the 20% isodse lines
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is 2 mm in soft tissue and 5 mm in lung tissue. For the 95% and 80% isodose lines
the maximum loss in range is 8 mm (for 95% isodose lines) and 10 mm (for 80%
isodose lines) in lung tissue. In soft tissue the maximum loss in range is 4 mm (for
95% isodose lines) and 3 mm (for 80% isodose lines).
Additionally, the effects of the Bragg peak degradation were investigated in terms
of the mean dose Dmean deposited in the CTV as well as the dose values D98% (dose
that is received by 98% of the volume) and D2%. For the CTV the underdosage
due to the lung modulation effects was increasing for a) an increasing modulation
power Pmod, b) an increasing depth of the tumor in lung, and c) a decreasing tumor
volume. No systematic differences between Dmean, D98%, and D2% were observed.
The maximum underdosage was ∼5% for Pmod = 800 µm. The average underdosage
was in the order of 2%. Note that Pmod = 800 µm is an extreme modulation power.
For a more common modulation power of 450 µm the maximum underdosage of the
CTV was roughly 3% with an average underdosage of ∼1%. For smaller modulation
powers there were cases where the underdosage of the CTV was smaller than 0.5%.
Concerning OARs, effects due to the Bragg peak degradation were only seen for
scenarios where an OAR was located distal to the CTV. The overdosage was up to
24% in terms of Dmean, however, this large relative overdosage corresponds to low
absolute dose values of only 0.3 Gy at maximum.
A gamma index analysis was performed to assess these dose deviations clinically. For
each treatment plan the dose distributions from the non-modulated and the mod-
ulated scenario were compared. For a gamma index 3%/1 mm (local) the passing
rates were 90.4% or larger for a modulation power of 800 µm. The average passing
rate for all treatment plans was 96.8%. For a modulation power of 450 µm the
minimal passing rate was 93.1% and the average passing rate was 98.5%.
At last, IMPT plans were investigated in order to evaluate whether the results for
the simple treatment plans consisting of only one field can be used to estimate the
dose uncertainties due to the Bragg peak degradation on more complex plans. The
dose reductions in the CTV were -1% and -3% for the two plans investigated and
for a modulation power of 450 µm. Hence, the dose uncertainties for complex IMPT
plans are in the order of the dose reductions observed for the simple treatment plans.
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Figure 3.8: Isodose lines for 95%, 80%, and 20% of the prescribed dose. In pink
for the non-modulated case, in green for the modulated case based on a
modulation power of 800 µm. In the first column the 95%, in the middle
column the 80%, and in the right column the 20% isodose lines. Different
patient cases are marked in white numbers. The CTV is marked in white,
the trachea in light green and the spinal cord in red. Figure taken from
(Baumann et al. 2019b).
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3.2 Contributions
Article 1:
K.-S. Baumann created the voxelized geometries and applied the density proba-
bility functions. K.-S. Baumann performed all MC simulations and analyzed the
data. K.-S. Baumann wrote the manuscript and created all figures.
M. Witt contributed to this study with his experimental investigations of modu-
lation powers using ex-vivo porcine lungs. M. Witt helped with the simulation of
high-resolution CT images of human lung samples.
U. Weber came up with the idea of modulating the density of lung voxels. U. Weber
originally had the idea of the mathematical model describing voxelized geometries.
U. Weber created the tool to optimize the density probability functions. U. Weber
substantively revised this manuscript.
R. Engenhart-Cabillic substantively revised this manuscript and was supervising
the work. R. Engenhart-Cabillic helped with the clinical assessment.
K. Zink substantively revised this manuscript and was supervising the work. K.
Zink helped with the physical assessment.
Article 2:
V. Flatten designed the study. V. Flatten optimized all treatment plans and
wrote the script to export the treatment plans into topas/geant4. V. Flatten
analyzed the simulation results. V. Flatten wrote the manuscript and created all
figures.
K.-S. Baumann helped with the design of the study and created all CT-based
phantoms. K.-S. Baumann created the density modulated CT-based phantoms and
executed the MC simulations as well as commissioned the beam monitor system of
the Marburg Ion-beam therapy center used in topas/geant4. K.-S. Baumann
helped with analyzing the simulation results.
U. Weber came up with the idea of modulating the density of lung voxels. U. Weber
originally had the idea of the mathematical model. U. Weber created the tool to
optimize the density probability functions.
R. Engenhart-Cabillic substantively revised this manuscript and was supervising
the work. R. Engenhart-Cabillic helped with the clinical assessment.
K. Zink substantively revised this manuscript and was supervising the work. K.
Zink helped with the physical assessment.
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Article 3:
K.-S. Baumann used the mathematical model to generate the density modula-
tion functions needed for the density modulation to reproduce the Bragg peak
degradation in the MC simulations. K.-S. Baumann created the density modulated
DICOM sets and executed the MC simulations as well as designed the beam moni-
tor system of the Marburg Ion-beam therapy center used in topas/geant4 for
all simulations. K.-S. Baumann analyzed the DVHs produced with Eclipse. K.-S.
Baumann wrote the manuscript and created all figures.
V. Flatten optimized the treatment plans and transferred these optimized plans to
the MC code TOPAS and subsequently generated the DVHs.
U. Weber came up with the idea of modulating the density of lung voxels. U. Weber
originally had the idea of the mathematical model. U. Weber created the tool to
optimize the density probability functions.
S. Lautenschläger and F. Eberle contributed to this work by contouring the DICOM
sets and helped with clinical information on treatment plans.
K. Zink substantively revised this manuscript and was supervising the work. K.
Zink helped with the physical assessment.
R. Engenhart-Cabillic substantively revised this manuscript and was supervising
the work. R. Engenhart-Cabillic helped with the clinical assessment.
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Chapter 4
Discussion
4.1 Mathematical model and modulation power
The microscopic voxelized geometry proved to be a useful tool to generate degraded
Bragg peaks. Using a simple mathematical model, the degradation effects of the
voxelized geometry can be predicted. It was possible to generate all modulation
powers as determined for human lung tissue samples and ex-vivo porcine lungs (Witt
2014). It was shown that the modulation power is directly proportional to the
structure size d of the voxels used in the microscopic geometry. This suggests that
the modulation power of human lungs is not the same at every position in the
lung. In regions with small structure sizes like the peripheral region, the modulation
power is predicted to be smaller compared to the central lung where the structures
are larger. However, detailed measurements are missing that provide information
about region-specific modulation powers.
Furthermore, the mathematical model can be used to determine the modulation
power from measured degraded dose distribution. This is done by optimizing the
mean value t and standard deviation σt of a normal distribution in order to minimize
the difference between the degraded dose distribution and the convolution of an
unperturbed pristine dose distribution with the normal distribution. The modulation
power equals Pmod = σ2t /t. The predicted modulation powers for the voxelized
geometries were validated using MC calculations. The actual modulation powers
agreed with the predictions within 3.7% or better.
Using the mathematical model, lung substitutes can be designed mimicking different
lung tissues that can be used for measurements in proton beams (Baumann et al.
2019a). For a given modulation power Pmod and geometrical thickness D of the lung
tissue the normal distribution F (t′|t, σt) can be derived via t = ρmean/ρH2O ·D and
σ2t = Pmod · t. Both the modulation power and thickness of lung tissue that shall be
mimicked can be chosen at will. An exemplary lung substitute is shown in figure 4.1:
the substitutes consist of pins each having a lateral extension of 4×4 mm2 and each
having the same shape. To design the shape of a pin it is divided into 100×100
columns while the height of each column is sampled following the normal distribution
F (t′|t, σt). The columns within the pin are re-arranged to form a pyramidal shape
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Figure 4.1: An exemplary lung substitute consisting of four pins. The shape of the
pins is designed using the mathematical model. Particles traversing the
lung substitute at different positions of the pins traverse different heights
of material and hence experience different energy losses resulting in a
Bragg peak degradation. Figure taken from (Baumann et al. 2019a)
in order to get a higher stability. The substitutes can be produced subsequently
using a 3D-printer. Particles traversing the substitute at different positions of the
pins traverse different heights of material and hence experience different energy
losses resulting in a Bragg peak degradation1. The so-designed lung substitutes
were validated with MC simulations and proven to reproduce the chosen modulation
power (Baumann et al. 2019a).
1This technique of modulating the beam is already being exploited in particle therapy with
carbon ions where ripple filters are used to improve the depth dose distributions of 12C ions (Weber
and Kraft 1999).
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4.2 Density modulation of clinical voxels
The microscopic heterogeneous voxelized geometries representing the human lung
tissue were replaced by coarser voxels with dimensions typical for treatment-planning
CT-images. The current problem is that in these clinical CT-images the heteroge-
neous structure of the lung tissue is not fully resolved and hence the consideration
of lung modulation effects is hardly possible. To solve this problem, density proba-
bility functions were derived for these clinical voxels. By modulating the density of
each voxel the Bragg peak degradation from the microscopic heterogeneous voxelized
geometries could be reproduced. The dose distributions generated with the density-
modulated voxels of clinical dimensions matched the dose distributions generated
using the microscopic voxelized geometries almost perfectly. The modulation pow-
ers agreed within 2.7% or better. Hence, a solution is established to reproduce the
Bragg peak degradation due to the heterogeneous lung tissue on the basis of clinical
treatment-planning CT-images. The whole range of modulation powers determined
for human lung tissue samples and ex-vivo porcine lungs has been covered using this
method. Additionally, it is in principle possible to derive the density modulation
function for any voxel size and modulation power making this tool usable for any
clinical CT-image and patient.
At last, it was shown that the Bragg peak degradation cannot be reproduced when
the density is not modulated but an average density is assigned to each voxel. This
corresponds to the current clinical state-of-the-art since an average density is applied
to each voxel in the CT-image since the heterogeneous structure of the lung tissue
is not fully resolved. This demonstrates the potential dose uncertainties due to the
current clinical practice. Furthermore, this demonstration motivates the need for
the solution presented in this study that enables an estimation of dose uncertainties
due to lung modulation effects.
4.3 Dependency of the lung modulation effects on
geometrical parameters
The dose uncertainties due to lung modulation effects were estimated using CT-based
phantoms. These phantoms were created to simulate typical anatomical scenarios
for lung cancer patients. The chest wall as well as the mediastinum or other distal
normal tissue were considered. Tumors of different volumes positioned at different
depths were inserted in the lung. In all cases, an undersdosage of the tumor volume
was found. Hence, the TPS overestimates the dose deposited in the target volume
if lung modulation effects are not considered during the treatment-panning process
which is currently not possible in state-of-the-art TPS. The underdosage of the target
volume increases with a) an increasing modulation power, b) an increasing path the
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protons are traversing through lung tissue, and c) a decreasing scaled tumor length
in beam direction. The results suggest that the difference in mean dose in the PTV
is roughly -2% for clinically realistic scenarios (an average tumor volume that is
located at 6 cm depth in lung using a modulation power of 250 µm).
4.4 Effects of the lung modulation on clinical treat-
ment plans
The influence of the Bragg peak degradation due to lung tissue was investigated
on treatment plans of lung cancer patients. For all cases the TPS overestimated
the dose deposited in the target volume and underestimated the dose deposited in
normal tissue or OARs located distal to the target volume. It was shown that this
effect increases with an increasing modulation power which is in agreements with the
findings from the CT-based phantom study. The maximum overestimation of the
mean dose Dmean in the CTV was 5% for an extreme modulation power of 800 µm
while the average overestimation was 2%. For a more realistic modulation power of
450 µm the maximum overestimation was 3% with an average of 1%.
Concerning the underestimation of dose deposited in OARs, it was shown that the
relative position between the target volume and OAR is crucial, since the Bragg
peak degradation leads to an overdosage of normal tissue at the distal end. Hence,
an overdosage is only expected for scenarios where the OAR is located distal to the
target volume. Such beam directions are normally avoided due to the range un-
certainties connected to PT as described in chapter 1.4. However, since a patient's
anatomy can oblige to use beams where an OAR is positioned distal to the PTV,
these cases were investigated anyway. The lung modulation effects resulted in a
maximum dose enhancement of ∼0.3 Gy in terms of the average dose in the cases
investigated. For the D2% the maximum enhancement was 1.5 Gy. However, the
resulting enhanced doses deposited in OARs were far from any dose constraints used
in the conventional treatment planning. Thus, the lung modulation effects on OARs
distal to the target volume are negligible for the cases investigated. Note that for
cases where the OAR is located nearer to or even directly next to the PTV, the
effects due to the Bragg peak degradation might become clinically relevant.
Concerning the dependency of the lung modulation effects on geometrical parame-
ters like depth of the tumor in lung and volume of the tumor, the findings from the
CT-based phantom study could be reproduced.
The treatment plans used in the study were held simple and consisted of only one
field in order to highlight the effects due to the Bragg peak degradation and to create
a large variety of clinical scenarios concerning the depth of tumor in lung or if OARs
are positioned distal to the PTV. However, two IMPT plans were investigated as
well to assess whether the results obtained with the help of simple treatment plans
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can be applied to more complex plans. For both IMPT plans the underdosage of the
CTV was in the order of the underdosage for the simple treatment plans. Hence,
the results from the study can be used to estimate the dose uncertainty due to lung
modulation effects for more complex plans.
The passing rate of the gamma index 3%/1 mm (local) was on average 96.8% for
an extreme modulation power of 800 µm. For a more realistic modulation power of
450 µm the average passing rate was 98.5%. The high passing rates are reasonable
since the investigation of isodose lines showed that the lung modulation effects lead
to a shift of these isodose lines. This shift is on average very small and hence, it is
covered by the distance-to-agreement in the gamma index. All gamma index passing
rates were clinically acceptable for the cases investigated. In combination with the
findings that the underdosage of the CTV is on average -1% and at maximum -3%
for a realistic modulation power, this supports the statement that the lung mod-
ulation effects are clinically tolerable in the current clinical context which will be
discussed in more detail in chapter 4.5.
What is more, this shift of the physical dose due to the Bragg peak degradation
might partially be balanced out by the biological effectiveness of protons: as de-
scribed in chapter 1.4 it is well-known that the RBE might be larger than 1.1 at the
end of the Bragg peak. Hence, the region of the larger RBE is congruent with the
region where the physical dose is reduced due to the lung modulation. However, the
larger RBE at the distal end could also potentially increase the effect of the lung
modulation that a larger dose is deposited in distal normal tissue.
Since it is not possible to include the Bragg peak degradation during the treatment-
planning process in current state-of-the-art TPS, potential PTV concepts might be
introduced. The Bragg peak degradation leads to a shift of the dose and hence a
reduction of the dose deposited both in the proximal and distal region of the target
volume. This shift could be compensated for by adding a corresponding margin at
the proximal and distal end of the CTV. In figure 4.2 (this figure corresponds to
figure 7 in article 3) the results of such a PTV concept are shown. The original
isotropic margin of 3 mm as used in the study was enlarged to 5 mm at the proximal
end and 7 mm at the distal end resulting in an acceptable dose coverage of the CTV.
However, when using such a PTV concept the dose deposited in distal normal tissue
is enhanced significantly. An alternative PTV concept might consist of a boost in
exactly the region where the dose is decreased due to the lung modulation effects.
By prescribing a larger dose in the 3 mm margin at both the proximal and distal
end, an acceptable dose coverage in the CTV can be achieved, however, the sparing
of distal normal tissue is better compared to the first PTV concept.
In all studies it was shown that the lung modulation effects strongly depend on the
modulation power. The larger the modulation power the larger the effects due to
the Bragg peak degradation. Hence, the knowledge of the patient-specific modu-
lation power is a crucial issue still to be solved. Until now, the modulation power
can only be estimated using measurements as performed by Witt (Witt 2014) or
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Titt et al. (Titt et al. 2015). To improve the accuracy of PT for lung cancer pa-
tients, the knowledge about the space-resolved modulation power for each patient is
essential.
4.5 Clinical context of dose uncertainties due to
lung modulation effects
As described in chapter 1.4, the lung modulation is not the only challenge con-
nected to PT of lung cancer patients. In a study by Paganetti (Paganetti 2012) an
overview of range uncertainties in PT is given. Range uncertainties occur due to
measurement uncertainties in water for the commissioning of the particle accelerator
(±0.3 mm), the patient setup (±0.7 mm) and differences between dose calculations
performed with the TPS and MC simulations as a gold standard (±2 mm). Further
range uncertainties arise due to uncertainties in the RBE models (0.8% of the range
or ∼3 mm (Carabe et al. 2012)) and the approximation of stopping powers from
x-ray HU (±1% of the range). The values as presented by Paganetti (Paganetti
2012) refer to the shift of the 80% distal dose and are average range uncertainties.
Furthermore, the values might be larger in lung cancer patients (Paganetti 2012).
The maximum shift of the 80% isodose lines due to the lung modulation effects
for an extreme modulation power of 800 µm for the patient plans investigated was
10 mm in lung and only 3 mm in soft tissue and hence smaller than the average
range uncertainties as described by Paganetti (Paganetti 2012).
Additionally, range and dose uncertainties arise due to possible changes of the pa-
tient's anatomy. Szeto et al. (Szeto et al. 2016) showed that an undercoverage of the
target volume between 2 GyE and 12 GyE can occur when anatomical changes are
not accounted for in the treatment-planning process. This corresponds to a relative
underdosage of between 3% and 18%. The largest underdosage found for the patient
plans investigated was 3% for a realistic modulation power of 450 µm.
Furthermore, motion plays an important role for lung cancer patients.
Dowdell et al. (Dowdell et al. 2013) investigated interplay effects for 5 lung cancer
patients. Due to the interplay effects the average dose in the target volume was
only between 88% to 92% of the prescribed dose. Hence, the effects due to motion
are significantly larger compared to the lung modulation effects. Note that these
interplay effects are highly patient-specific.
In conclusion, the effects due to the lung modulation are currently clinically toler-
able to a certain degree in the clinical context considering the various more critical
dose and range uncertainties in PT.
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Figure 4.2: The effects of different PTV concepts. In (a) the effects for a 3 mm
isotropic margin around the CTV. In (b) for a PTV concept that uses
an enlarged margin at the proximal and distal end. The concept in (c)
uses a 3 mm isotropic margin and a dose boost at the proximal and
distal end. The CTV and the margin as well as the resulting PTV are
marked in dashed lines. The red line marks the prescribed dose within
the PTV. Figure taken from (Baumann et al. 2019b)
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Chapter 5
Conclusion and outlook
The effects of the lung modulation due to the microscopic density heterogeneity of
lung tissue were investigated. With the help of microscopic voxelized geometries as
representatives of lung tissue degraded Bragg peaks were calculated with the MC
code topas/geant4. The degradation effects of these voxelized geometries can
be described by a normal distribution. This normal distribution gives the proba-
bility that a path through the geometry has a specific water-equivalent thickness.
Additionally, this normal distribution can be used to estimate the degraded dose
distribution by convolving an unperturbed pristine Bragg peak with this normal
distribution. Furthermore, the material characteristic modulation power can be de-
rived from the normal distribution.
Intensive MC simulations were carried out to validate this mathematical model. It
was shown that the simulated modulation powers for different voxelized geometries
agreed with the predictions from the mathematical model within 3.7% or better.
Subsequently, these microscopic voxelized geometries were replaced by clinical voxels
with an edge length of 2 mm. Hence, the transition from the microscopic lung tissue
as it is present in the patient to coarser clinical structures that cannot resolve the
fine lung structure is performed. By modulating the density of these clinical voxels
the degraded dose distributions could be reproduced while the modulation powers
agreed within 2.7% or better. The density probability function was derived from the
normal distribution. Thus, a solution is found to reproduce the Bragg peak degra-
dation due to the heterogeneous structure of lung tissue based on clinical CT-images
that do not resolve the microscopic structures of the human lung tissue.
Using this density modulation, the effects of the Bragg peak degradation were inves-
tigated on CT-based phantoms. These phantoms were designed to correspond to the
anatomical situation for lung cancer patients. Different tumor volumes were placed
at different depths in the lung. It was shown that state-of-the-art TPS overestimate
the dose deposited in the target volume and underestimate the dose deposited in
distal normal tissue when the lung modulation is not accounted for. It was shown
that this effect increases with an increasing modulation power, an increasing depth
of the tumor in lung, and a decreasing extent of the tumor in beam direction.
At last, the effects due to the lung modulation were investigated for clinical treat-
ment plans. The effects and dependencies found in the CT-based phantom study
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were reproduced. The overestimation of the mean dose in the CTV was 5% at max-
imum for an extreme modulation power of 800 µm. For a more realistic modulation
power the overestimation was 3% at maximum. For all cases investigated the effect
on OARs distal to the target volume was negligible. The investigation of treatment
plans confirms that the lung modulation effects are clinically tolerable to a certain
degree in the current clinical context considering the various more critical dose and
range uncertainties in PT. Additionally, by using corresponding PTV concepts as
suggested, the effects of the Bragg peak degradation might be accounted for.
An essential parameter describing the lung modulation is the modulation power of
the lung tissue. So far, there are only scarce experimental data quantifying the
modulation power. Hence, an issue still to be solved is a solution to determine
the modulation power of lung tissue for each patient individually. Currently under
investigation is the possibility to derive the modulation power from CT-images by
analyzing the histogram of predicted densities for different resolutions of the CT-
scanner. First results suggest that an estimation of the modulation power should be
possible on the basis of clinical CT-images.
Furthermore, techniques have to be developed to consider the lung modulation effects
during the treatment-planning process. The solution presented in this dissertation
can only estimate the dose uncertainties due to the Bragg peak degradation but can
currently not be used to consider the lung modulation effects during the treatment-
planning process. Such a consideration would enable a robust treatment planning. A
solution could be to directly use degraded beam data when optimizing the treatment
plans and hence, directly including the lung modulation effects in the optimization
and dose calculation process.
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Chapter 6
Side project: dosimetric calculations
in clinical proton beams
The aim of this project was to adjust the MC code topas/geant4 for dosime-
try calculations in high-energy photon and proton beams. The main goal was to
calculate beam quality correction factors kQ,Q0 for plane-parallel and cylindrical
ionization chambers in clinical proton beams.
The background is that most national and international dosimetry protocols for
the determination of absorbed dose in photon and proton beams (e.g. IAEA-
TRS398 (Andreo et al. 2000), AAPM TG-51 (Almond et al. 1999), DIN 6800-2 (DIN
2006), and DIN 6801-1 (DIN 2019)) are based on standards of absorbed dose to wa-
ter. The determination of the absorbed dose to water can be performed with air-filled
ionization chambers. These chambers are calibrated in a reference beam quality Q0
in order to get a correlation between the measured charge produced inside the cavity
and the absorbed dose to water. However, when an ionization chamber is used in a
beam quality Q different from the reference beam quality, the user has to correct the
chamber reading for the different response of the chamber in different beam quali-
ties. This beam quality correction factor kQ,Q0 corrects the chamber reading by a
few percent and is ideally determined for each chamber used and at exact the beam
quality Q at which the chamber will be operated. The experimental determination
using calorimetry requires a high experimental effort and hence, is not convenient
for most laboratories. The determination with the help of MC simulations is an
efficient alternative.
Currently, the IAEA TRS-398 Code of Practice (CoP) is being updated. Beneath
other things, fully MC calculated kQ,Q0 factors shall be provided in the upcoming
version which is not the case in the current version. Therefore, the RTNORM project
(RTNORM 2019) is helping the IAEA working group by providing MC calculated
kQ,Q0 factors. However, the data for MC calculated kQ,Q0 factors in proton beams
is scarce with only two studies (Gomà et al. 2016; Gomà and Sterpin 2019) that use
the MC code penh to calculate kQ,Q0 factors in proton beams in agreement with
experimentally determined values on the 1% level.
In order to provide more MC calculated kQ,Q0 factors in proton beams, especially
calculated with a MC code different than penh, topas (Perl et al. 2012) a toolkit
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based on the MC code geant4 (Agostinelli et al. 2003) shall be investigated for
its suitability to calculate kQ,Q0 factors in proton beams.
In general, kQ,Q0 factors are calculated with the use of MC codes as follows (Andreo
et al. 2013):
kQ,Q0 =
fQ
fQ0
Wair,Q
Wair,Q0
=
(
Dw/D¯air
)
Q(
Dw/D¯air
)
Q0
Wair,Q
Wair,Q0
(6.1)
Q denotes the user beam quality and Q0 the reference beam quality (mostly a 60Co
spectrum). Note that, when 60Co gamma radiation is the reference beam quality,
the subscript Q0 is typically omitted and kQ is used instead of kQ,Q0 . The factor f is
chamber-specific and depends on the beam quality. It gives the proportionality be-
tween the absorbed dose to water at the reference point when the chamber is absent
(Dw) and the average absorbed dose to air in the cavity of the air-filled ionization
chamber (D¯air) (Sempau et al. 2004). Wair,Q is the mean energy necessary to create
an ion pair in air depending on the beam quality Q.
Thus, for the calculation of kQ factors in proton beams calculations in both photon
and proton beams are necessary. Hence, at first, the MC code topas/geant4
has to be adjusted for calculations in proton beams (this was done in arti-
cle 4 (Wulff et al. 2018)). Subsequently, the code has to be adjusted for calcu-
lations in photon beams (this was done in article 5 (Baumann et al. 2019c)). At
last, topas/geant4 can be used to calculate kQ factors in proton beams for
real ionization chambers while the results have to be compared to experimentally
determined kQ factors (this was done in article 6 (Baumann et al. 2020)).
In article 4 the main task was to adjust the physics settings for calculations in clin-
ical proton beams. Therefore, a Fano cavity test was performed for different physics
lists and values of the parameter dRoverR. This parameter controls the length of a
CH step in relation to the residual range of the particle. It was shown that the Fano
cavity test is violated by less than 0.2% for protons when the physics module EM-
StandardOpt4 and a dRoverR = 0.05 is used. To adjust the production cut-off range
fQ factors for simple air-filled cavities were calculated in a 150 MeV proton beam
for various values of the production cut-off range. It was shown that the fQ factor
depends on the production cut and that the cut has to be smaller than 5 µm which
corresponds to ∼15 keV electrons in water. After adjusting the physics parameters,
fQ factors were calculated for the IBA NACP-02 and Farmer NE 2571 chamber for
various monoenergetic proton beams between 70 MeV and 250 MeV. Two differ-
ent nuclear interaction models (Binary cascade (BIC) and Bertini cascade (BERT))
were compared. The fQ factors agreed with fQ factors calculated by Gomà et al
(Gomà et al. 2016) within 0.6% or better. The difference in fQ factors between the
nuclear interaction models BIC and BERT was 0.3% at maximum. Hence, the MC
code topas/geant4 can provide reliable results of ionization chamber response
calculations in primary proton beams.
In the next step, topas/geant4 was adjusted for the calculation of fQ0 factors of
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simple air-filled cavities as representative of plane-parallel and cylindrical ionization
chambers in high-energy photon beams in article 5. Furthermore, fQ factors in
proton beams were calculated and corresponding fQ/fQ0 ratios were derived. These
fQ/fQ0 ratios are the basis of MC calculated kQ factors and the only part that
can be calculated using the MC method. Additionally, the same calculations were
performed with the MC codes penh and fluka (Salvat 2013; Ferrari et al. 2005;
Böhlen et al. 2014). The results were compared between the codes. It was shown that
the physics settings used for clinical proton beams cannot be used for high-energy
photon beams in topas/geant4. Especially the value for dRoverR had to be set
to a smaller value. The parameters used for the photon simulations were adapted
following a study by O'Brien et al. (O'Brien et al. 2016) who performed a Fano cavity
test for high-energy photon beams. The calculated fQ/fQ0 ratios agreed within 0.7%
or better between the MC codes topas/geant4, penh, and fluka. Hence,
the results produced with topas/geant4 are comparable to those produced with
penh. This suggests that topas/geant4 can be used for the calculation of kQ
factors in proton beams since it has been proven that penh is able to calculate kQ
factors in agreement with experimental values on the 1% level. In order to investi-
gate where the differences between the codes might originate from, spectral fluences
of photons and protons as well as secondary electrons were calculated with all codes.
The results showed excellent agreement between the MC codes for the spectral flu-
ences of photons and electrons in the high-energy photon field. This implies that the
underlying electromagnetic interaction models used in the different MC codes are
similar. For the spectral fluences of protons and secondary electrons in the proton
field differences were observed for the spectra of secondary protons and electrons
produced by prompt gamma photons. The spectra of primary protons and delta
electrons showed an almost perfect agreement between the codes. The differences
in the spectrum of secondary protons and electrons produced by prompt gamma
photons suggests that the underlying more complex nuclear interaction models tend
to slight differences between the codes.
After the physics settings were adjusted in the MC code topas/geant4, fQ0 ,
fQ, and kQ factors in proton beams were calculated for six plane-parallel and four
cylindrical ionization chambers in article 6. The fQ0 factors were calculated in
60Co
radiation and compared to MC calculated fQ0 factors published in the literature.
The fQ0 factors calculated with topas/geant4 agreed with those provided in
the literature within 0.7% or better. The variance among the values provided in
the literature was on the 1% level. Hence, topas/geant4 can be used for the
calculation of fQ0 factors for both plane-parallel and cylindrical ionization chambers
in 60Co beams as long as the physics settings are adapted accordingly. The fQ fac-
tors calculated with topas/geant4 in monoenergetic proton beams agreed with
MC calculated fQ factors (calculated with penh) published in the literature within
1.7% or better. The differences between the MC codes increased for higher energies.
The reason might be that possible differences in the nuclear interaction models lead
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to larger differences for higher energies. However, the results are not sufficient to
clarify the role of nuclear interaction models for the calculation of fQ factors in
proton beams without doubt. The kQ factors calculated with topas/geant4
were compared to kQ factors calculated with penh. Again, significant differences
appeared for high energies. For smaller energies the agreement was better. Addition-
ally, kQ factors calculated with topas/geant4 were compared to experimentally
determined kQ factors provided in the literature. The agreement was on the 1% level
with only two exceptions. Note that these findings are restricted to energies between
100 MeV and 160 MeV since no experimentally determined kQ factors are available
for different energies. Nevertheless, the results prove that topas/geant4 can be
used to calculate kQ factors in clinical proton beams.
In conclusion, the physics settings in topas/geant4 were adjusted for dosime-
try calculations in high-energy photon and proton beams. With the use of a Fano
cavity test the physics settings for the proton beams were adjusted. The physics
settings for the high-energy photon beams were adjusted following the results from
O'Brien et al. (O'Brien et al. 2016). Subsequently, fQ/fQ0 ratios for simple air-filled
cavities as representatives of plane-parallel and cylindrical ionization chambers were
calculated with different MC codes and compared to each other. The difference
in fQ/fQ0 ratios between the codes was 0.7% at maximum. Based on these find-
ing, topas/geant4 was used to calculate kQ factors in clinical proton beams in
agreement with experimental values on the 1% level.
In the next step, perturbation correction factors for ionization chambers in proton
beams shall be calculated. From the fQ factors that are already calculated, to-
tal perturbation correction factors pQ can be derived as pQ = fQ/(sw,air)Q while
(sw,air)Q is the water to air stopping power ratio. The results indicate that pQ is
significantly different than unity for some chambers and proton energies in contrast
to the assumption from the TRS-398 CoP. Especially the contributions from the
single chamber parts like chamber stem, central electrode, chamber wall, and sleeve
shall be investigated.
Additionally, the investigation of nuclear interaction models for the calculation of
fQ factors remains an issue to be solved. This investigation might be performed by
building ionization chambers step by step in different MC codes and compare the
results for calculated fQ factors after each step. Hence, one might find the chamber
part or material that causes the differences between the MC codes.
Furthermore, the comparison of MC calculated kQ factors with experimentally de-
termined values is restricted to energies between 100 MeV and 160 MeV at the
moment, since no experimentally determined values are published for different en-
ergies. Hence, the experimental determination of kQ factors for higher energies is
important. Especially, regarding the differences between the different MC codes for
high energies.
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Abstract
Sub-millimetre-sized heterogeneities such as lung parenchyma cause Bragg 
peak degradation which can lead to an underdose of the tumor and an overdose 
of healthy tissue when not accounted for in treatment planning. Since 
commonly used treatment-planning CTs do not resolve the fine structure of 
lungs, this degradation can hardly be considered.
We present a mathematical model capable of predicting and describing 
Bragg peak degradation due to a lung-equivalent geometry consisting of 
sub-millimetre voxels filled with either lung tissue or air. The material 
characteristic ‘modulation power’ is introduced to quantify the Bragg peak 
degradation. A strategy was developed to transfer the modulating effects of 
such fine structures to rougher structures such as 2 mm thick CT voxels, which 
is the resolution of typically used CTs. This is done by using the modulation 
power to derive a density distribution applicable to these voxels. By replacing 
the previously used sub-millimetre voxels by 2 mm thick voxels filled with 
lung tissue and modulating the lung tissue’s density in each voxel individually, 
we were able to reproduce the Bragg peak degradation. Hence a solution is 
found to include Bragg curve degradation due to lung-equivalent materials in 
Monte Carlo-based treatment-planning systems.
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1. Introduction
Since proposed for radiation therapy, ion beams are of increasing interest in radiation oncol-
ogy (Wilson 1946, Smith 2006). The characteristic dose profile of ions in homogeneous media 
consists of a low dose plateau at small depths followed by the so-called Bragg peak with a 
well-defined distal fall-off and—in the case of protons—no dose behind. This finite range and 
sharp distal fall-off of the energy deposition are the major advantages of protons in radiation 
therapy, creating the possibility of conformal dose distribution in the target while sparing sur-
rounding healthy tissue (Chang et al 2006).
It was shown that this distal fall-off is blurred and the Bragg peak is broadened when the 
particles pass through heterogeneous media (Urie et al 1986, Sawakuchi et al 2008). On the one 
hand this effect is deployed for the benefit of particle therapy, for example in the case of ripple 
filters that are used to broaden the Bragg peak of mono-energetic particles (Weber and Kraft 1999, 
Ringbaek et al 2014). On the other hand, if it is not considered correctly, the broadening due to 
the heterogeneity of human lungs can lead to an underdose of the target volume and an overdose 
of the healthy tissue distal to the target (Goitein 1977, Sawakuchi et al 2008), which could sig-
nificantly influence the dose distribution in lung cancer patients (Espana and Paganetti 2011). 
Furthermore, the fine structure of the lung is not fully resolved in typical CT images due to the 
restricted resolution, predicting a more homogeneous tissue distribution (Espana and Paganetti 
2011, Titt et al 2015), making it even more challenging to consider the Bragg peak degradation 
due to missing information in the CT image. The effect that the CT averages the density over the 
volume of a voxel can—in the case of lung parenchyma—lead to variations in the Bragg peak 
dose of up to 11% and the distal fall-off width of up to 1.1 mm compared to the dose distribution 
obtained when the heterogeneous structure is exactly considered (Perles et al 2011).
To visualise the broadening effect of lung parenchyma, Sell et  al and Titt et  al used a 
3d-printed geometry built up of voxels each consisting of either air or plastics and both meas-
ured and simulated the effect on a 150 and 200 MeV proton dose distribution in a water phan-
tom downstream from the voxelised geometry (Sell et al 2012, Titt et al 2015). Furthermore 
Titt et al quantified the Bragg peak degradation when irradiating a plastinated human lung. 
The distal fall-off width from 80% to 20% of the maximum dose increased by up to 60% com-
pared to an unperturbed reference curve, thus indicating that distal edge degradation must be 
expected in proton treatment of lung tumors.
In other works by Ringbaek et al and Witt et al a voxelised geometry similar to the one used 
by Titt et al was taken to develop a mathematical model capable of predicting and describing 
Bragg peak degradation due to lung-like materials (Witt et al 2015, Ringbaek et al 2017). This 
mathematical model was verified by Monte Carlo simulations.
In this study we present a simple solution to include and consider this Bragg peak degra-
dation in Monte Carlo codes and therefore Monte Carlo-based treatment-planning systems.
We implemented a voxelised geometry consisting of sub-millimetre voxels filled with 
either lung tissue or air in the Monte Carlo code Geant4 using the toolkit TOPAS. This geom-
etry is used to demonstrate and understand the modulating effects due to heterogeneous mat-
erials such as lung parenchyma.
The broadened dose distribution downstream from the voxelised geometry can be 
described by convolving an unperturbed reference curve with a normal distribution. From 
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the param eters of this normal distribution a material characteristic we refer to as ‘modulation 
power’ is derived, which quantifies the strength of the modulating effect.
Since the resolution of CT images typically used for treatment planning is too low to 
resolve such fine sub-millimetre voxels, a strategy is developed to transfer the modulating 
effects of such fine structures to rougher structures such as 2 mm thick voxels: the previously 
used voxelised geometry consisting of sub-millimetre voxels was replaced by 2 mm thick 
voxels filled with lung tissue. In subsequent simulations the density of the lung tissue in each 
voxel was artificially modulated individually following a density distribution we derived using 
the modulation power. When modulating the density we were able to reproduce the broadened 
dose distribution.
We thereby developed a simple tool to implement Bragg curve degradation due to hetero-
geneous materials such as lung parenchyma in Monte Carlo codes and MC-based treatment-
planning systems on the base of clinical CT data.
In an additional simulation the density of the lung tissue in each voxel was not modulated 
but kept constant to demonstrate the situation when using CT data where the fine structure of 
the sub-millimetre voxels is not resolved.
As a proof of principle of this strategy we also simulated the broadened Bragg curve down-
stream from a high-resolution CT of a human lung sample and derived the corresponding 
modulation power and density distribution for 2 mm thick voxels.
2. Materials and methods
2.1. Mathematical model
To describe the broadening effect on the Bragg peak when traversing heterogeneous materials 
such as lung parenchyma, a binary cube is taken similar to considerations from Ringbaek et al, Titt 
et al and Witt et al that consists of × ×n n nx y z voxels as shown in figure 1. nz is the number of vox-
els in beam direction z. nx, ny are the numbers of voxels in the lateral directions x and y. The voxel-
size in z direction d is called ‘structure size’. Each voxel consists of either the material lung tissue 
with a density ρ = 1.05l  g cm
−3 or air with a density ρ = 0.0012a  g cm
−3 (McConn et al 2011). 
Hence the voxelised geometry provides a binarised density distribution. In this study we dis-
tinguish between the terms ‘lung parenchyma’ and ‘lung tissue’: by lung tissue we mean the 
solid structures of the respiratory organ. Lung parenchyma is a collective term for the lung 
tissue and air in a human lung. The density of the lung parenchyma is hence dependent on the 
filling status. For an inflated lung the density is 0.26 g cm−3 (Schneider et al 1996).
The probability that the material lung tissue is assigned to a voxel is pl. A particle traversing 
this voxelised geometry will cross nz voxels. The probability F(k) that k voxels consist of lung 
tissue is given by the Bernoulli distribution:
⎜ ⎟
⎛
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p p1z l
k
l
n kz( ) ( ) (1)
Following the Moivre–Laplace central limit theorem this distribution can for large nz be 
approximated to a sufficient degree of accuracy by a normal distribution:
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where the expectation value µnl and the width σnl are given by:
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Hence, a particle traversing the voxelised geometry at one of ×n nx y possible paths will cross 
on average µnl voxels of lung tissue with a standard deviation of σnl voxels.
From this distribution the function σ|′F t t, t( ) can be derived giving the probability that the 
path a particle takes through the voxelised geometry has the water-equivalent thickness ′t :
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with t being the mean water-equivalent thickness:ρ
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where = ⋅D n dz  is the geometrical thickness of the voxelised geometry, ρ =: 1H O2  g cm
−3, 
and ρmean is the average water-equivalent density of the geometry. The approximation takes 
into account that ρ ρa l.
The width σt of the distribution can be calculated with σnl from equation (3) where nz  =  D/d 
and using that the difference in the water-equivalent thickness between a voxel filled with lung 
tissue and a voxel filled with air is ⋅ ρ ρ
ρ
−
d l a
H2O
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The values for ′t , t and σt are given in units of length in water. Hence the density ρmean from 
equation (5) is also given in water-equivalent units. However, the difference between water-
equivalent density and physical density caused by the stopping power ratio (ICRU 1994) is 
very small for lung tissue since it consists of over 85% water. We therefore approximate that 
the water-equivalent density is equal to the physical density in the case of lung tissue.
Using a normal distribution with the width σt to describe the broadening of the Bragg peak 
is in correspondence with other works (Titt et al 2015, Witt et al 2015, Ringbaek et al 2017). 
Mathematically the broadened dose distribution ∗b z( ) in depth z in water can be derived by a 
convolution of the unperturbed reference curve b0(z) with σ|′F t t, t( ):
∫ σ= ∗ = | +′ ′ ′∗ −∞
∞
b z F b z F t t b z t t, dt0 0( ) (     )( ) ( ) ( ) (7)
The displacement of the broadened dose distribution ∗b z( ) compared to the unperturbed ref-
erence curve b0(z) is always smaller than or equal to zero such shifting to smaller depths z, 
since the water-equivalent thickness ′t  is 0⩾ . Hence we use + ′z t( ) instead of the common 
convolution − ′z t( ). By the terms reference curve and broadened dose distribution we mean 
the ‘integrated depth dose distribution’ (IDD).
In figure 1 the broadening of the dose distribution due to the binary voxelised geometry 
and the use of the mathematical model are visualised: in the water phantom downstream from 
the voxelised geometry an unperturbed reference curve b0(z) and a broadened dose distribu-
tion ∗b z( ) are shown. The displacement t and the broadening σt of ∗b z( ) can be described by the 
convolution of the reference curve with the distribution σ|′F t t, t( ). The average displacement 
is given by t. It does not refer to the depth of the maximum of the Bragg peak but rather to 
the depth at the distal fall-off where the dose is  ∼82% of the maximum dose. This depth will 
be called zp82 in this study. The background that the shift refers better to this depth zp82 is that 
each dose distribution is the superposition of each single particle’s dose depositions, in which 
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connection each particle has a certain range following a normally distributed range distribu-
tion. The maximum of this range distribution lies in the depth of the  ∼82% maximum dose 
for all dose distributions (Bichsel et al 2000). The shift of this range distribution is quantified 
by t and its broadening is quantified by the parameter σt.
From the values of t and σt (see equations (5) and (6)) a material characteristic for inho-
mogeneous materials such as lung parenchyma can be introduced, which we call ‘modulation 
power’ Pmod (in analogy with ‘stopping power’ or ‘scatter power’):
σ ρ ρ
ρ ρ ρ
ρ ρ
ρ
ρ
ρ
≡ = ⋅
− −
− +
⋅
−
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1
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2
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Pmod has the unit of length in water and does not depend on the geometrical thickness D of 
the geometry, but rather on the size of the voxels in the beam direction, the so-called structure 
Figure 1. Schematic description of the MC set-up. The proton beam direction is in 
positive z, traversing a 20 mm thick slice of water and the binary voxelised geometry 
with a length in z of = ⋅ ≈D n d 50z  mm. Black voxels represent air, white ones 
lung tissue. The water phantom in which the dose distributions are scored is placed 
downstream from the voxelised geometry. To visualise the mathematical model an 
exemplary unperturbed reference curve b0(z) and a broadened dose distribution ∗b z( ) are 
shown. The broadening and displacement of ∗b z( ) can be described by the convolution 
of the reference curve with a normal distribution σ|′F t t, t( ) giving the probability that 
the path a particle is taking through the voxelised geometry has a water-equivalent 
thickness ′t . The displacement of ∗b z( ) is given by the mean value t and does not exactly 
refer to the maximum of the Bragg peak but rather to the depth zp82 where the dose of 
the distal fall-off is  ∼82% of the maximum dose. The broadening is given by the value 
of σt.
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size d. Furthermore Pmod can be easily determined by measuring dose distributions in a water 
phantom downstream from the lung parenchyma as done by Titt et al (2015) and Witt (2014). 
In the study by Witt (2014) the modulation power of porcine lungs for a 80 MeV u−1 carbon 
beam was measured to be in the range of 150–750 μm water-equivalent length.
Using Pmod the distribution σ|′F t t, t( ) from equation (4) can be derived for any geometrical 
thickness D using that = ⋅ρ
ρ
t Dmean
H2O
 and σ = ⋅P tt
2
mod .
2.2. σ|′F t t, t( ) for small geometries—especially CT voxels
However, for a given modulation power Pmod and average density ρmean the value of t decreases 
for decreasing D, which can lead to non-negligible contributions for negative water-equivalent 
thicknesses in σ|′F t t, t( ) from equation (4). This can especially be the case when D has the size 
of a CT voxel. This normally distributed σ|′F t t, t( ) can therefore not be used for thin targets. 
To just cut off σ|′F t t, t( ) at =′t 0 g cm−3 is not a suitable solution since this would result in a 
higher average water-equivalent thickness t.
Hence a different distribution |′F t D( ) must be developed without negative contributions 
describing the distribution of water-equivalent thicknesses ′t  of a thin target with geometrical 
thickness D.
To do so, in a first step the normally distributed σ|′F t t,T t( ) from equation  (4) with 
ρ ρ= ⋅t Tmean H O2/  and σ = ⋅P tt
2
mod  is derived for a sufficiently thick target with thickness 
= ⋅T n D with ∈n N assuring, that σ| ≈′F t t, 0T t( )  for <′t 0.
The requirements to |′F t D( ) then are:
 • |′F t D( ) consists of single weights wi based on fine steps of e.g. µ∆ = 50  m: 
= = ⋅ ∆|′w F t i Di ( ) with ∑ =w 1i
 • | =′F t D 0( )  for <′t 0
 • |′F t D( ) convolved n times with itself equals the normal distribution σ|′F t t,T t( ):
   σ| ∗ | ∗ | ≈ |′ ′ ′ ′F t D F t D F t D F t t... ,
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The last and most important requirement assures that n thin targets of thickness D have the 
same physical characteristics as the thick target of thickness = ⋅T n D, such as the same aver-
age water-equivalent thickness and the same modulation power Pmod.
There are various options to construct |′F t D( ) as discussed in section 4. We used a com-
bination of a shifted Poisson distribution and a single high weight w0 at =′t 0. The shifted 
Poisson distribution is defined only for positive values and has a shape similar to the normal 
distribution. The Poisson distribution was generalised for non-integers by replacing the facto-
rial function by the Gamma function. The weight w0 at =′t 0 is necessary to compensate for 
negative water-equivalent thicknesses ′t  that the normally distributed σ|′F t t,D t( ) for the thin 
target of thickness D would have.
|′F t D( ) is determined by optimising the parameters of the Poisson distribution and the 
single weight w0 to best fulfill equation (9).
An example for such a discrete distribution |′F t D( ) for a modulation power µ=P 800mod   m 
and a geometrical thickness D  =  2 mm is shown in figure 2 and compared to the normal dis-
tribution σ|′F t t,D t( ) for the thin target of thickness D: the solid line represents the normal 
distribution σ|′F t t,T t( ) for a target of thickness = ⋅T n D where normally σ| ≈′F t t, 0T t( )  for 
<′t 0. In this example n  =  20 and T  =  40 mm. The dashed line gives the normal distribution 
σ|′F t t,D t( ) for a target of thickness D with non-negligible contributions for negative ′t . In 
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circles the optimised discrete distribution |′F t D( ) is shown. The weight w0 at =′t 0 is scaled 
with a factor of 0.1 for better clarity. The result when convolving this distribution |′F t D( ) 
n  =  20 times with itself is showed in triangles. It matches the normal distribution σ|′F t t,T t( ). 
In this application folding 20 times proved to be sufficient. It should be noted, that the normal 
distribution σ|′F t t,T t( ) is only a temporary construct to derive |′F t D( ) and is not further used.
Generalising from this optimised function |′F t D( ) a density probability-function ρ |′F D( ) 
can be derived by substituting ′t  with ρ ρ= ⋅′ ′t D H O2/ . ρ |′F D( ) then gives the probability that 
a voxel of size D has a certain water-equivalent density ρ′. For lung tissue the physical density 
is approximately equal to the water-equivalent density as discussed in section 2.1.
2.3. Monte Carlo simulations
All simulations were performed with the TOPAS code (‘TOol for PArticle Simulation’) (Perl 
et al 2012) version 3.0.p1, based on Geant4 (‘GEometry ANd Tracking’) (Agostinelli et al 2003) 
version 10.02.p01. Previous studies have extensively validated the code against exper imental 
data (Perl et al 2012, Testa et al 2013). The default TOPAS physics list was used. The pro-
duction cut for all particles was set to 0.05 mm, corresponding to an energy of  ∼55 keV for 
electrons in water. The mean ionization potential for water was set to I  =  78 eV.
2.3.1. MC simulations for small voxels with a binary density distribution. A set-up as shown 
in figure 1 was used in TOPAS: a mono-energetic parallel proton beam with Gaussian profile 
(FWHM of 1 cm) traversed a 20 mm thick slice of water, the voxelised geometry represent-
ing lung parenchyma and was stopped in a water phantom downstream from the voxelised 
Figure 2. Deriving |′F t D( ) for small targets. In solid line the normal distribution 
σ|′F t t,T t( ) for the thickness = ⋅ = ⋅ =T n D 20 2 mm 40 mm     using a modulation power 
µ=P 800mod   m. In dashed line the normal distribution σ|′F t t,D t( ) for D  =  2 mm with 
non-negligible contributions for negative ′t . In circles the optimised discrete distribution 
|′F t D( ) with no negative ratios consisting of a single high weight w0 at =′t 0 and a 
shifted Poisson distribution generalised for non-integers by replacing the factorial 
function by the Gamma function. The weight w0 at =′t 0 was scaled with a factor of 
0.1 for better clarity. The result when convolving this distribution |′F t D( ) 20 times with 
itself is shown in triangles. For better clarity only every tenth step is shown. It matches 
the normal distribution σ|′F t t,T t( ).
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geometry. No nozzle geometry was used. The set-up was surrounded by vacuum. The proton’s 
energy was chosen to be 90 MeV u−1, so that the protons have enough energy to penetrate the 
voxelised geometry. To minimise energy-straggling effects which superimpose with the deg-
radation from the voxelised geometry, the energy was set as small as possible. The voxelised 
geometry consisted of ×100 100 voxels in lateral directions x and y with length of 0.5 mm. The 
thickness in z direction of the voxels d was varied between 129 μm and 1020 μm. The voxels 
consisted of either the material lung tissue with density ρ = 1.05l  g cm
−3 or air with density 
ρ = 0.0012a  g cm
−3, hence providing a binary density distribution as used in the mathematical 
model described in section 2.1. The probability pl that a voxel consisted of lung tissue was 
set to 0.25 resulting in the average density ρ = 0.26mean  g cm
−3 (as described in section 2.1 
and equation (5)), which is the density of an inflated lung (Schneider et al 1996). Using equa-
tion (8) these values of d and pl result in theoretical modulation powers Pmod between 100 and 
800 μm, hence covering the range of modulation powers of lung parenchyma measured by 
Witt (2014). The exact values of Pmod in dependence on d are listed in table 1. The composi-
tions and densities of lung tissue and air were taken from McConn et al (2011). The thickness 
of the whole voxelised geometry = ⋅D n dz  was held constant at roughly 50 mm.
The depth-dose distributions in the water phantom were scored with a resolution of 0.1 mm. 
Further on the lateral dose profile in x direction at depth zp82 was scored for each dose distribu-
tion. In a first simulation the depth-dose distribution was scored without the voxelised geom-
etry in the beam path to obtain an unperturbed reference curve b0(z). In following simulations 
the voxelised geometry was implemented and the broadened dose distributions ∗b z( ) were 
scored for each d.
To calculate the modulation powers Pmod analogue to equation (7) the values of t and σt of 
the normal distribution σ|′F t t, t( ) from equation (4) were optimised, so that the broadened dose 
distribution ∗b z( ) gained from the MC simulations fitted the unperturbed reference curve b0(z) 
convolved with σ|′F t t, t( ).
2.3.2. MC simulations for CT voxels of clinically relevant sizes. In the next step we present 
our solution to reproduce the Bragg peak degradation in Monte Carlo codes for the case that 
CT data are used where the small voxels of size d as used in the previous simulations are not 
resolved.
The modulation powers σ=P ttmod
2/  were calculated for each value of d using the values of t 
and σt obtained form the optimisation of σ|′F t t, t( ). From these Pmod the discrete density distri-
butions ρ |′F D( ) for 2 mm thick voxels were derived using the method described in section 2.2.
In the next step the binary voxelised geometry consisting of small voxels filled either with 
lung tissue or air as used in the previous simulations was replaced by a geometry consisting of 
× ×25 25 25 voxels each × ×2 2 2 mm3 in size, which is the voxel size of CTs typically used 
in lung cancer treatment. Each voxel was filled with lung tissue. For each Pmod a simulation 
was run where the density of the lung tissue in each voxel was modulated individually accord-
ing to the determined density distribution ρ |′F D( ). This was done by creating 500 different 
dicom sets each consisting of 25 slices. Each slice consisted of ×25 25 voxels filled with lung 
tissue. For each voxel the density of the lung tissue was randomly set to a value ρ′ with the 
corresponding probability ρ |′F D( ). The dicom slices thus consisted of voxels each filled with 
lung tissue, albeit with different, randomised densities. In TOPAS N primaries were simulated 
in 500 subsequent runs. In the first run, the first dicom set of 25 slices was read in and N/500 
particles were simulated. In the second run the second dicom set consisting of 25 slices was 
read in and N/500 particles were simulated. This was done for each of the 500 runs. At the end 
the dose distributions from each run were summed up.
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In principle it is possible to create an individual dicom set for each simulated particle. 
However, this leads to longer computing times in both the creation process of the dicom 
sets and the MC simulations. It was assumed that 500 dicom sets are a sufficiently good 
approximation.
In an additional simulation only one dicom set consisting of 25 slices was used for all N 
particles. Each voxel consisted of the material lung tissue. The density of the lung tissue was 
fixed at the value ρ = 0.26mean  g cm
−3 corresponding to the average density of an inflated lung. 
This density correlates to the density a CT image would provide, not capable of resolving the 
heterogeneous structure of the voxelised geometry or lung parenchyma in particular, hence 
only providing an average density. In all simulations the depth-dose distribution and lateral 
dose profile in x direction at the depth zp82 were scored.
2.3.3. The influence of the Bragg peak degradation on the dose distribution in a PTV. To 
visualise the broadening effect of a heterogeneous material on a treatment plan when planning 
on the base of CT images not capable of resolving the fine structure of lung parenchyma, the 
irradiation of a × ×10 10 30 mm3 planning target volume (PTV) was optimised for homoge-
neous dose. The same set-up as shown in figure 1 was used and the PTV was placed in the 
water phantom downstream from the voxelised geometry.
To optimise the treatment plan of the PTV, the voxelised geometry from figure  1 was 
replaced by a cube of × ×25 25 25 voxels each × ×2 2 2 mm3 in size homogeneously filled 
with lung tissue. The lung tissue’s density was set to ρ = 0.26 g cm−3. After scoring proton 
dose distributions for energies between 70 and 100 MeV u−1, the weight for each energy was 
optimised to obtain a homogeneous dose distribution within the PTV. This optimisation pro-
cess would correspond to the optimisation of a treatment plan based on CT images typically 
used in clinics, where the fine structure of the lung parenchyma is not resolved, so only an 
average density is provided. The target dose was set to 60 Gy.
The dose distribution for the optimised treatment plan was then simulated in two scenarios: 
in a first simulation the density of the lung tissue in each voxel was set to a constant ρ = 0.26 
g cm−3 as was the case in the optimisation process. In a second simulation the density of the 
lung tissue in each voxel was modulated using a density distribution derived for 2 mm thick 
voxels based on a modulation power µ=P 800mod   m. The randomisation of the density in 
each voxel was done as described in section 2.3.2. Using a modulation power of 800 μm an 
upwards estimation can be made, since the modulation power of lung parenchyma lies in the 
range from 150 μm to 750 μm.
2.3.4. MC simulation of a high-resolution CT of a human lung sample. To prove that the 
described mathematical model is applicable to real lung parenchyma and to determine the 
modulation power of human lung parenchyma, in an additional simulation the Bragg curve 
of 50 MeV u−1 protons after traversing a high-resolution CT of a human lung sample was 
calculated. The sample was prepared as described in Rau et al (1980) and Litzlbauer et al 
(2006). The sample consisted of × ×1000 1000 1000 voxels with an edge length of 0.004 mm 
resulting in a cube of × ×4 4 4 mm3. Since the CT data were not calibrated in the same way 
as common treatment-planning CTs, the data were binarised to voxels consisting of lung tis-
sue and voxels consisting of air using a threshold technique. An example is shown in figure 3. 
Black voxels represent air, white ones lung tissue.
As in the simulations before the dose distribution downstream from the CT data was scored, 
the modulation power Pmod was calculated from the Monte Carlo simulation results and a dis-
crete density distribution ρ |′F D( ) was derived for 2 mm thick voxels. In a second simulation 
the CT data were replaced by a geometry consisting of × ×2 2 2 voxels each × ×2 2 2 mm3 
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in size filled with lung tissue and the density of the lung tissue was modulated following the 
found density distribution as described in section 2.3.2.
3. Results
3.1. MC simulations for small voxels with a binary density distribution
The Bragg peak degradation due to the voxelised geometry from figure 1 consisting of small 
voxels filled with either lung tissue or air and hence providing a binary density distribution is 
shown in figure 4. In the upper graph the unperturbed reference curve and the dose distribu-
tions after traversing the geometry consisting of small voxels with a binary density distribu-
tion (BD) for µ=d 129  m and µ=d 1020  m are shown in dotted, straight and dashed lines. 
The corresponding theoretical modulation powers Pmod calculated using equation (8) with the 
values for d and pl  =  0.25 are µ≈P 100mod   m and µ≈P 800mod   m. The distal fall-off widths 
from 80% to 20% maximum dose (DFW) are 0.9 mm for the reference curve and 1.9 mm 
and 4.2 mm for the broadened curves corresponding to µ≈P 100mod   m and µ≈P 800mod   m, 
respectively. In correspondence to the degradation of the Bragg peak the maximum dose is 
decreased compared to the reference distribution. However, this is only the case for mono-
energetic particles. As shown later in this study, in spread out Bragg Peaks the maximal dose 
in the plateau is not reduced due to energy conservation. Hence the dose reduction of mono-
energetic beams can been seen; this effect is not, however, a suitable parameter to describe 
Bragg peak degradation.
In figure 4 in the upper graph the convolution of the reference curve with the optimised 
normal distributions σ|′F t t, t( ) from equation (4) presented in the lower graph are shown in 
symbols. For better clarity only every fifth data point is shown. They match the dose distribu-
tions from the geometry consisting of small voxels with a binary density distribution resulting 
in the same values for the DFW. The mean values t are 13.2 mm for both modulation powers 
and the widths σt are 1.1 mm and 3.2 mm. From these values the actual modulation powers of 
the voxelised geometry σ=P ttmod
2/  were calculated to be 100 μm and 793 μm, which is in 
good accordance with the theoretical values.
Figure 3. An exemplary section  of ×650 720 voxels of a binarised high-resolution 
CT of the human lung sample: black voxels represent air, white ones lung tissue. A 
threshold technique was used to binarise the CT data.
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Further on in the upper graph the depths zp82 for the reference curve and the broadened 
dose distributions are shown in vertical dotted lines. In correspondence in the lower graph at 
the displacements 0 mm and -13.2 mm vertical, dotted lines are shown. This visualises that the 
shift t refers to the depth zp82 as described in section 2.1 and not to the maximum of the Bragg 
peaks. This depth zp82 is 31.9 mm for both broadened dose distributions and 45.1 mm for the 
reference curve, resulting in a shift of 13.2 mm, equal to the value of t.
The results for the other values of d and Pmod are shown in table 1. The deviations between 
the theoretical values for Pmod (calculated with equation (8) and using the voxel size d and 
the probability pl  =  0.25) and the values for Pmod gained from the simulations and the optim-
isation of the convolution ( σ=P ttmod
2/ ) are on average 1.8% with a maximum deviation of 
4.2%. The DFWs increase with increasing modulation power.
3.2. MC simulations for CT voxels of clinically relevant sizes
To reproduce the Bragg peak degradation, density distributions ρ |′F D( ) for 2 mm thick voxels 
were derived using the values of Pmod gained from the previous simulations. These density 
distributions are shown in figure 5 for the modulation powers 100 μm and 800 μm.
Figure 4. Bragg peak degradation due to heterogeneous geometries. In straight, dashed 
and dotted lines in the upper graph the unperturbed reference curve and the dose 
distributions downstream the geometry consisting of small voxels with a binary density 
distribution (BD) for µ=d 129  m and µ=d 1020  m resulting in theoretical modulation 
powers µ≈P 100mod   m and µ≈P 800mod   m. In symbols (conv.) the results are shown 
when the reference curve is convolved with the optimised normal distributions σ|′F t t, t( ) 
from equation (4) shown in the lower graph. For better clarity only the region around 
the Bragg peak is shown. The statistical uncertainties from the MC simulations lie in the 
region of the line widths. In addition, vertical dotted lines are shown in depths of 45.1 mm 
and 31.9 mm, referring to the depths zp82 in the upper graph, and at displacements of 
0 mm and -13.2 mm in the lower graph to visualise, that the displacement refers to the 
depth zp82 and not to the maximum of the Bragg peak itself.
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The density distributions consist of a weight w0 at ρ =′ 0 g cm−3 and a shifted Poisson 
distribution generalised for non-integers by using the Gamma function instead of the facto-
rial function. For an increasing modulation power Pmod the distribution becomes broader, is 
shifted to the right and has a greater weight w0 at ρ =′ 0 g cm−3. For each density distribu-
tion the centre is at ρ = 0.26 g cm−3 correlating to the average density ρmean of the voxelised 
geometry.
Using these density distributions the geometry consisting of small voxels with a binary den-
sity distribution was replaced by a geometry consisting of 2 mm thick voxels filled with lung 
tissue and the density of the lung tissue was modulated for each voxel individually following 
ρ |′F D( ). The resulting dose distributions are shown in figure 6 in symbols (MD: modulated 
density) for the modulation powers µ≈P 100mod   m and µ≈P 800mod   m. For better clarity only 
every fifth data point and only the region around the Bragg peak is shown. The dose distribu-
tions for the same modulation powers after traversing the original geometry consisting of 
small voxels with a binary density distribution (BD) are shown in straight and dashed lines. 
The dose distributions when modulating the density almost perfectly match the broadened 
dose distributions downstream from the original voxelised geometry. The DFWs are 1.8 mm 
and 4.3 mm, compared to 1.9 mm and 4.2 mm for the distributions downstream from the origi-
nal voxelised geometry. The modulation powers for the dose distributions when modulating 
the density are 98 μm and 779 μm, hence reproducing the modulation power from the original 
voxelised geometry with an accuracy of 2%. The depths zp82 are 31.8 mm and 31.7 mm, result-
ing in a deviation of 0.1–0.2 mm compared to the original voxelised geometry.
The results for all Pmod-values are listed in table 1. For all modulation powers the devia-
tion in the DFWs compared to the original voxelised geometry are on average 1.7% with a 
maximal deviation of 5.3%. The modulation powers could be reproduced with an accuracy of 
on average 1.4%.
When the density was not modulated but instead held constant at the average density 
ρ = 0.26mean  g cm
−3 as shown by the dotted line in figure 6, the dose distribution is as narrow 
as the reference curve with a DFW of 0.9 mm. The depth zp82 is 31.9 mm.
Table 1. The values for the structure sizes d of the voxels and the corresponding 
theoretical values for the modulation powers Pmod
theo calculated with d and pl  =  0.25 
using equation  (8). Additionally the modulation powers σ=P ttmod
2/  gained from the 
simulation results after optimising σ|′F t t, t( ) for the geometry consisting of small voxels 
with a binary density distribution and the geometry consisting of 2 mm thick voxels 
filled with lung tissue, where the density of the lung tissue was modulated for each 
voxel individually. Also listed are the resulting distal fall-off widths DFW from 80% 
to 20% maximum dose and the FWHMs of the lateral dose distributions at depth zp82.
Small voxels with binary density
2 mm voxels with  
modulated density
d (μm)
Pmod
theo 
(μm)
Pmod  
(μm)
DFW 
(mm)
FWHM 
(mm)
Pmod  
(μm)
DFW 
(mm)
FWHM 
(mm)
129 101 100 1.9 11.0 98 1.8 11.3
256 200 209 2.3 11.3 208 2.3 11.3
384 301 301 2.8 10.8 304 2.7 11.3
510 399 403 3.1 10.9 396 3.1 11.3
641 502 486 3.4 11.9 483 3.4 11.3
769 602 606 3.8 11.5 598 3.7 11.2
892 698 724 4.1 11.5 705 4.1 11.2
1020 799 793 4.2 11.2 779 4.3 11.2
K-S Baumann et alPhys. Med. Biol. 62 (2017) 3997
4009
Figure 5. The optimised discrete density distributions ρ |′F D( ) for D  =  2 mm and the 
modulation powers µ=P 100mod   m and µ=P 800mod   m in circles and triangles. The 
data points are connected for better clarity. For the modulation power 800 μm the 
weight w0 at ρ =′ 0 g cm−3 is scaled with a factor of 0.5 for better clarity.
Figure 6. Reproducing the Bragg peak degradation when modulating the density 
of 2 mm thick voxels. The dose distributions after traversing the original geometry 
consisting of small voxels with a binary density distribution (BD) for the modulation 
powers µ≈P 100mod   m and µ≈P 800mod   m in solid and dashed lines. For the same 
values of Pmod the dose distributions when applying the density modulation to 2 mm 
thick voxels (MD) in symbols and when using the average density ρmean in dotted 
line. For better clarity only the region around the Bragg peak is shown. The statistical 
uncertainties from the MC simulations lie in the region of the line widths. The depth zp82 
is marked as a vertical dotted line.
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Table 1 also shows the FWHMs of the lateral dose distributions scored at depth zp82. The 
FWHM for the geometry consisting of small voxels with a binary density distribution vary 
between 10.8 mm and 11.9 mm whereas the FWHMs for the geometry consisting of 2 mm 
thick voxels filled with lung tissue where the lung tissue’s density was modulated are between 
11.2 mm and 11.3 mm.
3.3. The influence of the Bragg peak degradation on the dose distribution in a PTV
In figure 7 the results for the irradiation of a hypothetical PTV are shown. The PTV was placed 
in a water phantom downstream from a 50 mm thick slice of lung tissue. The irradiation was 
optimised using an average density of ρ = 0.26mean  g cm
−3 in each voxel of the lung tissue. 
The irradiation of the PTV was then simulated using this average density and additionally in 
a second scenario, where the density of the lung tissue in each voxel was modulated accord-
ing to a modulation power Pmod of 800 μm. The upper panel shows the 2d dose distribution 
in the x-z plane in the water phantom when irradiating through the geometry filled with lung 
tissue with a fixed density of 0.26 g cm−3. The black box represents the PTV. The dose in the 
PTV is almost perfectly homogeneously distributed with a sharp distal fall-off. Further on the 
isodoses 80%, 90% and 95% are indicated in colored lines. The PTV is completely enclosed 
by the 95% isodose. The lower panel shows the same 2d dose distribution, when irradiating 
through the lung tissue where the lung tissue’s density is modulated for each voxel individu-
ally using a density distribution based on a modulation power µ=P 800mod   m. The dose at 
the proximal and distal ends of the PTV is lower compared to the first case. Further on the 
isodoses now lie within the PTV at the distal end. The dose at the centre of the PTV is almost 
perfectly homogeneously distributed. The distal fall-off is broader compared to the first case, 
resulting in greater doses downstream from the PTV.
In figure 8 on the left side the 1d dose distribution along the beam axis is shown. The distal 
fall-off widths are 1.3 mm and 5.6 mm. The dose at the proximal end of the SOBP is lower for 
the degraded Bragg peak. As already described before the maximum dose in the plateau is the 
same for both distributions.
In figure 8 on the right side a dose-volume histogram is shown for the PTV and the healthy 
tissue, which in this case includes the whole volume around the PTV. The black line marks the 
volume receiving 95% of the prescribed dose. The histogram for the PTV and the unmodu-
lated, average density shows a sharp fall-off at  ∼60 Gy. The relative volume receiving 95% 
prescribed dose is 100%. For the modulated density representing real lung parenchyma the 
fall-off is broader and the relative volume irradiated with 95% prescribes dose is only 88%. 
The dose values D98% for 98% irradiated volume are 59.0 Gy and 47.0 Gy, respectively. In 
contrast to the clear underdose of the PTV the dose deposited in the healthy tissue is greater 
for the modulated density.
3.4. MC simulation of a high-resolution CT of a human lung sample
In figure 9 the unperturbed reference curve and the broadened dose distribution downstream 
from the high-resolution CT of a human lung sample and the dose distribution when replacing 
these CT data with a geometry consisting of × ×2 2 2 mm3 voxels filled with lung tissue and 
modulating the lung tissue’s density. For better clarity only every fifth data point is shown for 
the distribution gained from the density modulation. The values of t and σt from the distribu-
tion σ|′F t t, t( ) from equation (4) were optimised so that σ|′F t t, t( ) convolved with the reference 
curve fits the broadened dose distribution downstream from the high-resolution CT. From t 
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and σt the modulation power Pmod was calculated and used to derive a density distribution 
ρ |′F D( ) for 2 mm thick voxels.
The modulation power Pmod is µ66  m resulting in a DFW of 0.4 mm. When modulating the 
density of 2 mm thick voxels the modulation power is µ65  m resulting in the same DFW of 
0.4 mm. The DFW for the reference curve is 0.3 mm. The depth zp82 for the reference curve is 
22.6 mm and for the other two dose distributions it is 21.9 mm.
Figure 7. 2d dose distribution with and without Bragg peak degradation. In the upper 
panel the 2d dose distribution in the x-z plane in the water phantom when irradiating 
through the voxelised geometry with a fixed density ρ = 0.26 g cm−3. The black box 
represents the PTV. The lower panel shows the same dose distribution when irradiating 
through the voxelised geometry where the lung tissue’s density is modulated in each 
voxel individually. The isodoses 80%, 90% and 95% are indicated in colored lines.
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4. Discussion
The degradation of a Bragg peak due to a heterogeneous voxelised geometry in the beam 
line was shown. This degradation could be described successfully by a new model-based 
quantity called modulation power Pmod which depends on the structure size d of the hetero-
geneous geometry but is independent of the geometrical thickness D. The modulation power 
was derived from the function σ|′F t t, t( ) describing the probability that a path through the 
heterogeneous geometry has a water-equivalent thickness ′t . The value t equals the average 
water-equivalent thickness and describes the displacement of the depth zp82. The parameter σt
2 
describes the broadening compared to an unperturbed reference curve. For all structure sizes 
Figure 8. 1d dose distribution and dose-volume histogram with and without Bragg 
peak degradation. On the left side the 1d dose distribution along the beam axis for 
both irradiation modalities of the hypothetical PTV (average and modulated density). 
On the right side the dose-volume histogram is shown: in straight and dashed lines the 
histograms for both modalities. The healthy tissue includes the whole volume around 
the PTV.
Figure 9. Bragg peak degradation due to lung parenchyma. The broadened dose 
distribution after traversing the high-resolution CT of a human lung sample as a straight 
line. As circles the dose distribution when replacing these CT data with a cube of 
× ×2 2 2 mm3 voxels filled with lung tissue and modulating the lung tissue’s density. 
The unperturbed reference curve is shown as a dashed line. For better clarity only 
the region around the Bragg peak is shown. The statistical uncertainties from the MC 
simulations lie in the region of the line widths.
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σ|′F t t, t( ) could be optimised after t and σt so that the unperturbed reference curve convolved 
with σ|′F t t, t( ) was equal to the broadened depth-dose. σ=P ttmod 2/  could be derived from the 
results of the Monte Carlo simulations and was equal to the predictions from the mathematical 
model. This proves the correctness of the mathematical model.
From each modulation power it was possible to derive the water-equivalent density distri-
bution for 2 mm thick voxels, hence going from the binary density distribution in the original 
voxelised geometry to a discrete distribution based on several fine steps. The transition to 
clinically relevant CT data was achieved by replacing the original geometry consisting of 
small voxels by voxels measuring × ×2 2 2 mm3. The voxels were then homogeneously filled 
with lung tissue. By modulating the density of the lung tissue in each voxel individually 
according to the found density distribution, it was possible to reproduce the broadened dose 
distribution downstream from the original voxelised geometry almost perfectly. The devia-
tions in the DFWs were maximally 0.1 mm (5.3%). The approximation was made, that the 
physical density of lung tissue equals the water-equivalent density, which proved to be alright. 
That only 500 density modulations were executed, as described in section 2.3, is also a suf-
ficient approximation.
When the density of the lung tissue was not modulated but instead the average density 
ρ = 0.26mean  g cm
−3 was used, the dose distribution was as narrow as the reference curve. 
This average density correlates to the density a CT image would provide that is not capable of 
resolving the heterogeneous structures in the voxelised geometry. Considering the Bragg peak 
degradation due to the heterogeneous lung parenchyma is therefore not possible in treatment-
planning on the base of such CT data. However, if the modulation power of lung parenchyma 
is known—for example by measurements as performed by Titt et al (2015) and Witt (2014) 
or simulations of high-resolution CTs as done in this study—the density distribution for each 
voxel of a CT image can be derived. By modulating the density of each voxel inside the lung 
the broadening effect can be reproduced on the base of clinical CT data. Hence a solution is 
found to take into account the modulating effect of lung parenchyma in Monte Carlo-based 
treatment-planning systems. This could for example be done by indicating the voxels belong-
ing to the lung in the treatment-planning system. While optimising the plan the density in each 
voxel associated with the lung should then be modulated for each simulated particle individu-
ally using a density distribution as described in this study. The choice of the modulation power 
used to derive the density distribution is a topic we are currently working on. We expect that 
the modulation power is dependent on the position in the lung itself and is perhaps different 
for each patient.
Another critical point is lung motion which leads to a different average density of the lung 
and—as we assume—a different structure sizes d of the lung parenchyma due to varying fill-
ing conditions of the lung. This would influence the modulation power since it is dependent 
on the structure size, as shown in equation (8). Further on the density distribution would differ 
since it depends on the average density of the lung.
Therefore in a next step we will perform a sensitivity analysis by evaluating the effects of 
Bragg peak degradation due to lung parenchyma on the treatment plans of real patient CT data 
for different modulation powers.
In this study the functionality of the mathematical model and the usage of the density 
distribution was proven to work especially for 2 mm thick CT voxels and modulation powers 
between 100 μm and 800 μm, hence covering the range of modulation powers for porcine 
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lungs measured by Witt (2014). We expect that the values of modulation powers for human 
lungs are similar. However, measuring the modulation power in an actual patient is not pos-
sible. Next to measurements as performed by Titt et al (2015) and Witt (2014) and simulating 
high-resolution CTs, measurements with lung phantoms are a possible way to determine the 
modulation power of human lung tissue. In another study it was shown that porous materials 
have similar characteristics as lung tissue and can potentially be used to craft lung-like phan-
toms (Ringbaek et al 2017). For the case that the modulation power of human lung paren-
chyma is different from that of porcine lungs it should be pointed out that the mathematical 
model and usage of the density distribution can in principle be used for any modulation power.
We also proved the functionality of the mathematical model for higher energies up to 
220 MeV u−1. For higher energies the range straggling effect increases and interferes with the 
modulating effect of the heterogeneous materials used in this study making it harder to see 
these modulating effects. Hence only the results for the low energy of 90 MeV u−1 are shown.
The density distribution ρ |′F D( ) for targets of small thicknesses D used in this study was 
derived from the discrete distribution |′F t D( ) describing the probability that a target of thick-
ness D has the water-equivalent thickness ′t . |′F t D( ) consisted of a weight w0 at =′t 0 and a 
Poisson distribution generalised for non-integers by using the Gamma function instead of the 
factorial function. |′F t D( ) was optimised to fulfill the requirements that |′F t D( ) is discrete, 
has no negative ratios and that |′F t D( ) convolved n times with itself equals the normal distri-
bution σ|′F t t,T t( ) for a target of thickness = ⋅T n D.
However, there are infinite possibilities to optimise a distribution fulfilling these require-
ments. An example is shown in figure  10: this distribution is based on three weights at 
ρ =′ 0.00, 0.26 and 1.05 g cm−3. These densities correspond to the density of air, lung tissue 
and the average density of the voxelised geometry and hence an inflated lung.
Modulating the density of 2 mm thick voxels in a geometry consisting of n  =  20 voxels 
in beam direction using this distribution would result in the same dose distribution as when 
using the original density distribution from figure 5, since both distributions are optimised for 
n  =  20 convolutions. However, when modulating less than n  =  20 voxels, the results would 
Figure 10. Another possibility for the density distribution ρ |′F D( ) for D  =  2 mm and 
a modulation power µ=P 800mod   m. In contrast to the density distributions shown in 
figure 5 this one is based on three densities at 0.00, 0.26 and 1.05 g cm−3 corresponding 
to the densities of air, lung tissue and the average density of the voxelised geometry and 
hence an inflated lung.
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differ. For the extreme case that the density of only n  =  1 voxel is modulated, the density 
distribution based on three weights would result in a dose distribution with three Bragg peaks. 
The dose distribution from the original density distribution as shown in figure 5 would result 
in a broadened Bragg peak resulting from the Poisson distribution and an additional Bragg 
peak resulting from the weight w0.
Concerning the lateral scattering it was shown that only minor changes occur (<5%) when 
the geometry consisting of small voxels filled with either lung tissue or air is replaced by 
2 mm thick voxels filled with lung tissue. This is reasonable since the mass of air in the origi-
nal voxelised geometry is negligible and the mass fractions of the different elements in both 
geometries are therefore roughly the same, resulting in a similar effective atomic number Zeff.
The influence of Bragg peak degradation on a clinical target volume was demonstrated 
for a hypothetical PTV downstream from a heterogeneous geometry. When not considering 
Bragg peak degradation due to heterogeneous materials when optimising a treatment plan, an 
underdose of the PTV and an overdose of the healthy tissue downstream from the PTV are 
the consequences.
For the high-resolution CT of a human lung sample the modulation power was 66 μm 
resulting in a DFW of 0.4 mm for 4 mm lung parenchyma. The modulation power is low 
compared to the results by Witt (2014). The reason is that the CT data used in this study were 
prepared using a ‘critical point drying’ method (Litzlbauer et al 2006), resulting in a loss of 
water of up to 37%. As a consequence the structures of the lung tissue are reduced in size. 
Since the modulation power is proportional to this structure size d (see equation 8), Pmod is 
smaller than it would be in a non-dried lung.
Nevertheless, a discrete density distribution ρ |′F D( ) could be derived for 2 mm thick vox-
els. By modulating the density of 2 mm thick voxels we were able to reproduce the broadened 
dose distribution downstream from the high-resolution CT, hence proving that our strategy 
works for real lung parenchyma.
5. Conclusion
In this study we developed an efficient method to describe Bragg curve degradation using a 
mathematical model: the values t and σt of a normal distribution σ|′F t t, t( ) have to be adjusted 
so that an unperturbed reference curve convolved with σ|′F t t, t( ) equals the broadened dose 
distribution. The material characteristics ‘modulation power’ was introduced. It can be deter-
mined from the values of t and σt using that σ=P ttmod
2/ . The modulation power is independent 
on the actual thickness of a material and can easily be measured. From the modulation power 
a density distribution can be derived for any thickness of the material—especially for 2 mm 
thick voxels, which is the typical size of voxels in a CT image used for planning the treatment 
of lung cancers. By modulating the density of each 2 mm thick voxel individually follow-
ing this density distribution, we were able to reproduce broadened Bragg curves. Hence a 
simple tool is developed to include Bragg curve degradation in Monte Carlo-based treatment- 
planning systems on the base of clinical CT data.
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1. Introduction
Since first proposed by Wilson (1946), proton irradiation to treat cancer has evolved from an experimental 
treatment in research facilities to a routine treatment option in specialized cancer centers. In scanned proton 
beam facilities, each tumor is irradiated with an optimized combination of proton beams of different energies 
and positions, concentrating the Bragg peaks in a plateau which encloses the tumor. The low dose in the entrance 
channel and the high energy deposition at a finite range qualify for a good tumor control with a low toxicity in 
the surrounding tissue and organs (Schulz-Ertner and Tsujii 2007, Zhang et al 2010). As in all common radiation 
therapy treatments, treatment plans nowadays are optimized for the specific anatomy of the patient by calculating 
the specific dose distributions on the acquired CT images. Eventhough CT resolution allows a macroscopic 
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Abstract
The fine, sub-millimeter sized structure of lung tissue causes a degradation of the Bragg peak curve in 
particle therapy. The Bragg peak is degraded because particles of the same energy traverse lung tissue 
of different compositions of high and low density materials. Hence, they experience different energy 
losses resulting in variable ranges and a broadened Bragg peak. 
Since this fine structure of lung tissue is not resolved in standard treatment-planning CTs, current 
state-of-the-art dose calculation procedures used in the clinical routine are unable to account for this 
degradation. Neglecting this Bragg peak degradation in treatment planning can lead to an underdose 
in the target volume and an overdose distal to the target. 
Aim of this work is to systematically investigate the potential effects of the Bragg peak degradation on 
the dose distribution in dependence of different parameters like the tumor volume and its depth in lung. 
Proton plans were optimized on CT based phantoms without considering the Bragg peak 
degradation and afterwards recalculated with the Monte Carlo toolkit TOPAS: first, without 
consideration of the degradation and second, with the Bragg peak degradation accounted for. The 
direct comparison of these two dose distributions enables a quantification of the degradation effect. 
To carve out the dependencies of various parameters that could influence the Bragg peak degradation 
and thus the target dose, the simulations were performed for a variety of tumor sizes and shapes, as 
well as different positions within the lung. 
The results show that due to the Bragg peak degradation the mean dose in the target volume can 
be reduced by a few percent up to 14% (for extreme cases) depending on the geometry. It was shown 
that this effect increases with a decreasing tumor volume and increasing depth of the tumor. 
For the first time, a tumor specific estimation of the effect on the dose distribution due to the 
Bragg peak degradation in lung tissue is presented.
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visualization and delineation of the organs in combination with additional dose calculation information, no 
information about microscopic tissue characteristics can be obtained with a conventional CT scanner. The CT 
resolution results in an averaged representation of the lung as homogenous medium in CTs while on a microscopic 
scale it consists of pulmonary alveoli with a density close to water filled with air having a much smaller density. For 
ion therapy this is challenging as heterogeneous materials on a microscopic scale cause the Bragg peak to smear out 
(Urie et al 1986, Sawakuchi et al 2008). The smearing-out arises because some particles might pass through more 
lung tissue with a high density and others through more air cavities with a low density. Hence, these particles are 
slowed down unevenly resulting in different ranges and the degradation of the Bragg peak. Even though the Bragg 
peak degradation when traversing heterogeneous media has been known for some time and it was shown that 
this could have a significant impact on the target dose (Goitein 1977, Espana and Paganetti 2011), state-of-the-art 
treatment planning systems and routines do not account for this Bragg peak degradation, ignoring the potential of 
an underdose in the target volume and an overdose distal to the target (Goitein 1977, Sawakuchi et al 2008).
Nevertheless, first steps to include the Bragg peak degradation in treatment planning have been performed. 
To quantify the effect of the Bragg peak degradation on a depth dose curve, measurements in waterphantoms 
positioned downstream from 3D-printed and other porous lung substitutes (Sell et al 2012, Titt et al 2015, Ring-
baek et al 2017) have been performed. With the help of Monte Carlo simulations, the concept of the ‘modula-
tion power’ based on a mathematical model was introduced to describe and quantify the effects of the Bragg 
peak degredation on a mono-energetic Bragg peak (Witt et al 2015, Ringbaek et al 2017). Baumann et al (2017) 
introduced and extensively tested a mathematical model to reproduce this artificial Bragg peak degradation on 
rougher structures like CT voxels with dimensions in the millimeter range: by sequentially modulating the den-
sity of the CT voxels within the lung, the Bragg peak degradation can be reproduced. Hence, it is possible to 
reproduce the Bragg peak degradation due to lung tissue on the basis of clinically acquired CT images, although 
they do not resolve the fine structure of the lung tissue.
In this study, the effects of the Bragg peak degradation on various target volumes in dependence on their 
depth in lung were analyzed. As the individual anatomy of each patient and thus the tumor shape and its position 
in the lung differs, the comparison and analysis of the degradation effect is more evident and systematic when 
performing the calculation of this effect on geometrical, CT-based phantoms. For each of these dicom-based CT 
slab phantoms a treatment plan was optimized without considering the degradation. These plans were subse-
quently recalculated with TOPAS in two scenarios: with and without the density modulation reproducing the 
Bragg peak degradation. Therefore, we were able to perform Monte Carlo simulations for different tumor sizes 
and distances in lung on the regular CT, as well as on the modulated CTs as proposed by Baumann et al (2017). 
This allows the analysis of the effects of the Bragg peak degradation dependent on tumor size and the depth in 
lung and thus enabling an uncertainty estimation for proton therapy treatments for lung carcinomas in clinical 
cases. The effects of other parameters like the tumor shape, the energy and the planning setup on the Bragg peak 
degradation were also evaluated.
2. Materials and methods
2.1. CT modulation
As shown by Baumann et al (2017), on a macroscopic level the Bragg peak degradation can be reproduced by 
alternating the density of the voxel that the particle passes through between either the density of air or tissue. 
To reproduce the effect of the Bragg peak degradation a sequence of 100 CTs with differently randomized lung 
density voxels was implemented in the Monte Carlo simulations, as displayed in figure 1. The expectation value 
of the density of each voxel is 0.26 g cm−3 corresponding to the average density of an inflated lung (Schneider et al 
1996). The superposition of the dose distributions from each of the 100 randomized CTs modulates the density 
and hence the Bragg peak degradation is reproduced. A more detailed description of the mathematical model 
and the modulation process is described by Baumann et al (2017).
Measurements indicated that the modulation power for lung tissue ranges between 100 µm and 800 µm 
(Witt 2014). To be able to conduct an approximation for the effect of the Bragg peak degradation, a modulation 
of 450 µm was chosen for most setups in this study. Some simulations were repeated with a more probable modu-
lation power of 250 µm and a extreme modulation power of 800 µm, to allow an estimation of the influence of 
the modulation power.
2.2. Phantoms
To fulfill the objective of the pure assessment of the differences in the dose distribution especially in the target 
due to the Bragg peak degradation in lung tissue, a phantom study was conducted in a static setup so that organ 
motion was ignored. Reducing the phantom to the most simplistic case as shown in figure 2, each CT consisted of 
two water slabs of 2 cm thickness seperated by 25 cm of lung tissue, representing the lung enclosed by the thorax 
wall and the mediastinum or other distal tissue. The density of the water slabs was 1.00 g cm−3. The lung was 
set to have a density of 0.26 g cm−3 corresponding to the density of an inflated lung (Schneider et al 1996). The 
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CT voxels had a size of 1.5× 1.5× 1.5 mm3. The artificial tumors were represented by spheres or ellipsoids of 
different sizes with a density of 1.00 g cm−3 that were positioned at various depths within the lung.
Various phantoms and thus treatment plans were produced to allow an extensive evaluation of the dependen-
cies of the Bragg Peak degradation. In the following, a brief description of the varied parameters is given (com-
pare figure 2):
Figure 1. Schematic overview of the setup and the occurring effects on the depth dose curve, when ignoring (top) and accounting 
for (bottom) the Bragg peak degradation. On the left side, the phantom is shown for the CT clinical (averaged) case (lung window) 
in the upper part and modulated in the lower part for one exemplary tumor size and position. On the right side the resulting depth 
dose curves are shown for the CT averaged in black (top), a high modulation effect (modulation power 800 µm) in red and a low 
modulation effect (modulation power 250 µm) in blue (bottom).
Figure 2. The major variations of the used CT phantoms are displayed. Featuring two exemplary options for the five major 
differences in the phantom setups. From left to right, different depths of the tumor in the lung, different tumor volumes and shapes 
are visible. As well as a change in the thickness of the proximal and distal water slab. The yellow lines enclosing the tumor display the 
solid GTV and the larger red line surrounds the PTV, respectively.
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2.2.1. (a) Distance traveled in lung tissue
Six different depths in lung were investigated ranging from 2 cm to 20 cm (2 cm, 4 cm, 6 cm, 10 cm, 15 cm, 20 cm) 
for the distance (dL) between the beginning of the lung and the tumor center. The smallest and largest distance are 
displayed in figure 2.
2.2.2. (b) Size of tumor volume
Six different spherical volumes (1 cm3, 2 cm3, 6 cm3, 14 cm3, 25 cm3, 43 cm3) were chosen to be evaluated, the 
smallest, with a volume of 1 cm3, and largest, which has a volume of 43 cm3, are shown in figure 2.
2.2.3. (c) Shape of tumor volume
As tumor volumes in patients are not always shaped spherically, two different ellipsoids were investigated. The 
parameters a,b and c denote semi-axes of the ellipsoid. Length a always describes the axis parallel to the beam 
direction and b and c the axis perpendicular to the beam. Two axis had always the same length for both ellipsoids. 
The smaller ellipsoid (9 cm3) features the short axis (a  =  b  =  2 cm) twice and the long axis (c  =  4 cm) once while 
the larger one (19 cm3) features the short axis only once and thus the long axis twice (a  =  2 cm, b  =  c  =  4 cm). 
Both ellipsoids were irradiated with the short axis (as just described) and the long axis (by switching a↔ c ) in 
beam direction.
2.2.4. (d) Thickness of thorax wall
The simulations for the smallest tumor volume (1 cm3) were also performed with a thicker wall as displayed in 
figure 2.
2.2.5. (e) Tissue distal to the tumor volume
The simulations for the longest distance in lung were performed with and without the wall distal to the tumor. 
This represents tumors close to the mediastinum in comparison to tumors only surrounded by lung.
2.3. Planning setup and Monte Carlo simulations
Treatment plans for spot scanning protons were optimized using the commercially available treatment planning 
system Eclipse version 13.7 (Varian). One single field from the left side was optimized with a lateral spot spacing 
of 60% of the FWHM in air and an energy spacing of 3 MeV or 1 MeV for larger or smaller volumes, respectively. 
The volume optimized for was the PTV, which encloses the voxels identified as tumor (GTV) with a margin of 
3 mm lung tissue. 30 Gy RBE were planned to be applied in a single fraction.
All simulations were conducted with the Monte Carlo code TOPAS (TOol for PArticle Simulations) version 
3.1.p1 (Perl et al 2012) which is a Geant4 (GEometry ANd Tracking) (Agostinelli et al 2003) based toolkit focused 
on proton therapy applications. Each optimized RTplan was recalculated with TOPAS in two scenarios: with and 
without the Bragg Peak modulation model.
The dose distributions of both scenarios were scored as dose-to-water and compared by evaluating the mean 
dose (Dmean), the dose in at least 20% of the volume (D20) and 95% of the volume (D95), respectively. These three 
dose values were determined for both, the GTV and the PTV. To evaluate also small dependencies, the modula-
tion effects for the setups shown in figures 2(c)–(e) are presented with the strong modulation power of 800 µm. 
All other results are presented with a modulation power of 450 µm to give a more reasonable estimation of the 
effect.
3. Results
3.1. General effect of the Bragg peak degradation
Figures 3(a) and (c) show two exemplary depth-dose curves along the beam axis. For the first 2 cm the particles 
travel through the water slab and thus no modulation is observed. From depth 2 cm on, small discrepancies 
in dose can be observed as the particles traverse the lung. Reaching the Bragg peak plateau, the differences 
between the non-modulated scenario giving the dose distribution as predicted by the TPS and the modulated 
scenario giving the dose distribution, as it would be in the patient, increase and show the systematic effect of the 
degradation: on the one hand less dose at the beginning and the end of the spread out Bragg peak and on the other 
hand an higher dose distal to the Bragg peaks induced due to a broader fall off.
The dose curve for the modulated cases is smoother in the high-dose region showing that the Bragg peak deg-
radation leads to a smoothing effect on the dose in beam direction similar to a ripple filter (Ringbaek et al 2017).
The dose-volume histogram (DVH) presented in figures 3(b) and (d) show the influence of the Bragg peak 
degradation on the GTV. It can be observed, that the mean dose in the GTV is reduced in the modulated case in 
comparison to the predicted dose. In general, the dose coverage in significantly deteriorated.
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3.2. Dependency on depth in lung tissue and the tumor volume
Figure 4 shows the evaluated dose parameters (Dmean, D95 and D20) for the modulated and non-modulated cases in 
dependency on the depth of the tumor in lung and different tumor volumes. All results are presented as a relative 
difference of the modulated and TPS calculated dose, which is used as reference dose. To make an estimate of the 
statistical error done with the Monte Carlo simulation, several plans were recalculated with different random 
number seeds. The reference mean dose without the modulation effect was found to have an uncertainty of 
about 0.05% for the presented values, nevertheless as the modulation is produced by the sum of 100 dose plans 
with each one-hundredth of the total number of particles, the uncertainty is increased to roughly 0.5%. Thus all 
presented values have to be reviewed with an uncertainty of 0.5%, which corresponds in most cases to the marker 
size. For single voxel values such as the maximum and minimum dose the uncertainty is slightly, as only a minor 
part of the simulated particles contribute to the dose value of this voxel.
In the upper part of figure 4, the mean dose is evaluated for the PTV (a) and the GTV (b), respectively. A clear 
correlation between the tumor depth and the dose reduction can be observed: the greater the distance traveled in 
lung, the higher the dose difference. Additionally, a clear dependence on the tumor volume is visible: the smaller 
the tumor size, the larger the dose difference. Figures 4(a) and (b) show a almost linear relationship between 
tumor depth and the dose difference.
The highest deviation from the expected value of Dmean is found to be  −8% for the largest distance of 20 cm 
in combination with the smallest volume of 1 cm3. With decreasing distance in the lung it decreases below  −1%. 
The smallest differences occur for the largest sphere with a volume of 43 cm3. Dmean rises from  −1% at a 4 cm dis-
tance between the beginning of the lung and the sphere center to  −3% at 20 cm distance.
Even though both upper plots look quite similar, differences can be noted. On the one hand, the effect for the 
smallest tumor is higher when only the GTV is evaluated, while on the other hand the effect for the larger sized 
tumors is reduced for the GTV in larger distances, broadening the range covered in figure 4(b). For the GTV, the 
smallest tumor shows differences from a 0% difference at 2 cm lung distance up to  −9% at 20 cm, while differ-
ences for the largest tumor are between  −1% and  −2% for 4 cm and 20 cm, respectively.
In the bottom panel of figure 4 the relative differences of the dose values enclosing 95% (D95) and 20% (D20) 
of the volume, respectively, are shown. The D20 show more scatter but the trend of more passed lung resulting in 
a higher dose reduction is still valid. For the largest distance, a D20 dose difference between  −2% and  −11% is 
observed.
Figure 3. Depth-dose curves ((a) and (c)) through the central beam line and the corresponding DVHs ((b) and (d)) with and 
without simulation of the lung modulation effect. The modulating lung tissue, with a modulation power of 800 µm (red line)  
or 450 µm (orange line), starts at 2 cm. The depth dose curve in panel (a) and the corresponding dose-volume histogram in panel  
(b) feature a small tumor while panel (c) and (d) present a larger tumor extension.
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For the D95, the data points scatter more randomly. Some points show even a positive discrepancy between 
the modulated and original calculation. Thus no clear correlation can be found.
The lung modulation influences the dose at the distal end of the tumor the most. Thus, plans optimized in 
a way that all the high dose area coincidences with the distal region of the PTV show more effect on the D20. On 
the other hands plans barely surrounding the distal region with the proposed 95% of the planned dose, will show 
a significant reduction of the D95. For example, two identical volumes positioned in the dose distribution pre-
sented in figure 3(c) at depths 10–11.5 cm and 11–12.5 cm show a similar behavior in their decrease of the mean 
dose (around 1%). The D20 is decreased by 2% for the proximal volume and by only 1% for the distal volume. The 
big difference is observed for the D95: while the coverage for the proximal volume is even increased by 2% due to 
the smoothing effect of the Bragg peak degradation, the D95 for the distal volume is decreased by  −5% because 
of the strong impact of the degradation effect at the distal end. Thus, small variation in the optimized plan, which 
are not observable from the DVH but only from the actual dose distribution have a great influence on parameters 
like the D95.
In the further analysis only the mean dose is evaluated as (accounting to figure 4) it is a good indicator for the 
effects of the modulation.
3.3. Dependency on the shape of the radiated volume
It was found that the underdosage of the ellipsoid-shaped PTV depends on its orientation rather than on its 
volume: if the short axis was orientated in beam direction, the underdosage was about  −9% for both volumes. 
For the long axis in beam direction the underdose was around  −3%.
To be able to approximate the decrease of the mean dose not only for different positions in lung but also for 
different tumor sizes and shapes, an empirically found parameter is presented, which well describes the geo-
metrical dependencies:
LS = 2 · a
2
√
b · c (1)
a denotes the axis in beam direction (as described in section 2.2(d)). LS, which can be described as the scaled tumor 
length in beam direction, offers the possibility to normalize the different orientations of the tested ellipsoids with 
the spherical setups. This means if the x-axis in figure 4(a) is transformed from dL to dL/LS, the different slopes 
for the different tumor sizes are leveled into one and thus a simple approximation for all cases can be made.
Figure 4. Relative effect of the Bragg peak degradation on the dose distribution in dependency of the tumor depth in lung tissue 
with a modulation power of 450 µm for (a) the mean dose (Dmean) of the PTV and (b) the GTV and (c) for the D20 and (d) D95 dose, 
respectively. Different markers indicate the tumor volume. Note the different scaling in (d).
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3.4. Dependency on the lateral and longitudinal spot spacing
As the Bragg peak degradation changes the width of each Bragg peak in beam direction, differences in the energy 
spacing may have an influence on the outcome of the Bragg peak degradation effects.
For the simulations redone with a different energy (longitudinal) spacing, a higher dose difference was 
observed in the cases where a more narrow spot spacing was optimized. For the 1 MeV energy spacing, the under-
dosage showed an about 40% higher dose difference in comparison to the 3 MeV energy spacing. Plans with a 
wider energy spacing have often a lower conformity and the smoothing effect of the Bragg peak degradation flat-
tens the profile but does not reduce the mean dose significantly. For a high conformity plan, the smoothing leads 
to a more decreased mean dose. A higher conformity also allows the optimizer to spare dose in the surrounding 
normal tissue, which leads to a steeper dose fall-off which is also closer to the PTV. Figure 5 shows two different 
reference plans, which show the steeper gradient for the closer energy spacing. Of course, this can be accounted 
for during the planning procedure.
Regarding the lateral spot spacing, no difference within the uncertainties of the simulation with a lower lat-
eral spot spacing was observed.
3.5. Energy dependency
To analyze the dependency of the Bragg peak degradation on the energy, the plans for the 1 cm3 spherical tumor 
were also calculated with a thicker entrance wall (4 cm instead of 2 cm) leading to higher proton energies to enclose 
the tumor volume. Because this effect is expected to be smaller, the highest modulation power was chosen. The 
results are displayed in table 1. While for the GTV, only the small distances in lung show some discrepancies when 
the energy is increased, all dose differences for the mean PTV dose increase when applying a thicker wall. Higher 
proton energies have a smaller peak to plateau ratio as well as smaller lateral FWHM. Thus, lower energy plans 
might show less conformity than higher energy plans. As presented in section 3.4, a plan with higher conformity 
is more affected by the Bragg peak degradation. In general, applying higher proton energies increases the dose 
differences about additional  −2% for the PTV .
3.6. Effect of distal tissue
If the tumor is placed in the vicinity to the mediastinum, tissue follows distal to the tumor. Simulations for the 
2 cm3 tumor were performed to analyze the effects of the Bragg peak degradation with and without distal tissue. 
Again, the highest modulation power of 800 µm was used, to give a very conservative approximation. The results 
are presented in table 2. The mean dose was reduced by 19%, if the plan was optimized with no tissue distal to the 
tumor. However, with the optimization performed with distal tissue, the mean dose was only decreased by 10%, 
independent on the presence of distal tissue during the dose calculation. This outlines that the effect caused in the 
presence of distal tissue is solely caused by the optimized spot setting, as plans optimized with distal tissue feature 
more energy layers behind the tumor volume and thus leading to a smoother distal fall-off.
For a smaller distance of 6 cm and a larger distance between the PTV and the distal tissue, the effect is signifi-
cantly reduced as the case in brackets in table 2 shows. The closer the tumor lays to distal tissue and the more the 
0
20
40
60
80
100
0 2 4 6 8 10 12 14 16 18 20 22 24
)
%( esod
depth (cm)
1 MeV energy spacing
3 MeV energy spacing
tumor
Figure 5. Depth dose curve for reference plan of the same tumor set-up with a different longitudinal energy spacing.
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of PTV overlaps with the mediastinal wall, the smaller is the effect of the lung modulation. The occurrence of this 
effect depends on the settings of the machine in the treatment planning system.
3.7. Modulation power
As described in section 2.1 and by Baumann et al (2017), the modulation power is a parameter in the 
mathematical model used to reproduce the Bragg peak degradation, indicating the strength of the modulation 
effect. Measurements indicate a modulation power between 100 µm and 800 µm (Witt 2014). The modulation 
power in the simulations presented was chosen to be mostly 450 µm but also 800 µm to make a conservative 
approximation for clinical cases. As the modulation power has a great influence on the modulation effect, some 
of the simulations were redone with a modulation power of 250 µm as presented in figure 6 to also give a less 
conservative approximation of the Bragg peak degradation. As expected, a lower modulation power decreases the 
dose differences occurring due to the Bragg peak degradation. For a linear approximation a lower slope would be 
assigned. Still, the increase of the dose difference for both, the GTV and the PTV in dependency of the distance in 
lung is clearly visible. A lower modulation power of 250 µm reduces the effect further to 0% for a depth of 4 cm 
and to  −3% for the 20 cm depth.
3.8. Combined approximation of the degradation
As the aim was to allow an estimation of the change in the dose distribution for clinical cases, all data were 
combined in figure 7. To connect all different setups and results, the dose difference was plotted against the ratio 
of the penetration depth in lung and the scaled tumor length in beam direction as proposed in equation (1). This 
condenses all data allowing a linear approximation and thus enabling a prediction of the reduction of the mean 
dose in the tumor.
The GTV volumes and the depths in lung were chosen to represent a realistic variety over all possible lung 
tumor scenarios.
For a less conservative approach, figure 7 also gives the approximation for a modulation power of 250 µm, 
which seems to be clinically more likely. The slope was gained by a fit through all data calculated with 250 µm 
whereas the width of the uncertainty band was taken from the 800 µm fit.
4. Discussion
The presence of the Bragg peak degradation due to microscopic inhomogeneities is well known, however its 
effects are not accounted for in any TPS, hence the impact of the patient dose is not know.
In this phantom based study, the impact of the Bragg peak degradation on the dose of lung tumors was esti-
mated in dependence on different clinical treatment parameters such as the tumor depth in lung, the tumor 
volume and its shape, the proton energy and the energy spacing. All in all, the results show that the longer the 
Table 1. Dose differences for the mean dose of the GTV and the PTV, for a wall of 2 cm and a wall of 4 cm thickness (see figure 2). The 
tumor volume was 1 cm3 and the modulation power 800 µm.
GTVmean dose difference (%)
Depth 4 cm 6 cm 10 cm 15 cm
2 cm wall −4 −5 −9 −12
4 cm wall −3 −7 −9 −12
PTVmean dose difference (%)
Depth 4 cm 6 cm 10 cm 15 cm
2 cm wall −3 −4 −7 −11
4 cm wall −5 −7 −9 −13
Table 2. Dose differences for the PTV mean dose when calculated and optimized on a CT with or without tissue distal to the tumor. The 
distance in lung was 25 cm (6 cm) for all settings and the modulation power 800 µm.
PTVmean dose difference (%)
Calculated on CT with distal tissue Calculated on CT without distal tissue
Optimized on CT with distal tissue −10 [−4] −10 [−4]
Optimized on CT without distal tissue −19 [−5] −19 [−5]
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distance the particles travel through lung and the smaller the tumor volume, the higher is the difference between 
planned mean dose and actual mean dose of the target volume. In all cases an underdosage of the tumor vol-
ume was found. The most extreme case investigated in this work showed an underestimation of the mean dose 
of  −14% (800 µm,). But more clinical relevant setups (distance of 6 cm, modulation power of 250 µm, see fig-
ure 6) result in an underestimation of about 2%.
In general, it was found that the Bragg peak modulation smooths the dose distribution: hot spots are reduced 
leading to a steeper gradient in the DVH around a reduced mean value in comparison to the DVH predicted by 
the TPS.
Another dependency that was investigated was the energy selection by the TPS, which was found to have an 
influence on the dose distribution. All plans calculated with a thicker thorax wall and thus higher energy selection 
showed an increased dose difference. This correlates with the results obtained for the spot spacing as param-
eter under investigation: energy spacing has a relevant impact on the dose when the Bragg peak degradation is 
accounted for. An increased number of energy layers throughout the tumor (and not distal to the tumor) leads 
to a decrease of the weight of each spot. With the Bragg peak degradation the peak dose is decreased and as the 
missing dose is only distributed in the distal region, more spots result in a decreased peak dose thus a decreased 
mean dose.
At last, the effect of tissue distal to the tumor was investigated as it is the case when the tumor is attached to the 
meadiastinum. It was found that this has no direct influence on the dose calculated with and without the Bragg 
peak degradation accounted for. However, for the given TPS settings, the plan optimization process was highly 
influenced by distal tissue. When a plan is optimized with tissue distal to the tumor with the same margin around 
the tumor more energy layers have spots within this margin because a spot spacing of e.g. 1 MeV results in about 
1 mm distance in water but a far higher distance in air. Therefore, plans optimized with distal tissue feature a 
higher dose behind the tumor, resulting in a decreased dose reduction when accounting for the Bragg peak degra-
dation. For small tumor volumes, the dose difference could be decreased by a half.
It was possible to include most results in the dose difference band in figure 7. This band allows an estimation 
of the uncertainty when not including the Bragg peak degradation in lung tissue for many clinical cases. If an 
approximation of the effect on the dose distribution for clinical case is of interest, the average distance in lung 
needs to be estimated and the tumor length in beam direction needs to be measured and evaluated. With these 
information and the results presented in figure 7 the reduction of the mean dose can be estimated in a conserva-
tive approach or a more probable approach.
In comparison to the intra- and interfractional motion in proton treatment of lung cancer (Widesott et al 
2008, De Ruysscher et al 2015), the underestimation of 2% in the best case seems negligible, but differences 
around 10% that were also observed should rather not be neglected. Nevertheless, as tumor movement is more 
and more accounted for by robust planning, gating, tracking and plan-of-the-day concepts thus reducing the 
effect on the dose distribution to a minimum, future treatment concepts should aim for an incorporation of the 
Bragg peak degradation.
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Figure 6. The dose difference of the mean dose of the PTV and GTV for a modulation power of 250 µm, 450 µm and 800 µm, 
respectively is plotted against the distance in lung. As size, the smallest volume of 1 cm3 was chosen.
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As the measurements of the modulation power covers a broad range and the change in the modulation power 
shows the most severe changes in the dose effects, more data for the modulation power in human lungs are 
needed.
5. Conclusion
A detailed 3D systematic analysis of the effect of the Bragg peak degradation was performed. The results were 
presented in dependency of the distance through lung tissue, the size and shape of the treatment volume, as 
well as plan specific parameters as particle energy and spot distance. The effects were estimated for different 
modulation powers, giving a worst-case scenario and more likely scenarios. The results allow for the first time an 
approximation of the uncertainty on the mean dose for a clinical scanned proton treatment plan. Even though 
tumor movement affects the treatment outcome more than the Bragg peak degradation, an inclusion of the 
dose changes due to the Bragg peak degradation is bringing proton therapy for lung carcinomas closer to a high 
precision therapy.
References
Agostinelli S et al 2003 Geant4—a simulation toolkit Nucl. Instrum. Methods Phys. Res. A 506 250–303
Baumann K-S, Witt M, Weber U, Engenhart-Cabillic R and Zink K 2017 An efficient method to predict and include Bragg curve degradation 
due to lung-equivalent materials in Monte Carlo codes by applying a density modulation Phys. Med. Biol. 62 3997
De Ruysscher D, Sterpin E, Haustermans K and Depuydt T 2015 Tumour movement in proton therapy: solutions and remaining questions: 
a review Cancers 7 1143–53
Espana S and Paganetti H 2011 Uncertainties in planned dose due to the limited voxel size of the planning CT when treating lung tumors 
with proton therapy Phys. Med. Biol. 56 3843
Goitein M 1977 The measurement of tissue heterodensity to guide charged particle radiotherapy Int. J. Radiat. Oncol. Biol. Phys. 3 27–33
Perl J, Shin J, Schuemann J, Faddegon B and Paganetti H 2012 TOPAS: an innovative proton Monte Carlo platform for research and clinical 
applications Med. Phys. 39 6818–37
Ringbaek T P, Simeonov Y, Witt M, Engenhart-Cabillic R, Kraft G, Zink K and Weber U 2017 Modulation power of porous materials and 
usage as ripple filter in particle therapy Phys. Med. Biol. 62 2892
Sawakuchi G, Titt U, Mirkovic D and Mohan R 2008 Density heterogeneities and the influence of multiple Coulomb and nuclear scatterings 
on the Bragg peak distal edge of proton therapy beams Phys. Med. Biol. 53 4605–19
Schneider U, Pedroni E and Lomax A 1996 The calibration of CT Hounsfield units for radiotherapy treatment planning Phys. Med. Biol. 
41 111
Schulz-Ertner D and Tsujii H 2007 Particle radiation therapy using proton and heavier ion beams J. Clin. Oncol. 25 953–64
Sell M, Titt U, Perles L, Mirkovic D, Mohan R, Babert M and Oelfke U 2012 WE-E-BRB-02: evaluation of analytical proton dose predictions 
with a lunglike plastic phantom Med. Phys. 39 3956
Titt U, Sell M, Unkelbach J, Bangert M, Mirkovic D, Oelfke U and Mohan R 2015 Degradation of proton depth dose distribution attributable 
to microstructures in lung-equivalent material Med. Phys. 42 6425
Urie M, Goitein M, Holley W and Chen G 1986 Degradation of the Bragg peak due to inhomogeneities Phys. Med. Biol. 31 1
-18
-16
-14
-12
-10
-8
-6
-4
-2
0
0 5 10 15 20
)
%( ecnereffid esod
dL/LS
800 µm
450 µm
250 µm
Ellipsoids
4 cm Wall
800 µm
450 µm
250 µm
Figure 7. All dose differences for the mean dose are presented in a combined format as they are plotted against the depth in lung 
(dL) divided by the scaled tumor length in beam direction (LS) as proposed in equation (1). All PTV and GTV mean dose differences 
are displayed. The yellow band marks the fit through all data points as presented for a modulation power of 800 µm, visualizing the 
2σ-range of the dose differences in dependence of the parameters. The green band fits through all data points calculated with the  
450 µm modulation power. The red band has the same dimension as the yellow band but the slope is optimized to fit to all results 
present for a modulation power of 250 µm.
Phys. Med. Biol. 64 (2019) 155005 (11pp)
11
V Flatten et al
Widesott L, Amichetti M and Schwarz M 2008 Proton therapy in lung cancer: clinical outcomes and technical issues a systematic review 
Radiother. Oncol. 86 154–64
Wilson R 1946 Radiological use of fast protons Radiology 47 487–91
Witt M 2014 Modulationseffekte von Kohlenstoffionen bei der Bestrahlung von Lungen Master’s Thesis Technische Hochschule 
Mittelhessen—University of Applied Sciences, Giessen, Germany
Witt M, Weber U, Simeonov Y and Zink K 2015 SU-E-T-671: range-modulation effects of carbon ion beams in lung tissue Med. Phys. 
42 3491
Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, Cox J D and Chang J Y 2010 Intensity-modulated proton therapy reduces the dose to 
normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized 
radical radiotherapy for extensive stage iiib non-small-cell lung cancer: a virtual clinical study Int. J. Radiat. Oncol. Biol. Phys. 
77 357–66
Phys. Med. Biol. 64 (2019) 155005 (11pp)
RESEARCH Open Access
Effects of the Bragg peak degradation due
to lung tissue in proton therapy of lung
cancer patients
Kilian-Simon Baumann1,2* , Veronika Flatten1,2, Uli Weber3, Stefan Lautenschläger1,4, Fabian Eberle1,4,
Klemens Zink1,2,5 and Rita Engenhart-Cabillic1,4
Abstract
Purpose: To quantify the effects of the Bragg peak degradation due to lung tissue on treatment plans of lung
cancer patients with spot scanning proton therapy and to give a conservative approximation of these effects.
Methods and materials: Treatment plans of five lung cancer patients (tumors of sizes 2.7–46.4 cm3 at different
depths in the lung) were optimized without consideration of the Bragg peak degradation. These treatment plans
were recalculated with the Monte Carlo code TOPAS in two scenarios: in a first scenario, the treatment plans were
calculated without including the Bragg peak degradation to reproduce the dose distribution predicted by the
treatment-planning system (TPS). In a second scenario, the treatment plans were calculated while including the
Bragg peak degradation. Subsequently, the plans were compared by means of Dmean, D98% and D2% in the clinical
target volume (CTV) and organs at risk (OAR). Furthermore, isodose lines were investigated and a gamma index
analysis was performed.
Results: The Bragg peak degradation leads to a lower dose in the CTV and higher doses in OARs distal to the CTV
compared to the prediction from the TPS. The reduction of the mean dose in the CTV was − 5% at maximum
and − 2% on average. The deeper a tumor was located in the lung and the smaller its volume the bigger was the
effect on the CTV. The enhancement of the mean dose in OARs distal to the CTV was negligible for the cases
investigated.
Conclusions: Effects of the Bragg peak degradation due to lung tissue were investigated for lung cancer
treatment plans in proton therapy. This study confirms that these effects are clinically tolerable to a certain
degree in the current clinical context considering the various more critical dose uncertainties due to motion
and range uncertainties in proton therapy.
Keywords: Proton therapy, Lung modulation, Bragg peak degradation, Treatment planning
Background
Since proposed for radiation therapy, ion beams are of
increasing interest in radiation oncology [1, 2]. In homo-
geneous materials the dose profile of heavy charged par-
ticles such as protons consists of a low dose plateau at
small depths followed by the so-called Bragg peak where
most of the dose is deposited. The Bragg peak is
followed by a sharp distal fall-off. This finite range and
sharp distal fall-off of the dose deposition as well as the
comparable low entrance dose lead to a reduction in the
integral dose. These advantages of protons in radiation
therapy lead to the possibility of a conformal dose distri-
bution in the target while sparing surrounding healthy
tissue [3]. Mainly two approaches for the use of proton
therapy have evolved [4]: 1) to escalate the dose in the
tumor while allowing the same dose to organs at risk
(OAR) compared to conventional photon therapy and 2)
keeping the target dose constant compared to conven-
tional photon therapy and reducing the dose deposited
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to OARs as much as possible. Both approaches can be
considered for the treatment of lung cancer patients
with protons. On the one hand, it has been shown in
some studies that a dose escalation in the tumor
improves local control and survival in non-small cell
lung cancer (NSCLC) patients [4]. On the other hand,
the sparing of healthy tissue is of interest for tumors in
difficult anatomies where the tumor is located near to
sensitive structures or even enclosed by OARs. This is
often the case for lung cancer patients due to the
possible proximity of OARs like the heart, esophagus,
trachea, large blood vessels and the spinal cord [4].
For early-stage NSCLC patients the outcomes achieved
with proton therapy are similar to those achieved with
stereotactic body radiotherapy (SBRT) [4] despite excel-
lent dose distributions and sparing of OARs. This holds
especially for small peripheral lesions, since these are
mostly located far from critical structures (except for
ribs and chest wall) and hence a sparing of OARs is well
achievable with SBRT. However, for larger tumors,
especially those located near to OARS, proton therapy
might be superior to SBRT.
For locally advanced (stage III) lung cancer patients,
virtual clinical studies showed that in proton plans it is
possible to reduce the dose deposition in normal tissue,
especially in the heart, compared to photon plans [3–5].
Additionally, a phase II study with 44 patients showed
an enhanced median survival in a combined radio-
chemotherapy when irradiating with protons compared
to photons. The patients treated with protons showed
minimal grade 3 toxicities [4, 6].
In addition to the debatable benefits of proton therapy
compared to SBRT in lung cancers, some difficulties in
treating lung cancers with protons arise due to the
underlying physics as well as the technical application of
the proton beam. One of the main issues is the range of
protons that depends on the material in the beam path:
in case that the patient’s anatomy changes and hence is
different during the treatment compared to the treatment-
planning process, the range and hence the dose deposition
can be different to that predicted by the TPS. Hence, the
outcome of the treatment is vulnerable to changes in the
anatomy of the patient as the patient moves, is not opti-
mally positioned or the anatomy of the patient changes
between fractions, e.g. due to a shrinkage of the tumor or
weight loss [7–10]. Especially the change in the anatomy
between fractions causes a need in plan adaption
strategies for proton therapy [11].
Another issue is that the range of protons is predicted
based on X-ray CT images while the conversion of
stopping powers from X-ray CT images is inaccurate
[12, 13]. Furthermore, uncertainties in the dose depo-
sited arise from uncertainties in biological effectiveness
models [7, 14].
A crucial topic in the proton therapy of lung cancer
patients is motion management since interplay effects
due to respiratory motion or motion of the heart com-
bined with the precise application of actively scanned
proton beams can lead to a severe underdosage of the
target volume [15–20].
Another uncertainty in proton therapy of lung cancer
patients arises from the characteristics of the lung tissue
itself: The heterogeneous structure of the lung tissue
leads to a degradation of the Bragg peak and to a wider
distal fall-off [21, 22]. If this degradation is not consi-
dered correctly during the treatment planning of lung
cancer patients, it might lead to an underdosage of the
target volume and an overdosage of normal tissue distal
to the target volume [22, 23]. Although this degradation
has been described in numerous works [24–29], it can-
not be considered in the clinical treatment-planning
process and dose calculation on treatment-planning CT
images. The reason is that due to the restricted reso-
lution of treatment-planning CTs, the microscopic struc-
ture of lung tissue is not resolved sufficiently and a more
homogeneous tissue distribution is predicted [26, 30].
Baumann et al. [29] introduced and extensively tested
an efficient method to consider the Bragg peak degrad-
ation on the base of typically used treatment-planning
CT data in Monte Carlo codes by applying a density
modulation to voxels associated with the lung. Flatten
et al. [31] used this model to estimate the effects of the
Bragg peak degradation based on a phantom study
where spherical tumors of different sizes were placed at
different depths in the lung and the underdosage of the
target volume was quantified. The result showed that
the underdosage of the target volume increases with an
increasing depth of the tumor in lung and a decreasing
tumor volume. The maximum underdosage in terms of
the mean dose was − 15% compared to the dose distri-
bution predicted by the treatment-planning system that
did not consider the Bragg peak degradation.
In this study the effects of the Bragg peak degradation
were investigated on clinical cases for various anatomical
locations of the tumor in the lung and different treat-
ment plans. We chose simple field configurations so that
the results can be used by a large variety of proton cen-
ters. The goal is to give upwards estimations for the dose
uncertainty in the target volume and OARs. For that, we
included also extreme cases (e.g small tumor volumes
and large depths in lung) to quantify the maximum
degradation effect in realistic patient anatomies.
Methods and materials
Selection of patients
We investigated five exemplary clinical cases with tumor
volumes between 2.7 cm3 and 46.4 cm3. The tumors
were located in the right lung in the upper lobe (two
Baumann et al. Radiation Oncology          (2019) 14:183 Page 2 of 15
cases) or the central lobe (three cases). We chose the
clinical cases to have tumors located in the center of the
lung as well as tumors that are located near to soft tissue
or OARs. In doing so we are able to investigate different
depth of the tumor in the lung as well as the effects of
the Bragg peak degradation on surrounding normal tis-
sue and OARs. For two cases the tumor was located
near to the spinal cord. No tumor was located directly at
the thorax wall in order to always have lung tissue
between the thorax wall and the tumor and hence in the
beam path. The patients were originally treated with
photons and retrospectively re-planned with protons for
this study. We used different beam directions in the
proton plans to generate different path lengths in the
lung (see Fig. 1 and Table 1).
As described in the introduction, small tumor volumes
as investigated in this study might not benefit from pro-
ton therapy compared to SBRT and hence tend to be
less relevant for proton therapy. Yet, small tumor
volumes have been treated with protons at different cen-
ters [32–34], with volumes going down to only 1 cm3.
Furthermore, Flatten et al. [31] showed that the effects
of the Bragg peak degradation increase with a decreasing
tumor volume. Thus, we investigated these small tumors
as well, in particular to derive an upwards estimation for
larger and thus clinically more relevant tumor volumes.
Treatment planning
All treatment plans were optimized with Eclipse v.13.7
(VARIAN) using the non-linear universal proton optimizer,
v.13.7.15. The total prescribed dose was 30Gy (RBE) and
the only planning objective was to deliver at least 95% of
the prescription dose to at least 98% of the planning target
volume (PTV). For small tumor volumes we accepted hot
spots (up to 115% of the prescribed dose) in the PTV. The
PTV was the clinical target volume (CTV) plus an isotropic
margin of 3mm, although most PTV concepts proposed in
the literature [7, 34–36] are field specific and account for
uncertainties of the proton’s range or the positioning of the
patient. However, in the majority of clinical situations, an
isotropic margin around the CTV is used for treatment
planning as done in this study. Additionally, we planned on
static CT data, ignoring movements of the anatomy due to
respiration in both the planning and dose calculation. By
excluding any effects due to motion, positioning of the
patient or range uncertainties, we are able to extract the
pure effects of the Bragg peak degradation. We analyzed
these effects on the CTV and not the PTV, since the CTV
Fig. 1 CT slices of one exemplary patient (patient 1): for the beam directions 0°, 270° and 315° plans were optimized individually consisting of
one single field. On the bottom right the sum of these plans is shown. The CTV is marked in white, trachea in light green and spinal cord in red.
On the right a color bar is given indicating the relative dose
Baumann et al. Radiation Oncology          (2019) 14:183 Page 3 of 15
is the clinically relevant structure. Since for each optimized
plan the dose deposited in the OARs was below any critical
value we did not include any constraints for OARs in the
treatment-plan optimization.
We decided to investigate simple treatment plans
consisting of only one single field coming from ei-
ther 0°, 270° or 315°. We used different beam direc-
tions to generate different depths of the CTV in the
lung. The distal spot spacing was 3 mm, the lateral
spot spacing was 0.45 times the full-width-half-max-
imum (FWHM) in air. The FWHM for 70 MeV pro-
tons was 32.5 mm and for 221 MeV protons it was
8.1 mm.
The different beam directions are shown in Fig. 1 for
one exemplary patient. As described later in the text, we
also made a sum plan of the three single field plans for
each patient as shown in Fig. 1 bottom right. In Fig. 2
the remaining four patients are shown with one
exemplary treatment plan each.
Although some of these beams may not be the
best choice from a clinical point of view (e.g. OARs
distal to the PTV, large depth of the tumor in the
lung), we decided to investigate these cases anyway
to give an upwards estimation for the effects of the
Bragg peak degradation also for worst-case scenarios.
The motivation for using simple treatment plans is
to highlight the effects of the Bragg peak degrad-
ation. Furthermore, there is no gold standard in plan
design for lung cancer patients, especially concerning
the choice of number of fields and beam directions,
although several proton centers have already treated
lung cancer patients with protons [6, 32–34]. Thus,
in keeping the treatment plans simple, we can assure
that the results from this study are usable for as
many different proton centers as possible since the
dependencies of the Bragg peak degradation (e.g. on
the depth of tumor in lung) can be assessed more
easily using simple treatment plans compared to
complex IMPT plans.
In order to assess whether the results from this study
can be used to estimate the effects of the Bragg peak
degradation for more complex plans, we investigated
two IMPT plans, one each for patient 1 and 5 as shown
in Fig. 3. The choice fell on these two patients since they
have the largest and smallest tumor volume (compare
Table 1). Multi-field optimization was enabled to
optimize three fields for each plan. The same PTV con-
cept and planning objectives were used as for the simple
plans. For patient 1 the beam directions were 180°, 270°
and 330°. For patient 5 the beam directions 10°, 180° and
270° were used.
Simulations
Simulations were performed using the Monte Carlo code
TOPAS (Tool for Particle Simulations) version 3.1.p1 [37],
a toolkit based on Geant4 (Geometry And Tracking) ver-
sion geant4–10-03-patch-01 [38]. We used the same beam
data in both TOPAS and Eclipse and commissioned these
data to match the beam delivery system at the Ion-Beam
Therapy Center Marburg. Dose calculation results in
water between TOPAS and Eclipse agreed well. The
passing rate of the gamma index 1%/1mm for voxels with
dose values greater than 20% of the maximum dose was
larger than 98% for single spots. It is known that dif-
ferences between dose calculation algorithms as used in
Eclipse and Monte Carlo codes such as TOPAS exist
especially for dose calculations in the lung [39]. Hence, all
dose calculations were performed with TOPAS so that
differences in the dose calculation between TOPAS and
Eclipse do not falsify the results.
Each treatment plan optimized with Eclipse was
recalculated in TOPAS in two scenarios: In the first
scenario, each optimized treatment plan was calculated
on the original CT data. Hence, this calculation cor-
responds to the prediction from the treatment-planning
system. In a second scenario, the plans were recalculated
while considering the Bragg Peak degradation. To do so,
we used the mathematical model presented by Baumann
et al. [29]. The strength of the Bragg peak degradation is
quantified by the material characteristic “modulation
power” Pmod: The greater the modulation power of a
heterogeneous material like lung tissue the broader the
Table 1 Volumes of the CTVs and lungs for the five patients and minimum and maximum diameter of the CTVs as well as depths in
lung of the CTVs for each beam direction. The depth of the CTV corresponds to the path length through lung tissue for the spot at
the isocenter
Patient Lung volume
in cm3
Volume of
CTV in cm3
min./max.
diameter of
CTV in cm
Depth of CTV in cm for different beam directions
0° 270° 315°
1 2294 46.4 2.9/4.2 6.2 3.3 3.6
2 1882 4.2 1.8/2.3 1.8 2.1 1.5
3 1705 32.1 3.5/5.2 12.2 9.2 9.2
4 1780 6.2 2.2/2.4 6.9 2.7 5.3
5 1600 2.7 1.6/2.0 4.5 3.8 3.6
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Bragg peak and the less steep the distal fall-off as shown
in Fig. 4. Based on the modulation power a density dis-
tribution can be derived. When modulating the density
of each voxel associated with the lung within the patient
following this density distribution, the Bragg peak deg-
radation due to the lung tissue is being reproduced [29].
The dose distributions for each plan obtained from using
the original CT data (non-modulated case) and when ap-
plying the density modulation (modulated case) were
compared in means of cumulative dose volume histo-
grams (DVH), mean doses Dmean, D98% and D2% in the
CTV and OARs. Additionally, we investigated the differ-
ences in the dose distribution when combining the dose
distributions from the single plans (beam directions 0°,
Fig. 3 CT slices of the patients 1 and 5 (marked in red numbers) with the dose distributions for the optimized IMPT plans. The CTV is marked in
white, trachea in light green and spinal cord in red. On the right a color bar is given indicating the relative dose
Fig. 2 CT slices of the remaining patients. The patient’s numbers are marked in red. For each patient one exemplary plan is shown. The CTV is
marked in white, trachea in light green and spinal cord in red. On the right a color bar is given indicating the relative dose
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270° and 315°) for each patient to an added-up dose
distribution to investigate the influence of the number of
irradiated fields on the degradation effects.
In a study by Witt [40] the modulation powers of por-
cine lungs were measured in proton beams to be in the
range from 300 μm to 750 μm. Since the measurements
were performed with complete lungs, the measured
modulation powers correspond to integrated modulation
powers of all the structures of the lung being arranged
in the beam that cannot be identified in CT images. The
modulation power increases with increasing structure
sizes [29]. Thus, the modulation power varies with the
position in the lung. In the peripheral region of the lung
the modulation power tends to be smaller compared to
the central lung where the size of the structures is
greater. For almost each measurement the modulation
power was in the range from 300 μm to 500 μm with an
average of 450 μm. For one measurement the modula-
tion power was 750 μm. However, for this measurement
the lung was positioned in a way that a large bronchial
structure was in the beam line.
To clarify whether these results obtained with porcine
lungs are applicable for human lung tissue, high-resolution
CT images with a resolution of 4 μm of human lung tissue
samples were investigated by Witt [40] and Baumann et al.
[29]. The so-gained modulation powers were in the range
from 50 μm to 250 μm. The authors discussed that the
preparation of the tissue samples resulted in a noticeable
loss of water of up to 37% and hence in a reduction of the
sizes of the lung structures. Therefore, the modulation
powers gained in this investigation are lower compared to
the measurements with porcine lungs.
Both the measurements with porcine lungs and the
investigation of human lung tissue samples indicate that
the modulation power of lung tissue is in the order of
some hundred micrometers. However, until now there is
no possibility to determine a patient-specific modulation
power for each region of the lung. Therefore, in this
study we investigated the effects of the Bragg peak
degradation based on modulation powers of 100 μm,
250 μm, 450 μm and 800 μm, covering the whole range
of modulation powers found in the measurements of
porcine lungs and the investigation of human lung
tissue samples with some additional buffer to determine
the minimum and maximum degradation effects in
exemplary clinical cases. For the IMPT plans we only used
a modulation power of 450 μm.
Results
In Fig. 5 on the left side the DVH for patient 1 and the
beam direction 270° is shown for the CTV and the OAR
trachea. The Monte Carlo calculated DVH for each vol-
ume is shown for the non-modulated case representing
the dose distribution predicted by the treatment-planning
system and the modulated cases where the Bragg peak
degradation based on modulation powers between 100 μm
and 800 μm is considered. The dose coverage of the CTV
decreases with an increasing modulation power. The dose
deposited in the trachea increases with an increasing modu-
lation power. On the right side the depth dose curves along
the center of the beam for the non-modulated scenario and
the modulated one based on the maximum modulation
power of 800 μm are shown. The positions of the body, the
lung and the CTV are marked by dashed black lines. We
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Fig. 4 Depth dose curves of protons in water. In black the Bragg curve as predicted by the treatment-planning system that does not consider
the Bragg peak degradation due to the lung tissue. In red and blue the degraded Bragg curves based on modulation powers Pmod of 100 μm
and 800 μm. The greater the modulation power the broader the Bragg peak and the less steep the distal fall-off
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decided to show the results for the extreme modulation
power of 800 μm since for a smaller modulation power the
effects are not visible as clearly: when entering the body
both dose distributions are the same. In the lung the effects
of the degradation can be seen resulting in a broader dose
curve and a less steep fall-off for the modulated case.
Within the CTV there is a slightly higher dose for the non-
modulated case. In the lung distal to the CTV there is a
significantly higher dose for the non-modulated case. The
background is that in this case a spot is used by the TPS
where the Bragg peak is located distal to the CTV in order
to achieve a sufficient dose coverage within the CTV. This
peak is smoothed in the modulated case as described by
Flatten et al. [31]. In the body distal to the lung the
dose for the modulated case is higher due to the
broader fall-off resulting in a larger range and hence a
higher dose deposition.
In Fig. 6 exemplary isodose lines [41, 42] for 95, 80
and 20% of the prescribed dose are shown for the non-
modulated case (pink) and the modulated case based on
a modulation power of 800 μm (green). Additionally, the
CTV is marked in white, the trachea in light green and
the spinal cord in red. Again, we decided to show the
results for the extreme modulation power of 800 μm.
The 95% isodose lines are shown in the left column, the
80% in the middle column and the 20% in the right
column. In the first line the isodose lines for patient 1
(marked with a white number) are shown for the beam
direction 270°. The regions enclosed by the 95 and 80%
isodose lines are larger for the non-modulated cases
indicating the underdosage of the CTV due to the Bragg
peak degradation (compare DVH and depth dose in
Fig. 5). The 20% isodose line for the modulated case
reaches farther compared to the non-modulated case.
The same effects can be seen for all patients.
The greater range of the 20% isodose lines shows the
potential risk of an overdosage in OARs distal to the
target volume. Especially for patient 3 and 4 in Fig. 6 the
isodose lines for 20% of the prescribed dose reach into
the spinal cord. However, the additional range of the
20% isodose lines is 2 mm at maximum for these two
patients. The maximum shift of each isodose line for the
modulated case compared to the non-modulated case
for the patients as shown in Fig. 6 are listed in Table 2.
A negative sign marks a shorter range compared to the
non-modulated case. The range uncertainties of the iso-
dose lines in lung (patient 1 and patient 2 except for the
20% isodose line) are larger compared to those in tissue
(patient 3 and 4 all isodose lines and 20% isodose line of
patient 1).
To quantify the effects shown in Figs. 5 and 6 in terms
of dose, the absolute dose values for the non-modulated
case and the differences in percent of the mean dose
Dmean, D98% (the dose that is received by 98% percent of
the volume) and D2% between the modulated cases and
the non-modulated case for patient 1 are reported in
Table 3 for the CTV, the trachea and the spinal cord.
The D98% is taken to quantify the minimum dose re-
ceived by a volume while the D2% is taken to quantify
the maximum dose received by a volume. For the OARs
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Fig. 5 Left side: Cumulative dose-volume histogram for the CTV and trachea for patient 1 and the beam direction 270° for both the non-
modulated case and the modulated cases based on modulation powers between 100 μm and 800 μm. Right side: depth dose curve along the
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the mean dose Dmean and the D2% as a quantification of
the maximum dose are shown.
The mean dose Dmean, D98% and D2% in the CTV are
smaller for the modulated cases compared to the non-
modulated case and hence the prediction from the
treatment-planning system. The differences increase
with an increasing modulation power. The largest
differences can be seen for the beam direction 0°
(corresponding to the largest depth in lung) and the
maximum modulation power of 800 μm. Concerning the
OARs trachea and spinal cord, the doses deposited in
the modulated cases are greater compared to the non-
modulated case for the beam directions 270° and 315°.
The differences increase with an increasing modulation
power. The maximum difference in the mean dose
Dmean is + 24% for the trachea as well as the spinal cord.
However, these relative deviations correspond to low
absolute deviations of 0.3 Gy and < 0.1 Gy, respectively.
The largest difference for the D2% value for the trachea
is + 24% and + 21% for the spinal cord. These deviations
correspond to 1.5 Gy and 0.2 Gy, respectively. It can be
seen, that the effects of the Bragg peak degradation on
the OARs are almost non-existent for a beam direction
0° since in this case no OAR is positioned distal to the
PTV. The effects on the trachea are largest for the beam
direction 270°. For the spinal cord the effects are largest
for the beam direction 315°.
In Table 4 the absolute dose values and the differences
in percent of the mean dose Dmean, D98% and D2% for
the CTV between the modulated cases and the non-
modulated case are shown for the patients 2 to 5. The
results are given for a modulation power of 800 μm to
Fig. 6 Isodose lines for 95, 80 and 20% of the prescribed dose. In pink for the non-modulated case, in green for the modulated case based on a
modulation power of 800 μm. In the first column the 95%, in the middle column the 80% and in the right column the 20% isodose lines.
Different patient cases are marked in white numbers. The CTV is marked in white, the trachea in light green and the spinal cord in red
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give an estimation of the maximum effects. Additionally,
the results for a more realistic modulation power of
450 μm are given. The deviations between the modulated
cases and the non-modulated case for the OARs are as
small and negligible as for patient 1 and hence not
shown for the other patients. As it is the case with
patient 1, the dose coverage of the CTV in the modulated
cases is lower compared to the non-modulated case.
For a modulation power of 800 μm the maximum
differences in the mean dose Dmean as well as the D98% are
roughly − 5%. For the D2% it is about − 4%. The average
difference in the mean dose Dmean is in the order of − 2%,
for D98% it is − 3% and for D2% it is about − 2%.
For a more realistic modulation power of 450 μm the
maximum differences in the mean dose Dmean, the D98%
as well as the D2% are roughly − 3%. The average
difference in the mean dose Dmean is in the order of − 1%,
for D98% it is roughly − 2% and for D2% it is − 1%.
Additionally, we looked at the differences in the mean
dose Dmean, D98% and D2% for the CTV between the
modulated cases and the non-modulated case when all
three plans from the beam directions 0°, 270° and 315°
are combined. As for the irradiation with one single
field, in the combined scenario with three fields, the
differences between the modulated cases and the non-
modulated case are at maximum about − 5% for a modu-
lation power of 800 μm. For a modulation power of
450 μm the maximum difference is about − 3%.
In Table 5 the passing rates for the gamma index
3%/1mm (local) are shown for each patient and the dose
distributions based on modulation powers of 450 μm and
800 μm. All voxels with at least 20% of the maximum dose
were included in the analysis. We chose to set a small
Table 3 Absolute dose values for the non-modulated case and differences in percent of the mean dose Dmean, D98% (only for the
CTV) and D2% for the CTV and OARs between the modulated and the non-modulated cases for patient 1
Modulation CTV Trachea Spinal cord
Dmean D98% D2% Dmean D2% Dmean D2%
beam direction: 0° (depth in lung: 6.2 cm)
Dnon-mod in Gy (RBE) 29.9 25.7 32.2 0.1 0.5 < 0.1 0.1
100 μm −0.3% −0.4% −0.4% −1% + 1% 0% − 1%
200 μm −0.7% − 1.2% − 0.8% 0% + 1% 0% − 1%
450 μm − 1.3% − 3.0% − 1.2% 0% + 2% 0% − 1%
800 μm −2.1% −4.9% − 1.8% 0% + 2% + 1% − 1%
beam direction: 270° (depth in lung: 3.3 cm)
Dnon-mod in Gy (RBE) 30.1 27.3 30.4 1.1 5.6 0.1 0.7
100 μm −0.2% −0.1% −0.2% + 7% + 9% + 2% + 6%
200 μm −0.5% −1.0% − 0.3% + 12% + 13% + 2% + 9%
450 μm − 0.5% −2.2% − 0.5% + 16% + 17% + 7% + 14%
800 μm − 0.9% −4.1% −0.6% + 24% + 24% + 9% + 21%
beam direction: 315° (depth in lung: 3.6 cm)
Dnon-mod in Gy (RBE) 29.8 26.6 41.6 0.2 1.0 0.1 0.7
100 μm 0.0% 0.0% + 0.1% + 3% + 2% + 6% + 7%
200 μm −0.4% −1.5% −0.2% + 2% + 1% + 11% + 11%
450 μm −0.8% −1.5% − 0.4% + 2% + 2% + 15% + 14%
800 μm − 1.5% −3.0% − 0.6% + 5% + 5% + 24% + 21%
Table 2 Maximum shift in mm of the isodose lines for the
modulated case based on a modulation power of 800 μm
compared to the non-modulated case for the patients and
beam directions as shown in Fig. 6. A negative sign stands
for a shorter range
Patient/beam
direction
Maximum range uncertainty in mm for isodose lines
95% 80% 20%
1 / 270° −8 −5 3
2 / 0° −8 −10 5
3 / 270° −4 −3 2
4 / 315° −2 −2 2
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distance-to-agreement since the effect of the Bragg peak
degradation leads to a broadening of the Bragg peak and
hence a small shift in the dose (compare Figs. 5 and 6).
The allowed dose difference was set to 3% since this is
roughly the average effect on the mean dose in the CTV
for a modulation power of 800 μm. For a modulation
power of 800 μm, the minimal passing rate is 90.4% for
patient 5 and the beam direction 315° corresponding to
the maximum difference in the mean dose (compare
Table 3). The average passing rate is 96.8%. For a modula-
tion power of 450 μm the minimum passing rate is 93.1%
and the average passing rate is 98.5%. We also investigated
the gamma index when including only those voxels with
at least 80% of the maximum dose. For this gamma index
the minimum passing rate is 84.0% with an average
passing rate of 94.6% for a modulation power of 800 μm.
In order to assess whether the results from this study
being derived using simple treatment plans can be used
to estimate the dose uncertainty due to the Bragg peak
degradation on more complex plans like IMPT plans, we
investigated two IMPT plans - one each for patient 1
and 5. The reduction of the mean dose Dmean of the
CTV was − 1% for patient 1 and a modulation power of
450 μm. For patient 5 it was about − 3%. For patient 1,
the reduction of the mean dose of the CTV approxi-
mately corresponds to the average dose reduction for
the simple treatments plans with beam directions 0°,
270° and 315° (compare Table 3). For patient 5 the dose
reduction for the IMPT plan is in the order of the
maximum effect for the simple treatment plans.
Discussion
The influence of the Bragg peak degradation due to lung
tissue on treatment plans of lung cancer patients was in-
vestigated. For all cases the treatment-planning system
overestimated the dose delivered to the CTV and in
some cases underestimated the dose delivered to distal
OARs. This effect increases with an increasing modula-
tion power. The maximum underestimation of the mean
dose Dmean is − 5% for the CTV and an extreme modula-
tion power of 800 μm. The average underestimation is in
the order − 2%. This extreme modulation power of
Table 4 Absolute dose values for the non-modulated case and differences in percent of the mean dose Dmean, D98% and D2%
between the modulated and the non-modulated cases for the CTV and the patients 2 to 5. The modulation powers used in these
cases are 450 μm and 800 μm
Patient Modulation Beam direction: 0° Beam direction: 270° Beam direction: 315°
Dmean D98% D2% Dmean D98% D2% Dmean D98% D2%
2 Dnon-mod in Gy (RBE) 29.9 23.4 32.0 30.1 25.2 31.1 30.0 22.1 32.3
450 μm −1.8% −0.7% −0.2% − 1.1% − 0.8% − 0.7% −1.1% − 1.5% − 0.7%
800 μm − 3.1% − 2.9% − 3.8% − 1.9% −1.4% − 1.1% − 2.0% − 2.5% −1.2%
3 Dnon-mod in Gy (RBE) 30.0 25.8 32.2 30.1 28.3 31.5 30.0 27.0 31.9
450 μm −1.1% −1.4% −0.9% −0.6% −2.9% − 0.5% − 0.8% − 2.2% − 0.8%
800 μm − 1.8% −2.8% −1.5% − 1.1% −5.1% −0.8% −1.4% − 4.2% − 1.1%
4 Dnon-mod in Gy (RBE) 30.0 25.7 31.0 30.0 24.2 32.2 30.0 26.8 30.8
450 μm −1.3% −2.5% −0.8% −0.6% −1.2% − 0.3% − 0.6% −1.1% − 0.4%
800 μm − 2.2% −4.2% − 1.2% −1.0% −2.0% − 0.5% −1.0% −2.0% − 0.7%
5 Dnon-mod in Gy (RBE) 30.1 27.2 32.8 30.0 23.7 31.6 30.1 27.9 33.8
450 μm −2.6% −0.5% −1.1% −2.0% −3.0% − 2.1% −3.0% − 1.5% −3.2%
800 μm −4.7% − 2.8% −2.1% − 3.1% − 4.6% − 3.2% − 4.9% −2.5% −4.3%
Table 5 Passing rates in percent of the gamma index 3%/1 mm
including all voxels with at least 20% of the maximum dose for all
patients depending on the modulation power and beam
direction
Patient Modulation
power
Beam direction
0° 270° 315°
1 450 μm 98.5 97.2 99.0
800 μm 96.4 95.4 97.3
2 450 μm 97.3 99.3 99.9
800 μm 94.7 95.5 99.2
3 450 μm 99.5 99.8 99.6
800 μm 98.8 99.0 99.0
4 450 μm 99.9 100 99.9
800 μm 99.6 100 99.9
5 450 μm 96.0 98.2 93.1
800 μm 91.7 95.6 90.4
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800 μm can occur in cases where a larger bronchial
structure in the lung is positioned in the proton beam.
However, for a more realistic modulation power of
450 μm, the underestimation of the mean dose Dmean is
only about − 3% at maximum. The average underestimation
is roughly − 1%.
Concerning the effects on OARs, it was shown that
the effects are dependent on the beam direction which
defines the relative position between the target volume
and OAR for a given anatomy: As shown in Fig. 5 on
the right side, the Bragg peak degradation results in a
higher dose distal to the Bragg peak. Hence, only OARs
distal to the PTV can receive a higher dose than pre-
dicted by the treatment-planning system. Due to range
uncertainties in proton therapy it would typically be
avoided to arrange fields in a way that an OAR is located
directly distal to the PTV. Nevertheless, in some cases
this is inevitable for example when the patient has been
previously irradiated in this region or due to technical
limitations of the beam delivery system. Additionally,
anatomical characteristics could enforce an irradiation
where an OAR is positioned distal to the PTV as it is
the case with patient 3 as shown in Fig. 2: for the beam
directions 315° and 270° the spinal cord is positioned
distal to the PTV. However, for the beam direction 0°
the beam crosses the heart and the distance in lung is
quite large. Since a patient’s anatomy can oblige to use
beams where an OAR is positioned distal to the PTV,
we also investigated these cases. The underestimation of
the mean dose Dmean in the OARs trachea and spinal
cord was 0.3 Gy at maximum. For the D2% quantifying
the maximum dose deposited in these OARs it was 1.5 Gy
at maximum. The resulting enhanced dose deposited to
OARs is far from any dose constraints used in the
conventional treatment planning. Thus, the effects of the
Bragg Peak degradation on OARs distal to the PTV are
negligible for the cases investigated. However, in cases
where the OAR is located directly distal to the PTV the
effects might be larger and significant.
We were able to reproduce the findings from Flatten
et al. [31] that the effects of the Bragg peak degradation
increase with an increasing depth of the tumor in the lung
and a decreasing tumor volume: for example, for patient 1
the underdosage of the CTV increases from − 0.5% to
− 1% (for a modulation power of 450 μm) between the
beam direction 270° where the tumor depth is 3.3 cm and
the beam direction 0° where the depth is 4.6 cm.
When comparing the results from patient 1 for the
beam direction 315° with the results from patient 5 for
the beam direction 315° one can see that in both cases
the tumor is at a depth of 3.6 cm (see Table 1). However,
the CTV of patient 1 is with 46.4 cm3 much larger
compared to patient 5 with a volume of 2.7 cm3. The
effect of the Bragg peak degradation on the mean dose
in the CTV for patient 1 is with − 1% much smaller
compared to patient 5 with − 3% (for a modulation
power of 450 μm).
Regarding the number of fields used to irradiate the
CTV, it was shown that as expected, the effect of the
Bragg peak degradation is independent on the number
of fields as long as these fields are optimized
individually.
Concerning the complexity of the irradiation plans,
we decided to investigate simple plans with only one
single field as described in the Methods & materials
section. By investigating different beam directions, a
large variety of scenarios (depth of tumor in lung,
OAR distal to the PTV) has been covered and even
for the worst cases the underdosage of the CTV was
− 5% at maximum for an extreme modulation power
of 800 μm and only about − 3% for a more realistic
modulation power of 450 μm. To assess whether these
results can be applied to more complex treatment
plans, we investigated two IMPT plans for a realistic
modulation power of 450 μm. For both patients the
reduction of the mean dose of the CTV was in the
same order compared to the simple treatment plans.
This supports the statement that the results found in
this study – although being derived using simple
treatment plans – can be used to estimate the dose
uncertainties due to the Bragg peak degradation for
more complex plans.
The passing rate of the gamma index was on average
96.8% for a modulation power of 800 μm and 98.5% for
a modulation power of 450 μm. The minimum passing
rate for a realistic modulation power of 450 μm was
93.1%. The high passing rate of the gamma index is rea-
sonable because as shown in Figs. 5 and 6 the Bragg
peak degradation leads to a shift of the isodose lines.
This shift is on average very small and hence covered by
the distance-to-agreement in the gamma index. For all
cases investigated in this study the passing rate was
clinically acceptable. In addition to the finding that the
reduction of the mean dose is on average only in the order
of − 1% and at maximum − 3% for a realistic modulation
power of 450 μm, this supports that the effects of the
Bragg peak degradation are clinically tolerable.
What is more, it is well-known in the literature
that the relative biological effectiveness (RBE) of
protons is larger than 1.1 at the distal part of the
Bragg peak [43]. At the moment, this change in RBE
is not considered in commonly used treatment-
planning systems, hence, this larger biological effect
might partially balance out the physical underdosage
of the target volume due to the Bragg peak degrad-
ation which mainly occurs at the distal end of the
Bragg peak and hence the target volume (compare
Fig. 5). However, this change in RBE could also
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potentially increase the effects of the larger dose de-
posited in normal tissue distal to the Bragg peak.
The Bragg peak degradation due to lung tissue is only
one of various issues in proton therapy in general and in
proton therapy of lung cancer patients in particular as
mentioned in the introduction. Thus, the dose and range
uncertainties due to this degradation shall be compared
to these other uncertainties in order to quantify its im-
portance in the current clinical context. In a study by
Paganetti [7] an overview of range uncertainties is given.
Range uncertainties in proton therapy arise – among
other things – from measurement uncertainties in water
for commissioning (±0.3 mm), patient setup (±0.7 mm)
or differences in the dose calculation between the
treatment-planning system and Monte Carlo codes as a
gold standard for dose calculation (±2 mm). Other
reasons for range uncertainties are due to the conversion
of x-ray HU to stopping powers (±1% of the range) or
biological effects (~ 0.8% of the range or ~ 3mm [14]).
These range uncertainties refer to the range of the 80%
distal dose and correspond to average values. Further-
more, these uncertainties might be bigger in lung treat-
ments [7]. The maximum range uncertainties for the
80% isodose lines due to the Bragg peak degradation
based on an extreme modulation power of 800 μm found
in this study (see Table 2) are 10 mm in lung and 4mm
in tissue and hence are in the order of the mentioned
average range uncertainties. Note that the values given
by Paganetti [7] are average values while the range
uncertainties investigated in this study are maximum
values.
Additionally, range and dose uncertainties arise when
changes of the anatomy due to weight loss or a shrink-
age of the tumor are not accounted for. Szeto et al. [10]
analyzed robust intensity modulated treatment plans of
16 patients with locally advanced NSCLC. The treatment
dose was recalculated based on daily anatomy variations.
Eight patients had an undercoverage of the target vol-
ume larger than 2 GyE with a maximum of 12 GyE in
terms of the D99 (dose that is received by 99% of the
target volume). With a prescribed dose of 66 GyE this
corresponds to relative deviations in the D99% of 3% to
18%. The maximum difference in the D98% found in this
study was 3% for a realistic modulation power of 450 μm.
Another crucial issue in proton therapy of lung cancer
patients is motion. Dowdell et al. [20] investigated treat-
ment plans for 5 lung cancer patients. Due to the inter-
play effects caused by the patient’s motion, the mean
dose in the target volume was only 88% to 92% of the
prescribed dose. These interplay effects are however
highly patient specific.
At last, we want to introduce and discuss two possible
PTV concepts to account for and to avoid an under-
dosage of the target volume due to the Bragg peak
degradation: following the range shifts as shown in Fig. 6,
one possible PTV concept could be to increase the mar-
gin around the CTV at both the distal and proximal end.
The effects of such a PTV concept are depicted in Fig. 7:
the dose distributions in a water phantom downstream
from 80mm of lung tissue with a modulation power of
450 μm are shown for the non-modulated (black) and
the modulated case (yellow). The CTV marked with
dashed lines is at depths between 34 mm and 47mm. In
(a) the dose distributions can be seen for a PTV concept
as used in this study with an isotropic margin of 3 mm
around the CTV. The red line marks the prescribed dose
within the CTV and PTV. In (b) the dose distributions
are shown for the case where the PTV is the CTV plus a
margin of 5 mm at the proximal end and a margin of
7 mm at the distal end. The dose coverage within the
CTV and PTV is better compared to (a). The disadvantage
of such a PTV concept is that the dose distribution
reaches farther and hence leads to a higher integral dose
in the normal tissue and maybe OARs distal to the PTV.
To avoid this larger range and additional dose de-
posited in normal tissue, another PTV concept might
be used as depicted in Fig. 7c: in this case the same
PTV concept as in (a) is used (isotropic margin of 3
mm around the CTV), however, during the
treatment-planning process a larger dose is prescribed
within the margin at both the proximal as well as the
distal end. In this case we used a 3% larger dose in
the proximal and a 6% larger dose in the distal mar-
gin. By doing so a comparable dose distribution in
the CTV as in Fig. 7b can be achieved, however, the
dose deposited in normal tissue is smaller due to the
shorter range. Note that such a PTV concept is con-
nected to challenges since it is hard to guarantee a
dose homogeneity in such a small volume. Further-
more, a difference of only 3% in dose in such a small
volume is in the order of the uncertainties in proton
therapy as discussed above, hence, it would hardly be
possible to measure this difference in dose (e.g. as
part of quality assurance).
For both PTV concepts an exact knowledge of the
anatomy (depth of tumor in lung, tumor volume,
location of tumor relative to soft tissue) is important
to choose the appropriate values for the additional
margin (case b) or the additional dose (case c). Fur-
thermore, the knowledge of the modulation power
within the lung tissue is important, since this defines
the range and dose uncertainties connected to the
Bragg peak degradation. Unfortunately, there is
currently no solution to determine the modulation
power in patients in-vivo. This is a critical issue still
to be solved.
Altogether, the effects of the Bragg peak degrad-
ation are at maximum about 5% concerning the
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underestimation of the mean dose Dmean in the CTV
when optimizing the treatment plan without consider-
ing the degradation due to the lung tissue. Compared
to the range and dose uncertainties in proton therapy
of lung cancer patients due to the addressed reasons,
the effects of the Bragg peak degradation are clinically
tolerable to a certain degree in the current clinical
context. However, these mentioned dose uncertainties
are constantly being reduced which might change this
clinical context. Hence, a consideration of the Bragg
peak degradation could become more relevant in the
future and would bring proton therapy for lung can-
cer patients closer to a high-precision therapy. The
effects of the degradation might be accounted for in
the treatment-planning process by applying a corre-
sponding PTV concept as suggested in this study.
What is more, this PTV concept and hence the dose
deposition in the patient could be optimized when
having a detailed knowledge of the lung tissue’s
modulation power. In our opinion, the exact deter-
mination of this modulation power is one crucial
issue still to be solved.
Conclusion
The effects of the Bragg peak degradation due to lung
tissue on lung cancer patients were investigated. The
maximum effect on the mean dose Dmean in the CTV ac-
cording to this study was about 5% at maximum for an
extreme modulation power of 800 μm, a long distance
travelled through lung and a small tumor volume. For a
more realistic modulation power of 450 μm the max-
imum effect was only about 3% in terms of Dmean. For
OARs the effect was negligible for the cases investigated.
This study confirms that the effects of the Bragg peak
degradation are clinically tolerable to a certain degree in
the current clinical context considering the various more
critical dose uncertainties due to motion and range un-
certainties in proton therapy. Furthermore, these effects
might be accounted for by using corresponding PTV
concepts as suggested in this study.
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Abstract
Monte Carlo (MC) calculations are a fundamental tool for the investigation of ionization chambers 
(ICs) in radiation fields, and for calculations in the scope of IC reference dosimetry. Geant4, as 
used for the toolkit TOPAS, is a major general purpose code, generally suitable for investigating 
ICs in primary proton beams. To provide reliable results, the impact of parameter settings and the 
limitations of the underlying condensed history (CH) algorithm need to be known.
A Fano cavity test was implemented in Geant4 (10.03.p1) for protons, based on the existing 
version for electrons distributed with the Geant4 release. This self-consistent test allows the 
calculation to be compared with the expected result for the typical IC-like geometry of an air-
filled cavity surrounded by a higher density material. Various user-selectable parameters of the 
CH implementation in the EMStandardOpt4 physics-list were tested for incident proton energies 
between 30 and 250 MeV. Using TOPAS (3.1.p1) the influence of production cuts was investigated 
for bare air-cavities in water, irradiated by primary protons. Detailed IC geometries for an NACP-02 
plane-parallel chamber and an NE2571 Farmer-chamber were created. The overall factor fQ as a ratio 
between the dose-to-water and dose to the sensitive air-volume was calculated for incident proton 
energies between 70 and 250 MeV.
The Fano test demonstrated the EMStandardOpt4 physics-list with the WentzelIV multiple 
scattering model as appropriate for IC calculations. If protons start perpendicular to the air cavity, 
no further step-size limitations are required to pass the test within 0.1%. For an isotropic source, 
limitations of the maximum step length within the air cavity and its surrounding as well as a 
limitation of the maximum fractional energy loss per step were required to pass within 0.2%. A 
production cut of  ⩽5 μm or  ∼15 keV for all particles yielded a constant result for fQ of bare air-filled 
cavities. The overall factor fQ for the detailed NACP-02 and NE2571 chamber models calculated 
with TOPAS agreed with the values of Gomà et al (2016 Phys. Med. Biol. 61 2389) within statistical 
uncertainties (1σ) of  <0.3% for almost all energies with a maximum deviation of 0.6% at 250 MeV 
for the NE2571. The selection of hadronic scattering models (QGSP_BIC versus QGSP_BERT) in 
TOPAS impacted the results at the highest energies by 0.3%  ±  0.1%.
Based on the Fano cavity test, the Geant4/TOPAS Monte Carlo code, in its investigated version, 
can provide reliable results for IC calculations. Agreement with the detailed IC models and the 
published values of Gomà et al can be achieved when production cuts are reduced from the TOPAS 
default values. The calculations confirm the reported agreement of Gomà et al for kQ,Q0 with IAEA-
TRS398 values within the given uncertainties. An additional uncertainty for the MC-calculated kQ,Q0 
of  ∼0.3% by hadronic interaction models should be considered.
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1. Introduction
At the time of writing, 64 proton therapy facilities are in clinical operation and a further 40 are under construction5. 
In order to guarantee successful treatment and to make the clinical outcomes of these centers comparable, the 
absorbed dose in the target needs to be known precisely. Although some centers employ Faraday-cup-based 
dosimetry as a method for reference dosimetry (Palmans and Vatnitsky 2015), and a portable calorimeter is 
even being envisioned for use in the UK (Green et al 2017), the most common procedure to relate the output 
of the proton treatment machine to the absorbed dose is the use of air-filled ionization chambers in water. As 
ionization chambers are typically calibrated in 60Co beams, the proton beam-quality at the user end needs to be 
corrected for. This step takes into account the different stopping-power ratios between water and air Sw,air and the 
differing mean energy to create an ion pair in air, W/e. Further, specific ionization chamber perturbation factors 
pQ for different proton beam qualities Q need to be included in this overall correction. Currently, only the IAEA 
TRS398 code of practice (Andreo et al 2001) and ICRU78 (International Commission on Radiation Units and 
Measurements 2007) contain tabulated data for the beam-quality correction factor kQ,Q0 for commonly used 
ionization chambers, while the latter standard directly uses the values of TRS398. The kQ,Q0 values in TRS398 
assume a pQ  =  1 for protons. There is good evidence that pQ stays nearly constant for the range of proton 
treatment energies and can be considered as unity within 1% (Palmans and Vatnitsky 2015). Nevertheless, it 
can be expected that Monte Carlo (MC)-based kQ,Q0 factors with detailed ionization chamber calculations will 
update and extend the tabulations, most likely with lower uncertainties. This is one of the goals of the RTNORM-
Project6 organized by EURAMET, aiming to update the IAEA TRS398 kQ,Q0 values.
Recently, Gomà et al (2016) used the PENELOPE-based code PENH (Salvat 2013) in combination with the 
GAMOS toolkit (Arce et al 2014) to calculate kQ,Q0 factors for a variety of ionization chambers. They showed an 
agreement with the TRS398 values within respective uncertainties of 2.3% or better. Sorriaux et al (2017) per-
formed Geant4 calculations to investigate how the broad-beam conditions requested by TRS398 impact the kQ,Q0 
values in scanned beams or double-scattering beams.
The MC calculation of the ionization chamber response is known to be demanding for the condensed history 
(CH) implementations of charged particles, as the high-density gradient between the surrounding material and 
air in the cavity can cause significant artifacts. The so-called Fano cavity test can be used to test the accuracy of the 
MC code’s CH implementation for various code-specific settings in a self-consistent way. Different varieties of 
this test exist, and they all aim to create a situation in which the Fano-theorem holds (Andreo et al 2017) and the 
calculation result is known a priori, normalized to the used cross-sections. The deemed pass-rate is typically set 
to  ∼0.1%, to consider a code ‘artifact-free’.
The EGSnrc (Kawrakow 2000, Kawrakow et al 2017) and PENELOPE (Sempau and Andreo 2006, Salvat 
et al 2014) codes have been demonstrated to calculate the ionization chamber for photon/electron response at 
the  ∼0.1% level. The electron transport of Geant4 (Agnostelli et al 2003) was benchmarked by a Fano cavity test 
in Elles et al (2008), showing an agreement of  ∼1%. Subsequently, a Fano cavity test was part of the validation for 
each new release of Geant4, but the published results were strongly step-size dependent and up to a few percent 
(Ivanchenko et al 2011). More recently, O’Brien and Sawakuchi (2017) demonstrated that the electron Geant4 
CH implementation, relying on the Goudsmit–Saunderson multiple Coulomb scattering (MCS) theory, leads to 
an agreement within 0.1%.
General purpose codes capable of simulating transport for charged particles other than electrons have not 
yet been benchmarked as thoroughly. Given the limited scattering of protons compared to electrons, the possible 
artifacts in the CH-transport can generally be expected to be smaller. Nevertheless, they need to be known for the 
meaningful reporting of results in this type of calculation. Sterpin et al (2014) presented a version of the Fano 
cavity test for protons, and demonstrated that the Urban model for multiple scattering (Geant4Collaboration 
2016) in the CH approach is dependent on various step-size limitations. They did not, however, come to a con-
clusion on the optimum settings for Geant4. Lourenco et al (2017) implemented a Fano cavity test for FLUKA 
with protons and showed that the test is passed at the 0.1% level if the maximum step-size in the FLUKA CH 
algorithm is restricted.
The TOPAS MC code (Perl et al 2012) is becoming a valuable tool for various problems in proton therapy due 
to its flexible and versatile parameter system. TOPAS is built upon Geant4 and hence uses the same physics mod-
els, processes and interaction cross-sections. In the present study, we used the TOPAS system version 3.1.p1 based 
on Geant4 10.03.p1 to calculate the factor fQ following (Sempau and Andreo 2006) as
fQ = Dw/Dgas (1)
5 https://ptcog.ch
6 http://rtnorm.eu
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with Dw being the dose-to-water in a small reference volume at the reference depth and Dgas as the dose to the 
sensitive air-volume of an ionization chamber model. We used models of the cylindrical NE2571 and the plane-
parallel NACP-02 ionization chamber in proton beams at different initial energies. Note, the quantity fQ is the 
proton specific part of a MC-calculated beam-quality correction factor (Andreo et al 2013)
kQ,Q0 =
fQ
fQ0
Wair,Q
Wair,Q0
 (2)
with Wair being the mean energy needed to create an ion pair in air for the beam-qualities Q and Q0. Following 
this approach, the quantity fQ can also be understood as
fQ = pQ · Sw,air (3)
in proton beams.
Beforehand, by applying a Fano cavity test, the current CH implementation in TOPAS/Geant4 was investi-
gated, and settings leading to reliable calculation results were defined.
It is supposed that f Q0, i.e. equation (1) in a 
60Co field, has been explored sufficiently in the past in the context 
of the kQ,Q0-factors for primary photon and electron beams (Sempau et al 2004, Zink and Wulff 2008, Wulff et al 
2008a, Muir and Rogers 2010, Muir et al 2012, Zink and Wulff 2012, Erazo and Lallena 2013), and is thus not 
covered in this work.
2. Methods
For all calculations Geant4 (Agnostelli et al 2003) version 10.03.p1 and TOPAS (Perl et al 2012) version 3.1.p1 
have been used. Details of the geometries, sources and transport parameters are given in the subsequent sections.
2.1. Proton transport in Geant4
The Geant4 code groups electromagnetic (EM) interactions of the charged particles in the condensed history 
approach. The latter is implemented following a mixed algorithm, which simulates the discrete collisions with 
energy loss above a user-defined threshold one by one and groups the angular deflection of all soft collisions at 
the end of a given step employing the appropriate MCS theory (Geant4Collaboration 2016). As a real trajectory 
is not a straight line, step length corrections and lateral displacements are considered at the end of the step, where 
a mean scattering angle is applied.
The multiple scattering in the artificial CH step is calculated according to the appropriate MCS theory. Geant4 
offers different models, and depending on the version and different default physics-lists, defines the employed 
models and their parameters. The default physics-list for electromagnetic interactions used in TOPAS version 
3.0.p1 is EMStandardOpt4, which makes use of the WentzelVI model (Ivanchenko et al 2010). Makarova et al 
(2017) compared the MCS models for protons in Geant4 with the Molière/Fano/Hanson theory and showed 
better agreement in the proton-therapy energy range for the WentzelVI model than the Urban model, which is 
used in various other physics-lists of Geant4. More recently, Fuchs et al (2017) compared the Geant4 models for 
the proton MCS against measurements of Gottschalk et al (1993). They concluded on the satisfactory agreement 
of the characteristic MCS angle with experiments when using the WentzelVI model. This model is based on the 
Wentzel MCS scattering function for small scattering angles below 0.2 radian, while larger angles are calculated 
using the single Coulomb scattering model (Ivanchenko et al 2010, Allison et al 2016).
The length of a CH-step is limited by tracking limits, such as geometric boundaries and physics-related 
parameters, which control the maximum fractional energy loss in a single step (dRoverR), for example. Further 
competing step limitations are combined in the G4MscStepLimitType, which provides a conservative reduction 
based on particle ranges and geometrical considerations (Ivanchenko et al 2010, Geant4Collaboration 2016). As 
part of this, the RangeFactor is a multiplier to the particle range with a value of less than unity.
As particles lose energy, their CH step length gradually decreases until it becomes smaller than the finalRange, 
below which the particle is ranged out in a single straight step. In the vicinity of geometrical boundaries, the MCS 
is disabled and particles are transported via single scattering in a region controlled by the skin parameter as a mul-
tiplier for the mean free path length of elastic scattering (Geant4Collaboration 2016).
The simulation of elastic and non-elastic nuclear interactions is sampled discretely and leads to interceptions 
of the continuous CH transport. Another indirect step limitation is the simulation of hard or discrete interac-
tions in the ionization process. When the energy transfer between subsequent CH steps exceeds a user-defined 
limit, the CH process is discontinued and a discrete scattering event occurs resulting in a secondary particle. Gen-
erally, the more limitations are applied to the CH, the less the results are susceptible to artifacts, but the longer the 
simulation times become. This logic applies to all the charged particles in Geant4.
The parameter controlling the production of secondaries is given in a unit of range in Geant4. The rationale 
for using a range instead of energy for the production thresholds is the theoretically more precise location for the 
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energy release (Geant4Collaboration 2016). The default values for range cuts in TOPAS version 3.0.p1 are set to 
0.05 mm. For secondary delta electrons, which carry a non-negligible amount of energy, this relates to an energy 
of approximately 54 keV if released in water and 2 keV in air. In the case of an ionization chamber-like geometry 
with a large density change between the wall and cavity, this situation possibly leads to a fluence artifact. Reduc-
ing the production cut generally increases the simulation time, hence a balance between accuracy and efficiency 
needs to be found.
2.2. Investigation of production cuts
The impact of range-cuts was investigated by calculating the factor fQ within TOPAS using its default settings.
A set of single simulations with a bare air-filled cylindrical (radius  =  3 mm/length  =  20 mm) and plane par-
allel (radius  =  5 mm/height  =  2.5 mm) cavity placed at 2 cm depth in water was performed, testing different 
range cuts between 0.065 and 43.2 μm, which correspond to 1 and 50 keV for electrons in water. The cut was 
applied to photons, electrons/positrons and protons within the cavity and a 5 mm wide region surrounding it. 
Additionally, the dose to water was calculated in a small reference volume (radius  =  5 mm/height  =  0.25 mm) 
using the same approach. The geometry was irradiated by a square field of 10× 10 cm2 with 150 MeV mono-
energetic protons. The dose to water Dw and dose to the sensitive air-volume Dgas were scored with the DoseToMe-
dium-scorer, and the factor fQ was calculated afterwards.
2.3. A Fano cavity test for protons in Geant4
The release of Geant4 (10.03p1) contains an implementation of the efficient Fano cavity test as introduced by 
Sempau and Andreo (2006). The basic idea is to calculate the dose deposited in an ionization chamber-like, plane-
parallel geometry irradiated with a perpendicular 1D, mono-energetic line source of energy E0. By choosing 
a radius r of the chamber that is larger than the maximum range of charged particles, the reciprocity theorem 
holds, i.e. the geometry is identical to a plane-parallel chamber being irradiated by a laterally extended source. 
The geometry effectively consists of three slabs, mimicking a cavity of thickness zgas surrounded by walls with 
thickness zwall  that are larger than the maximum range of the initial protons (see figure 1). The source density 
is sampled according to the local mass-density in the wall with ρwall and the gas-filled cavity ρgas, and, as long as 
the density effect is the same throughout the geometry, the result is irradiation under the conditions of charged 
particle equilibrium. If no interactions then occur that lead to uncharged, long-range secondary particles, the 
quantity Q can be defined as (Sempau and Andreo 2006):
Q =
∆E
N · E0
(
1+
2ρwallzwall
ρgaszgas
)
 (4)
for ∆E as energy deposited with N simulated particles. Any deviation of Q from unity violates the Fano theorem 
and indicates an artifact in the condensed history implementation.
The existing implementation of the fanoCavity2 code was used and a few modifications were applied. 
The density effect correction was disabled by a modified version of the G4hBetheBlochModel class. Besides the 
line source in the original version, which keeps the direction of initial particles perpendicular to the slab, an 
option for sampling protons along the line with uniform distribution of directions over 4π was added.
The implementation of the Fano cavity test only considers EM interactions by setting the cut-offs for second-
ary particle production to infinity. This effectively disables the generation of any secondary particle. At the same 
Figure 1. Slab-geometry for the Fano test with a line-source of primary protons (central line). The broken horizontal lines indicate 
an extra region in the wall for reducing the step size. For details see text.
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time, this can be considered as a conservative approximation, leading to rather large steps as range cuts of a few 
mm are applied in a normal calculation.
Various user-accessible transport parameters (see section 2.1) were altered to study the sensitivity of the 
results to different step-limitations. dRoverR was reduced from its default of 0.1 down to 0.005. The MscMu-
HadRangeFactor was varied from the default of 0.2 in steps down to 0.01, the skin parameter was increased from 
the default of 1 to 3. Most calculations were performed with the fUseDistanceToBoundary step-limit type for 
hadrons, but we also compared them to the default fUseMinimal. Additionally, the maximum deflection angle in 
the WentzelVI model above which a single scattering is performed was changed from the default value 0.2–0.05 
radian. Furthermore, an optional fixed step limitation in the cavity and the wall was applied in some of the calcul-
ations, by defining an extra region with a 1 mm thickness around the cavity.
The remaining transport parameters for the Fano cavity test were based on the EMStandardOpt4 physics-list 
of version Geant4 10.03.p1. The factor Q in equation (4) was calculated for initial energies between 30 and 250 
MeV for either water or carbon as a material. In both cases, the mass-density of the cavity was reduced by a factor 
1000 compared to the surrounding.
2.4. Ionization chamber calculations in TOPAS
Ionization chamber models for the NE2571 thimble type and NACP-02 plane-parallel type ionization chambers 
were created in TOPAS. Both have been used in many MC-based studies in the past and a large set of direct kQ 
measurements in photons and electrons exist for them. The geometry details were taken from Andreo et al (2013) 
for the NE2571 and from the work of Zink and Wulff (2012) for the NACP-02. The latter model was adjusted 
slightly to match exactly the mass-densities and thicknesses as used in Gomà et al (2016).
The mean excitation energies of carbon, water and air were used exactly as in the work of Gomà et al, with 
Iair = 85.7 eV, Iw = 78 eV and ICarbon = 81.1 eV to allow for a direct comparison. This matches the recommenda-
tions of ICRU (International Commission on Radiation Units and Measurements 2014), with a slight discrep-
ancy of 0.1 eV for carbon.
The ionization chamber models were placed at 2 cm depth in a water-phantom with a 5 cm thickness and 
irradiated by mono-energetic, parallel proton beams at 70, 100, 150, 200 and 250 MeV with a field size of 10× 10 
cm2. The dose to water Dw was calculated in a disc of 250 μm height and a radius of 1 cm, placed with its geometric 
center at a depth of 2 cm.
The production cuts for photons, electrons/positrons and protons were changed from the default of 50 μm 
to 1 μm (see section 3.1 below) in the chamber geometry and water volume, respectively, plus an additional small 
region around it.
Following the findings of O’Brien and Sawakuchi (2017), we selected the Goudsmit–Saunderson model for 
electrons in all simulations as an addition to the used EMStandardOpt4 physics-list. Note, this is also the change 
in the EMStandardOpt4 list of the recently published version 10.4 of Geant4. Based on the findings of the Fano 
cavity test, one calculation for the NACP-02 chamber was also tested with a limitation of dRoverR  =  0.05 and a 
maximum step-size of 1 mm within the ionization chamber geometry and a 1 mm surrounding layer of water. 
Further, the effect of changing the step-limit type to fUseDistanceToBoundary was tested.
Two different hadronic interaction models were compared. Besides the TOPAS default binary cascade 
(QGSP_BIC) of Geant4, the Bertini cascade (QGSP_BERT) was tested. All other physics options were left at the 
TOPAS 3.1.p1 defaults, i.e. setting EMRangeMin  =  100 eV, EMRangeMax  =  500 MeV and including the G4De-
cayPhysics, G4IonBinaryCascadePhysics, G4HadronElasticPhysicsHP and G4StoppingPhysics classes.
3. Results and discussion
3.1. Impact of secondary particle production thresholds
In figure 2 the impact of the different production cuts on the calculated fQ values is shown. The cut was applied 
to photons, electrons/positrons and protons. Secondary electrons have a range that is roughly one order of 
magnitude longer compared to protons. Hence, the lower production cut mainly affects the fluence and thus 
dose contribution by electrons. There is a clear variation, and a convergence is reached for the production cuts 
 ⩽5 μm. This corresponds to a threshold for secondary electrons below  ∼15 keV. The change in calculation time 
between the 50 μm and 1 μm was a factor of  ∼1.3.
One can discuss the required threshold from a cavity theory point of view. In the energy regime of proton 
therapy, the ionization chamber is expected to behave under Bragg–Gray or Spencer–Attix conditions (Interna-
tional Commission on Radiation Units and Measurements 2007). This requires a constant fluence of secondary 
δ-electrons, and when using a cut-off in terms of range, a fluence-artifact can result between the interface of 
two regions with different media. One would need to create region-based cut-off values to avoid such a fluence 
artifact; however, this was considered much more complicated than selecting a sufficiently small value for the 
complete geometry. Additionally, one could select different production cuts for different secondary particles—
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but as discussed above, the main impact of reduced cuts can be expected for δ-electrons. Different values for the 
different particle types were not investigated, but given the fact that at the price of a longer calculation time there 
is no disadvantage, we applied the cut to all protons and electrons/positrons without investigating different cuts 
by particle type. Furthermore, a technical limitation of the investigated TOPAS release prohibited the choice 
based on particle type.
The optimal results for production cuts of 20 keV, at least for electrons, is somehow expected. The depend-
ence of Sw,air values was demonstrated by Medin and Andreo (1997) for protons and later by Sànchez-Parcerisa 
et al (2013) for carbon ions, and the cut-off energy Δ in the evaluation of the Spencer–Attix stopping power 
ratios is typically set to 10 keV. This energy corresponds to the mean chord length of electrons passing a typical 
ionization chamber cavity (Wulff et al 2008b, Andreo et al 2017). If no fluence perturbation existed, fQ calculated 
here should simply correspond to the water-to-air stopping power ratios in the proton beams. An agreement 
with the TRS398 Sw,air values, which are based on the fluence calculations with the PETRA MC code (Medin and 
Andreo 1997), is reached for secondary electron production cuts at about 15 keV, as shown in figure 2.
In their study on ionization chamber correction factors in proton beams, Sorriaux et al (2017) used a produc-
tion threshold of 5 μm for protons, electrons/positrons and 1 mm for all other particles. According to the results 
shown here (figure 2), this is an appropriate choice, although the authors did not give a rationale for the setting.
Generally, the default of TOPAS with 50 μm seems too large for application in ionization-chamber-related 
calculations. In the subsequent calculations, the production cuts were set to 1 μm for all particles.
3.2. Fano cavity test
When using a line source with protons starting perpendicular to the cavity, all calculations for water and carbon 
agreed with the expected result at 0.1% level within a 1σ statistical uncertainty of  ⩽0.05%. This means the 
implementation of CH within the WentzelIV model, as part of the EMStandardOpt4 physics-list, is sufficiently 
accurate for this situation. This result is different from the findings of Sterpin et al (2014), who also used a 
parallel/perpendicular proton beam incident to a plane-parallel chamber. In their test, restrictions of maximum 
step-sizes to 10−2 mm for Geant4 (version 9.5.p02) with the Urban MCS model were necessary to pass the Fano 
test, although in a different implementation.
In contrast to the results when particles start perpendicular to the cavity, the source which samples directions 
isotropically along the line led to larger deviations, as shown in figure 3. From all tested transport parameters (see 
section 2.3), only the reduction of fractional energy loss per step dRoverR to a value of 0.005 yielded an agreement 
within 0.1%. This, however, led to an increase of a factor twelve in the calculation time and was deemed rather 
impractical. Note, the calculation times at 250 MeV using default transport parameters was  ∼30 min on a single 
Intel Xeon 2.3 GHz CPU.
The reduction of step-size to  ⩽1 mm in the cavity and in a region 1 mm around it allowed for an agreement 
within 0.5% at 250 MeV. Note, the result stayed constant even for step-size limitations of 10−3 mm, even though 
one could expect an improvement in the result with shorter steps. However, in our implementation, the step-size 
was only limited in the cavity and its direct surrounding within 1 mm. A combination of step-size reduction to 
Figure 2. The calculated fQ at 150 MeV for bare air-cavities in water as a function of the production threshold for secondary 
electrons in TOPAS. The 1σ statistical uncertainty is smaller than the symbol size. The lines are a guide to the eyes. The abscissa is 
given in units of keV and μm. The horizontal line corresponds to the TRS398 value for Sw,air at 150 MeV with a respective uncertainty 
of 1% (broken lines).
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1 mm and dRoverR  =  0.05 was identified as a reasonable compromise, allowing for an agreement at the 0.2% 
level (see figure 3). As expected, this gain in accuracy came at the expense of an increased calculation time with a 
factor 1.3–4 between 30 and 250 MeV.
One needs to view the results within the conditions of the test implementation here. With the cut-offs for 
secondary particle production set to infinity, the primary protons have larger steps, as in a typical calculation. 
As outlined in the previous section for ionization chamber calculations, we identified the need to limit the pro-
duction cuts to rather small values, which effectively limits the step sizes. Furthermore, in a realistic ionization 
chamber simulation, more complex geometries with layers of different materials exist, which impose geometric 
limitations. The calculation of the expected response for an isotropic source is considered an extreme case, as 
some protons start directly at the cavity boundary with directions parallel to it, which typically does not occur in 
normal situations.
3.3. Ionization chamber calculations TOPAS
Figures 4 and 5 show the calculated fQ values for the NACP-02 and NE2571 ionization chamber models. The 
values are given as a function of incident energy and residual range Rres, respectively, together with the values 
from Gomà et al (2016) and corresponding values from the TRS398 protocol. The latter was deduced from the 
tabulated kQ,Q0 values, Sw,air for 
60Co, the fit function for Sw,air in protons and Wair/e for protons and electrons, as 
found in TRS398 together with the respective uncertainty estimates for each value. The overall calculation time 
for a single data point was the equivalent of up to 330 days on a single 2.4 GHz-CPU, and was distributed over 800 
CPUs of a cluster.
Except for the highest energy of 250 MeV, the fQ values for the NACP-02 model agree with the published 
values of Gomà et al within the statistical uncertainties (figure 4). A slightly better agreement with the values is 
achieved for the calculations using the QGSP_BERT model. This is surprising as Gomà et al used the QGSP_BIC 
model for the simulation outside the ionization chamber model. The TOPAS calculations for the NE2571 show, 
however, a slightly better agreement with the Gomà et al values when the QGSP_BIC nuclear interaction mod-
els are used (figure 5). The remaining maximum deviations are 0.5% and 0.6% for the NACP-02 and NE2571 
respectively at the highest energies, which is just slightly out of the combined two standard statistical uncertain-
ties (<0.3%) for the NE2571. This is a noteworthy level of agreement considering the completely independent 
geometry and physics implementations between the PENH/PENELOPE and Geant4 MC codes.
In general, despite the good agreement of the fQ values with Gomà et al, the discrepancy in our results for the 
two non-elastic scattering models can be interpreted as a systematic uncertainty in this type of calculation. It is 
not clear per se which of the two hadronic models yields more realistic results, even though the impact is small 
with the maximum 0.3%  ±  0.1%. Jarlskog and Paganetti (2008) demonstrated the best agreement between 
multilayer Faraday cup measurements and Geant4 calculations when selecting the binary cascade. On the other 
hand, Patel et al (2017) investigated the physics-list options for accurate LET calculations in an experimental 
setup. They came to a conclusion on the best results for the FTFP_BERT physics-list. As long as no conclusion can 
be drawn on which model is the more accurate, one can at least add a  ∼0.3% contribution of type B uncertainties 
to the kQ,Q0 results of Gomà et al.
Figure 3. Results for the Fano cavity test with an isotropic source of protons in Geant4 10.03.p1 for water (circles) and carbon 
(squares). The full symbols show results using the EMStandardOpt4(opt4) physics-list. The open symbols represent results for 
dRoverR  =  0.05 and a step-size limit of 1 mm in the cavity and surrounding. The lines are a guide to the eyes. The horizontal line 
indicates a deviation of 0.1% from the expected result Q (see equation (4)).
Phys. Med. Biol. 63 (2018) 115013 (10pp)
8J Wulff et al
The impact of reducing dRoverR and the introduction of an additional step limitation (see section 3.2) 
resulted in no significant change of the results outside the statistical uncertainty. As discussed, the already exist-
ing step-limitations, and the fact that the protons are entering the cavity predominantly perpendicularly, obvi-
ously does not lead to observable artifacts in this type of calculation.
The agreement with the TRS398 protocol for the NACP-02 is just within the uncertainties given therein and 
shows only a small variation with energy, in accordance with an assumed unity pQ in TRS398. The agreement for 
NE2571 is, however, less good, and fQ varies by almost 3.5% over the considered energy range. The shape of the 
data-point distribution in figure 5 is presumably caused by the fact that the cylindrical ion chamber was placed 
with its center at 2 cm. At this depth, the lower energy beams already exhibit a gradient in the proximal rise of the 
proton depth-dose distribution that is large enough to show a gradient effect (Palmans 2006) and clearly leads to 
a deviation of pQ  =  1. This could, in principle, be compensated by placing the ionization chamber with its refer-
ence point at a larger depth. Interestingly, this is considered in the reference conditions of TR398 for heavy ion 
beams, while it is not the case for primary proton beams. At any rate, these results demonstrate the usefulness of 
MC calculations, if smaller uncertainties in the kQ,Q0 values are aimed for.
Figure 4. The calculated fQ as a function of energy and residual range for the NACP-02 plane-parallel ionization chamber, i.e. the 
ratio between the dose to a thin disc of water and the sensitive air volume of the ionization chamber model at 2 cm depth. Results 
are shown for calculations in TOPAS3.1.p1/Geant4 10.03.p1 using the binary cascade nuclear interaction model (BIC) and Bertini 
cascade (BERT). Values from Gomà et al are directly taken from their publication. The full line represents the values taken from 
TRS398 with the uncertainty given therein (broken line).
Figure 5. TOPAS calculated fQ for the NE2571 cylindrical ionization chamber at 2 cm depth in water. The results are shown for 
calculations using the binary cascade nuclear interaction model (BIC) and Bertini cascade (BERT) of TOPAS3.1.p1/Geant4 
10.03.p1. Values from Gomà et al are taken from the publication. The full line represents the values taken from TRS398 with the 
uncertainty given therein (broken line).
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4. Conclusion
Based on the Fano cavity test, the Geant4/TOPAS Monte Carlo code, in its investigated version, can provide 
reliable results of ion chamber response calculations in primary proton beams. When selecting appropriate 
production cuts, the fQ values of Gomà et al (2016) for the NACP-02 and NE2571 chamber can be reproduced 
and thus confirmed with TOPAS calculations. Apart from a small additional systematic uncertainty in the work 
of Gomà et al, the present work supports their published kQ,Q0 values. The shown agreement of our calculations 
with the TRS398 values needs to be emphasized. The values and corresponding estimated uncertainties can still be 
considered usable today, despite the fact that TRS398 was published 18 years ago, with the limited computational 
tools and measurements available at that time. Nevertheless, the RTNORM-Project will update these values with 
smaller uncertainties in the future.
The findings of the present work could help other researchers determine appropriate simulation parameters, 
such as the physics-list and production cut-off selection, when using TOPAS for ionization-chamber-related 
simulations in proton beams. The appropriate settings in Geant4/TOPAS when calculating kQ,Q0 values in pri-
mary megavoltage photon and electron beams need to be determined in future studies.
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Purpose: The purpose of this work is to analyze whether the Monte Carlo codes PENH, FLUKA, and
GEANT4/TOPAS are suitable to calculate absorbed doses and fQ=fQ0 ratios in therapeutic high-energy
photon and proton beams.
Methods: We used PENH, FLUKA, GEANT4/TOPAS, and EGSNRC to calculate the absorbed dose to water in
a reference water cavity and the absorbed dose to air in two air cavities representative of a plane-par-
allel and a cylindrical ionization chamber in a 1.25 MeV photon beam and a 150 MeV proton beam
— EGSNRC was only used for the photon beam calculations. The physics and transport settings in each
code were adjusted to simulate the particle transport as detailed as reasonably possible. From these
absorbed doses, fQ0 factors, fQ factors, and fQ=fQ0 ratios (which are the basis of Monte Carlo calcu-
lated beam quality correction factors kQ;Q0 ) were calculated and compared between the codes. Addi-
tionally, we calculated the spectra of primary particles and secondary electrons in the reference water
cavity, as well as the integrated depth–dose curve of 150 MeV protons in water.
Results: The absorbed doses agreed within 1.4% or better between the individual codes for both the
photon and proton simulations. The fQ0 and fQ factors agreed within 0.5% or better for the individual
codes for both beam qualities. The resulting fQ=fQ0 ratios for 150 MeV protons agreed within 0.7%
or better. For the 1.25 MeV photon beam, the spectra of photons and secondary electrons agreed
almost perfectly. For the 150 MeV proton simulation, we observed differences in the spectra of sec-
ondary protons whereas the spectra of primary protons and low-energy delta electrons also agreed
almost perfectly. The first 2 mm of the entrance channel of the 150 MeV proton Bragg curve agreed
almost perfectly while for greater depths, the differences in the integrated dose were up to 1.5%.
Conclusion: PENH, FLUKA, and GEANT4/TOPAS are capable of calculating beam quality correction fac-
tors in proton beams. The differences in the fQ0 and fQ factors between the codes are 0.5% at maxi-
mum. The differences in the fQ=fQ0 ratios are 0.7% at maximum. © 2019 The Authors. Medical
Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Med-
icine. [https://doi.org/10.1002/mp.13737]
Key words: beam quality correction factors dosimetry high-energy photon and proton radiation
Monte Carlo simulation radiation therapy
1. INTRODUCTION
Current national and international dosimetry protocols for the
determination of absorbed dose in photon beams (e.g.,
AAPM TG-511 or IAEA TRS-3982 or the DIN 6800-23) as
well as proton beams (e.g., IAEA TRS-3982) are based on
standards of absorbed dose to water. The absorbed dose to
water can be determined with air-filled ionization chambers.
When using these chambers, the user needs to correct the
chamber reading with the beam quality correction factor
kQ;Q0 . This correction factor accounts for the different
response of the chamber in the calibration beam quality Q0
and the clinical or user beam quality Q (e.g., MV photons or
high-energy protons) and typically corrects the ionization
chamber reading by a few percent. Ideally, these kQ;Q0 factors
should be determined directly using calorimetry for each
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chamber model used and at exactly the radiation quality Q at
which the chamber will be operated. Although performed in
several studies,4–8 the experimental determination of these
kQ;Q0 factors requires a high experimental effort and is not
convenient for most laboratories. Furthermore, standard labo-
ratories do not have access to all beam qualities Q — this
holds especially for proton and carbon ion beams. Hence, the
calculation of beam quality correction factors by means of
Monte Carlo simulations is an efficient alternative.
At the time, the IAEA TRS-398 Code of Practice (CoP) is
currently being updated. Within this framework, the
RTNORM project9 is supporting the IAEA working group
with experimental as well as Monte Carlo calculated kQ;Q0
factors for different ionization chambers and beam qualities
such as photons and protons. Whereas the use of Monte
Carlo codes for the determination of kQ;Q0 factors in high-en-
ergy photon and electron beams has been extensively tested
and is well established in the literature for the Monte Carlo
codes EGSNRC and PENELOPE,10–14 data for protons are scarce
with only one study by Goma et al.15 where PENH was used to
calculate kQ;Q0 factors in clinical proton beams in agreement
with experimental data within 1% or better. Furthermore, data
for ions heavier than protons are nonexistent. Although PENH
has been shown appropriate for the calculation of kQ;Q0 fac-
tors in proton beams,15 this code cannot transport ions heav-
ier than protons. Hence, to provide more data for protons and
especially heavier ions, the use of general purpose codes such
as FLUKA and Geant4, primarily designed for high-energy
physics applications, needs to be investigated for the use in
ionization chamber calculations. A first study proved that
TOPAS, a toolkit based on Geant4, may be used to calculate
fQ factors in proton beams.
16 On this basis, its usage for the
determination of beam quality correction factors in clinical
photon and especially proton beams shall be investigated in
this work.
Hence, the aim of this work is to assess whether FLUKA and
GEANT4/TOPAS are suitable to calculate kQ;Q0 factors in clinical
photon and proton beams. To do so, the fQ0 and fQ factors as
well as the fQ=fQ0 ratios were calculated for simplified beam
settings and simplified geometries representing ionization
chambers at typical water depths. The fQ=fQ0 ratio is the basis
of kQ;Q0 factors and the only part that can be calculated with
the Monte Carlo method. The residual part consists of the
Wair;Q/Wair;Q0 ratio that has to be determined experimentally
(or can be taken from the literature17). Hence, if a Monte
Carlo code is able to calculate fQ=fQ0 ratios, it can be used to
determine kQ;Q0 factors. We compared the results with the
already established Monte Carlo codes EGSNRC and PENH. The
comparison of the fQ0 factors with the results from EGSNRC is
necessary to verify if FLUKA and GEANT4/TOPAS can be used for
photon calculations since EGSNRC is well established for high-
energy photon calculations and benchmarked against experi-
mental data.18,19 The comparison of the fQ factors and fQ=fQ0
ratios with the results from PENH is necessary to verify if
FLUKA and GEANT4/TOPAS can be used for the calculation of
fQ=fQ0 ratios and hence kQ;Q0 factors in proton beams since
PENH has been shown appropriate for the calculation of kQ;Q0
factors in proton beams.15 By choosing simplified beam set-
tings and simplified geometries, we could ensure the use of
the same geometry descriptions in each of the Monte Carlo
codes used so that only the differences in the particle trans-
port and the physics settings will have an impact on the
absorbed dose predictions. The particle transport parameters
and the lists of physics models used in each of these Monte
Carlo codes were adjusted to simulate the transport of pri-
mary photons and protons as well as their secondary elec-
trons at clinically relevant energies as detailed as reasonably
possible.
2. MATERIALS AND METHODS
Simulations were performed with the Monte Carlo codes
PENH, FLUKA, GEANT4/TOPAS, and EGSNRC. In the next subsec-
tion, the geometry and beam parameters are explained. In the
following subsection, the calculated quantities are described.
In the subsections thereafter, the particle transport for each of
the Monte Carlo codes used is described. To report the Monte
Carlo simulations, we followed the recommendations of the
AAPM Research Committee Task Group 268.20
2.A. Geometries, materials, and source parameters
For each Monte Carlo code, the geometries as shown in
Fig. 1 were used: A water cavity used as reference consisting
of a disk with a diameter of 10 mm and a thickness in beam
direction of 0.25 mm. The first air cavity was a disk with a
diameter of 10 mm and a thickness in beam direction of
2.5 mm representing a plane-parallel chamber. The investi-
gated volume was  0.2 cm3, comparable to the Scan-
ditronix NACP02 chamber with an active volume of
0.16 cm3 or the PTW-34001 Roos chamber with an active
volume of 0.35 cm3.21
The second air cavity was a cylinder with a height of
20 mm and a diameter of 6 mm representing a cylindrical
ionization chamber. The investigated volume was  0.6 cm3,
comparable to the Farmer chamber Exradin A12 with an
active volume of 0.65 cm322 or the NE2571 chamber with an
active volume of 0.69 cm3.21
These volumes were positioned in a water phantom of
20 9 20 9 15 cm3 for the irradiation with photons and
20 9 20 9 10 cm3 for protons. The center of each volume
marked with an “x” in Fig. 1 was positioned in the center of
the beam at a depth of 5 cm in the water phantom for the irra-
diation with photons and at a depth of 2 cm for protons.
Table I shows the elemental compositions of water and air
used in the Monte Carlo simulations. For all elements, only
the main isotopes were considered (e.g., no 17O but only 16O
in water as well as air). Water had a density of 1.0 g/cm3 and
a mean ionization potential of Iw ¼ 78 eV.17,23 For air, the
density was 1.20479 mg/cm3 and the mean ionization poten-
tial was set to Iair ¼ 85:7 eV.17
As a 60Co source, we used a monoenergetic 1.25 MeV
photon beam14 applied in an homogeneous field of
10 9 10 cm2. The beam had no divergence and the space
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between the source and the water phantom was filled with
vacuum.
For the irradiation with protons, the same settings were
used. The energy of the protons was 150 MeV (also monoen-
ergetic). The simulations for protons were not performed with
the EGSNRC code since it can only transport photons, electrons,
and positrons.
Concerning the beam quality and depths of the volumes,
the setup corresponds to the recommendations of the TRS-
398 Code of Practice for the 1.25 MeV photons.2 For
monoenergetic protons, TRS-398 suggests the plateau region
at a depth of 3 g cm2. However, several works24,25 estab-
lished a depth of 2 g cm2 for protons, which is the depth
also used in this work.
2.B. Calculated quantities
The absorbed dose to water (Dw) in the water-filled vol-
ume from Fig. 1 and the absorbed dose to air (Dair) in the air-
filled volumes were calculated with each Monte Carlo code
for photons and each code excluding EGSNRC for protons.
From these results, the factor fQ was calculated as
12:
fQ ¼ DwDair
 
Q
(1)
where Q denotes the beam quality.
Using this factor fQ, the beam quality correction factor
kQ;Q0 can be derived
26:
kQ;Q0 ¼
fQ
fQ0
Wair;Q
Wair;Q0
(2)
where Wair is the mean energy required to create an ion pair
in air for the beam qualities Q0 and Q. In this work, the beam
quality Q0 corresponds to 1.25 MeV monoenergetic photons
applied in a homogeneous, parallel beam of 10 9 10 cm2
representing a 60Co beam and the beam quality Q corre-
sponds to 150 MeV monoenergetic protons applied in a
homogeneous, parallel beam of 10 9 10 cm2.
In this study, only the ratios fQ=fQ0 from Eq. 2 and not the
beam quality correction factors kQ;Q0 were investigated since
the fQ=fQ0 ratios are the only part of the beam quality correc-
tion factors that can be calculated with Monte Carlo codes.
The ratio of the Wair values has to be determined experimen-
tally or can be taken from the literature (e.g., the ICRU report
9017). Additionally, the aim of this study is to investigate
whether the Monte Carlo codes used are feasible for ioniza-
tion chamber calculations in general and not to calculate any
real beam quality correction factors.
In addition to the determination of the fQ=fQ0 ratios, the
spectra of the primary particles (photons or protons) as well
as the spectra of secondary electrons were scored in the
water-filled reference volume in order to try to explain differ-
ences in the particle transport and physics models for the dif-
ferent Monte Carlo codes.
As shown in a recent study by Pfuhl et al.,27 the dose
buildup effects which are present in the entrance channel of a
proton Bragg curve provide an excellent test of both the elec-
tromagnetic interaction models (delta electron buildup in the
first few millimeters) as well as the nuclear interaction mod-
els (secondary proton buildup in the first few cm) imple-
mented in a radiation transport code. Therefore, the
integrated depth–dose curve of 150 MeV protons was calcu-
lated with all three studied proton transport codes (PENH,
FLUKA, GEANT4/TOPAS). The Bragg curve was scored in a
10 9 10 9 20 cm3 water phantom when irradiating with a
pencil beam of 150 MeV protons. The same physics settings
as in the cavity simulations were used. The binning of the
scored dose distribution was 10 9 10 cm2 laterally and
0.1 mm in the direction of beam.
In the following subsections, the Monte Carlo codes used
are described shortly.
2.C. Monte Carlo code 1: PENH
PENH
28 is an extension of the Monte Carlo code PENELOPE29
that includes the transport of protons based on their electro-
magnetic interactions in matter. Proton nuclear interactions
(a) (b) (c)
FIG. 1. Geometries used for the simulations: (a) reference volume: a water-
filled plane-parallel volume with a diameter of 10 mm and a height of
0.25 mm, (b) air-filled plane-parallel volume with a diameter of 10 mm and
a height of 2.5 mm and (c) air-filled cylindrical volume with a height of
20 mm and a diameter of 6 mm. The direction of the broad beam is marked
with black arrows on the left. [Color figure can be viewed at wileyonlinelibra
ry.com]
TABLE I. Elemental compositions of water and air used in the simulations.
All fractions are given in mass fractions.
Element Water Air
1H 0.111894 0.0
12C 0.0 0.000124
14N 0.0 0.755268
16O 0.888106 0.231781
40Ar 0.0 0.012827
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and prompt-gamma emission are included for a limited num-
ber of isotopes: 1H, 12C, 14N, 16O, 31P, 40Ca.30 Both PENELOPE
and PENH have been reported to pass the Fano test within
0.1%31,33 for the energy range of interest to this work. Fur-
thermore, PENH has been shown to yield kQ factors in proton
beams in good agreement with experimental data.15 Photon,
electron, and positron cross sections, as well as transport sim-
ulation parameters are described in detail in Ref. [29] Cross
sections for proton electromagnetic interactions are described
in Ref. [28] Cross sections for proton nuclear interactions
and prompt-gamma emission are described in Ref. [30], as it
is also described the approximate transport of secondary
charged particles heavier than protons. Neutrons are not
transported.
To improve efficiency without compromising on accuracy,
the geometry of all PENH simulations was constructed as fol-
lows15: (a) a scoring volume (see Fig. 1), (b) a 540 lm-thick
“skin” (around the scoring volume)— with a thickness equal
to the continuous slowing down approximation range
(RCSDA) in water of a 200 keV electron, multiplied by a safety
factor of 1.2 to account for the possibility that an electron
may travel a distance beyond its RCSDA due to energy-loss
straggling31 (c) a 5 mm envelope around the skin and (d) the
water phantom. In the scoring volume and 540 lm-thick
skin, we performed detailed simulation (i.e., every single
interaction was simulated as a catastrophic event32); whereas
in the 5 mm-thick envelope and the water phantom, we used
a mixed (class II32) simulation scheme. The absorption ener-
gies (Eabs) and transport simulation parameters (C1, C2, Wcc,
Wcr and DSMAX) used in these regions are detailed in Table II.
No variance reduction techniques were used.
As the main program, we used PENEASY.34 We scored the
energy deposited in the scoring volume with the
tallyEnergyDeposition and the fluence dif-
ferential in energy with the tallyFlu-
enceTrackLength. The output of the
tallyEnergyDeposition (in units of eV/his-
tory) was converted to absorbed dose (in units of gray) by
converting eV to joules (J) and dividing the energy by the
density and volume of the scoring volume. The output of the
tallyFluenceTrackLength (in units of cm/
eV per history) was converted to MeV1 cm2 by converting
eV to MeV and dividing by the volume of the water cavity.
Statistical uncertainties were estimated using the history-by-
history method.29
2.D. Monte Carlo code 2: FLUKA
The second code chosen for the comparison is the Monte
Carlo code FLUKA35,36 (FLUKA2011 Version 2c.6). Originally
developed for high-energy physics applications, nowadays it
is also widely used for simulations in proton and heavy ion
therapy.37–40 The code is capable of transporting various
kinds of particles including photons, electrons, positrons,
neutrons, protons, and heavy ions. Charged particles can be
transported down to 1 keV and their energy loss is treated in
a condensed history approach. Single Coulomb scattering
events are condensed in a multiple scattering algorithm.
Hadron–nucleus interactions are treated via the PEANUT
model. The models implemented in FLUKA are under ongoing
development38 and are frequently updated.
Also for FLUKA, a Fano cavity test was performed by Lour-
enco et al.41 (for proton transport only) with the result that
FLUKA passes the test within 0.15% if the step size in the mul-
tiple Coulomb scattering algorithm is set small enough com-
pared to the dimensions of the cavity of interest (step size of
0.01 cm in the case of Lourenco et al. where the radii of the
plane-parallel cavities were between 0.78 cm and 4.08 cm
and the cavities were positioned at a depth where the charged
particle equilibrium is reached41).
In FLUKA, the user can in most cases not choose between
different physics models (unlike, e.g., in Geant4), but only
enhance their precision level in certain steps. On the one
hand, this reduces the flexibility of the code but, on the other
hand, its predictions are well reproducible and very robust.
For all FLUKA simulations performed in this work, the phy-
sics models were set to the highest precision level (e.g., full
Rayleigh and Coulomb scatter corrections, heavy fragment
evaporation, and coalescence) and both the transport and pro-
duction thresholds for charged particles and photons were set
to 1 keV in the region of interest (the region around and
within the scoring cavities; see also Section 2.C). In order to
further enhance the transport precision for the simulations of
the energy deposition in the small cavities, the multiple Cou-
lomb scattering was suppressed in these regions by adding
the MULSOPT card to the input file. Using this card, single
scattering was activated and the minimum step length for
multiple Coulomb scattering was increased by a factor of
10 000 to force the code to simulate the Coulomb scattering
as detailed as possible.
Since the standard material definitions in FLUKA consider
the natural isotopic composition of a given element (e.g., car-
bon consists of 98.9% 12C and 1.1% 13C), but in our material
definitions (see Table I), only the main isotopes are present
(e.g., carbon consists of 100% 12C), the FLUKA material defi-
nitions were adapted.
The statistical uncertainties were estimated by calculating
the standard deviation of the results from independent runs
performed with different random seeds.36
2.E. Monte Carlo code 3: GEANT4/TOPAS
Simulations were performed with the TOPAS code (“TOol
for PArticle Simulation”)42 version 3.1.p1, a toolkit based on
Geant4 (“GEometry ANd Tracking”)43 version geant4-10-03-
patch-01. Since TOPAS is based on GEANT4, it uses the
same physics models, processes, and interaction cross sec-
tions. Previous studies have extensively validated the code
against experimental data.44,42 The code is capable of trans-
porting various kinds of particles including photons, elec-
trons, positrons, neutrons, protons, and heavy ions.
In Geant4, electromagnetic (EM) interactions of the
charged particles are grouped in the condensed history (CH)
approach. While discrete collisions with an energy loss above
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a user-defined threshold are simulated one by one, angular
deflections of all soft collisions are grouped at the end of a
given step using a given multiple scattering (MSC) theory.45
Since a real trajectory is not a straight line, the lateral dis-
placement is considered at the end of the step.
For the simulations with TOPAS, we investigated both the
physics lists g4em-standard_opt3 and g4em-standard_opt4.
The physics list g4em-standard_opt3 makes use of the
G4UrbanMscModel46 for the multiple scattering of all
charged particles. O’Brien et al.47 showed that when using
the Urban scattering model, the Fano test is passed in clinical
photon radiation fields within 0.1%. The physics list g4em-s-
tandard_opt4 makes use of the WentzelVI model48 as well as
the Goudsmit–Saunderson model49,50 for the multiple scatter-
ing: For electrons and positrons with energies below
100 MeV, the Goudsmit–Saunderson model is used. For elec-
trons and positrons with an energy above 100 Mev and for
protons with energies below 500 MeV, the WentzelVI model
is used. It was shown that the WentzelVI model shows better
agreement in the proton therapy range compared to the Urban
model.51 Furthermore, Wulff et al.16 showed that the Fano test
is passed in clinical proton beams within 0.1%–0.2% (de-
pending on the beam geometry) when using the physics list
g4em-standard_opt4.
The results obtained when using the physics list g4em-s-
tandard_opt4 for the photon simulations were unreasonable
in terms of the fQ factor as described in Appendix A. For the
proton simulations, the differences for the results between the
physics lists g4em-standard_opt3 and g4em-standard_opt4
were small (<0.4% in terms of the fQ factor). Hence, we
decided to only show the results obtained with the physics list
g4em-standard_opt3 in the main text and show the results
from the physics list g4em-standard_opt4 in Appendix A.
The length of a step in the CH is limited by tracking limits,
such as geometric boundaries and physics-related parameters.
A parameter to control the step length is the parameter
dRoverR which defines the maximum length of one single
step in relation to the range of the particle. For the photon
simulations, this parameter dRoverR was set to 0.003 follow-
ing O’Brien et al.47 The fixed step size limiter Maxi-
mumStepSize was disabled (by setting it to 1000 m) also
following O’Brien et al.47 For the proton simulations, the
parameter dRoverR was set to 0.05 following a study by
Wulff et al.16 and the MaximumStepSize was set to 1000 m,
too. Further step limitations are combined in the G4MscSte-
pLimitType which was set to fUseDistanceToBoundary for
electrons and positrons in the used physics list.
While losing energy, the CH step length for each particle
decreases until it is smaller than the finalRange, below which
the particle is ranged out in a single straight step. The
finalRange was set to 1 nm in the photon simulations and to
100 nm in the proton simulations.
For Compton scattering simulations, the
G4KleinNishinaModel53 was used. For ion ionization, the
G4IonParametrisedLossModel based on the ICRU7354 ion
stopping data was applied.
The simulation of nonelastic nuclear interactions was
managed by the physics list g4h-phy_QGSP_BIC_HP. For
inelastic nucleon–nucleus processes, the Binary Cascade
model55 was used. To get inelastic cross sections, the
G4BGGNucleonInelasticXS was taken for protons and
neutrons.
For elastic scattering processes, the G4ChipsElasticModel
was used for protons and neutrons from 0 to 100 TeV.
ChipsProtonElasticXS provided the proton cross sections
while G4NeutronElasticXS provided the neutron cross
sections.
The default physics list g4ion-binarycascade was imple-
mented so that the Binary Cascade model was also used for
inelastic nuclear interactions of ions. The physics list g4decay
was implemented in order to calculate the decay of particles
like muons. Furthermore, the physics lists g4h-elastic_HP and
g4stopping were used for high-precission calculation of elastic
processes of hadrons and to activate and provide the nuclear
capture of negatively charged particles at rest.
The parameter controlling the production of secondaries is
given in units of length in Geant4. The reason for this is that
using a range instead of energy for the production thresholds
is theoretically the more precise determination of the location
for the energy release.45 The production cut for all particles
was set to 0.5 mm in the whole geometry (which corresponds
to  200 keV electrons in water), except in a region envelop-
ing and including the scoring volume where the cut was set to
0.065 lm (which corresponds to  1 keV electrons in water).
For the simulations of the air-filled cavities, the cut in air was
set to 47.2 lm, which corresponds to 990 eV electrons in air.
The enveloping region was — equally to the setup in PENH in
Section 2.C set to be equal to the RCSDA in water of 200 keV
electrons, multiplied by a safety factor of 1.2.
The parameters explained in the text are also listed in
Tables III and IV. No variance reduction techniques were
used. The statistical uncertainties were estimated by combin-
ing the uncertainties from independent runs performed with
different random seeds as described in Ref. [56].
TABLE II. Absorption energies and transport simulation parameters used in PENH simulations.
Region EabsðeÞ EabsðcÞ EabsðeþÞ EabsðpÞ C1 C2 Wcc Wcr DSMAX
Scoring volume 1 keV 1 keV 1 keV 1 MeV 0 0 0 0 n/a
540 lm skin 1 keV 1 keV 1 keV 1 MeV 0 0 0 0 n/a
5 mm envelope 200 keV 1 keV 200 keV 1 MeV 0.05 0.05 10 keV 1 keV 200 lm
Water phantom 200 keV 1 keV 200 keV 1 MeV 0.1 0.1 10 keV 1 keV 2 mm
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To score the spectral fluence of primary photons and pro-
tons as well as the spectra of secondary electrons, we did not
use the default scorer fluence provided by TOPAS. Instead,
we took a self-programmed scorer as described in the
Appendix B.
2.F. Monte Carlo code 4: EGSNRC
The EGSNRC code is capable of transporting photons, elec-
trons, and positrons and is widely used for dosimetric applica-
tions in medical physics. It was included in this study as a
benchmark for the 1.25 MeV photon case; details of the trans-
port models and physics behind the code can be found in Ref.
[57]. It has been shown that the code is able to calculate the
response of ionization chambers with an accuracy of 0.1% nor-
malized to its own cross sections.58,59 All simulations in this
study were performed with the EGSNRC version 2017, applying
the user codes egs_chamber60 for dose calculations and cav-
ity61 as well as FLURZnrc62 for fluence calculations. Photons,
electrons, and positrons were transported down to a kinetic
energy of 1 keV (total energy of 512 keV for electrons/posi-
trons). The energy thresholds for the production of secondary
particles from electron interactions (d-electrons/bremsstrah-
lungs-photons) was set to AE = 512 keV (d-electrons) and
AP = 1 keV (bremsstrahlungs-photons). Further transport
parameters and applied cross sections are summarized in
Table V. Statistical uncertainties were estimated using the his-
tory-by-history method.63
3. RESULTS
3.A. Absorbed dose in the water and air cavities
The results for the absorbed dose in the different
geometries given in Fig. 1 for the Monte Carlo codes
investigated are shown in Fig. 2; in panel (a) for the irra-
diation with 1.25 MeV photons and in panel (b) for the
irradiation with 150 MeV protons. In the bottom graphs,
the deviations relative to the PENH results are shown to
visualize the relative differences between the codes. Since
no experimental data are available, we chose to investigate
the deviations relative to one of the Monte Carlo codes
used. Our choice fell on PENH because, among the codes
capable of transporting both electrons and protons, it was
the one that reached the smallest statistical uncertainty
within a reasonable calculation time. However, this normal-
ization is still arbitrary and does not claim that PENH gave
the most accurate results.
For the irradiation with photons, the absorbed doses in the
water-filled reference volume are for all Monte Carlo codes
 12% larger than the absorbed doses in the air-filled vol-
umes.
The absorbed doses for the Monte Carlo codes PENH and
EGSNRC agree within one standard deviation for the air-filled
volumes and within two standard deviations for the water-
filled volume. The largest deviation between these two codes
is 0.1%. The absorbed doses calculated with FLUKA are up to
1.4% larger compared to PENH, those calculated with GEANT4/
TOPAS are up to 0.5% larger.
For the irradiation with protons, the absorbed doses in the
water-filled reference volume are for all Monte Carlo codes
 13% larger than the absorbed doses in the air-filled vol-
umes.
The absorbed doses calculated with FLUKA are up to 0.5%
smaller compared to PENH, those obtained with GEANT4/TOPAS
are up to 1.0% smaller.
3.B. fQ0 factors, fQ factors, and fQ=fQ0 ratios
In Fig. 3, the fQ0 and fQ factors calculated with Eq. 1 as
well as the fQ=fQ0 ratios are summarized.
The fQ0 factors for the irradiation with 1.25 MeV photons
shown in panel (a) are in the range of  1.120–1.125. The
results for all codes agree within two standard deviations or
better. The largest deviation is between FLUKA and GEANT4/
TOPAS for the plane-parallel cavity with 0.4% .
The fQ factors for the irradiation with 150 MeV protons
are shown in panel (b). For both volumes, the fQ factors are
in the range of 1.130–1.138. Except for the plane-parallel vol-
ume and the codes PENH and GEANT4/TOPAS, the results for all
codes coincide within two standard deviations. The largest
deviation is that between PENH and GEANT4/TOPAS for the
plane-parallel volume with 0.5%.
In panel (c), the fQ=fQ0 ratios are shown for 150 MeV
protons and both air-filled volumes. The fQ=fQ0 ratios are
TABLE III. Production cuts and transport simulation parameters used in GEANT4/TOPAS for the photon and proton simulations.
Region Production cut in lm Maximum stepsize in m
dRoverR finalRange in nm
Photon-sim. Proton-sim. Photon-sim. Proton-sim.
Scoring volume and envelope 0.065 for water and 47.2 for air 1000 0.003 0.05 1 100
Water phantom 500 1000 0.003 0.05 1 100
TABLE IV. Multiple scattering models used in GEANT4/TOPAS for the photon
and proton simulations.
Radiation
field
Multiple scattering model
for eþ/e
Multiple scattering model
for primaries
1.25 MeV
photons
Urban model /
150 MeV
protons
Goudsmit–Saunderson
(E ≤ 100 MeV)
Wentzel VI (E > 100 MeV)
Wentzel VI (E ≤ 500 MeV)
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in the range of 1.005–1.015. For both volumes, the results
for all codes coincide within two standard deviations or
better. The largest difference can be seen for the plane-
parallel volume and the codes PENH and FLUKA with a devi-
ation of 0.7%.
The ratios fQ=fQ0 from Fig. 3 were calculated for each of
the codes PENH, FLUKA and GEANT4/TOPAS using the fQ0 and fQ
factors both calculated with the same code. While fQ has to
be calculated with a code capable of transporting protons if
Q is a proton radiation field, the fQ0 factor could theoretically
be calculated using another code such as EGSNRC being a com-
monly used code for the calculations of photons. In Table VI,
the fQ=fQ0 ratios for the codes PENH, FLUKA, and GEANT4/TOPAS
are listed for both air-filled volumes once determined using
the fQ0 and fQ factors both calculated with the same code vs
the results when using fQ0 calculated with EGSNRC. The differ-
ences are smaller than or equal to their statistical uncertain-
ties; hence, we cannot conclude any differences.
3.C. Spectral fluences in water
Figure 4 shows the spectral fluences in water of the pho-
tons (a) and the secondary electrons (b) within the water-
filled reference volume for the irradiation with 1.25 MeV
photons. The peak of the primary photons at an energy of
1.25 MeV can clearly be seen. The spectrum of the Comp-
ton-scattered photons with the peak of the backscattered pho-
tons at an energy of  0.2 MeV is also clearly visible.
Accordingly, the Compton edge can be seen in the spectral
fluence of the secondary electrons at an energy of
 1.05 MeV. The broad Compton spectrum is clearly visible,
too. The spectra for both the photons and electrons agree
almost perfectly between all Monte Carlo codes.
The spectral fluence in water of protons in the
150 MeV proton beam at the cavity position is shown in
fig. 5(a). The peak of the primary protons lies at an
energy of  139 MeV (corresponding to 150 MeV minus
TABLE V. Transport simulation parameters used in the EGSNRC simulations.
Photon cross section NIST
Brems cross section KM
Brems angular sampling KM
Electron Impact Ionization ik
Rayleigh scattering ON
Spin effects ON
Bound Compton Scattering ON
Radiative Compton corrections ON
Atomic relaxations ON
Pair angular sampling KM
Triplet production ON
PE angular sampling ON
Photonuclear attenuation ON
Photonuclear cross section default
Boundary crossing algorithm Exact
Skin depth for BCA 3
Electron-step algorithm EGSNRC
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FIG. 2. Absorbed dose in Gy per primary scored in each volume from Fig. 1 for all Monte Carlo codes. (a) 1.25 MeV photons, (b) 150 MeV protons. In the bot-
tom graph, the deviations relative to PENH are shown (see text for explanation). The statistical uncertainties of the absolute absorbed doses are smaller than the
symbol size. The statistical uncertainties represented by bars in the bottom graphs correspond to one standard deviation. [Color figure can be viewed at wileyon
linelibrary.com]
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the energy loss in the first 2 cm of water). The spectrum
of the secondary protons ranges over the whole spectrum
up to the primary protons. Differences between the indi-
vidual codes can be observed for very low energies up to
 20 MeV and higher energies between 125 and
135 MeV. The spectral fluence of the secondary protons
scored with PENH develops a small peak at an energy of
 80 MeV. This might be due to the fact that in PENH
fragments heavier than protons (like deuterons) are simu-
lated as secondary protons and the energy of these “pro-
tons” is adjusted to match the range of the real
fragments.30 In this case, these fragments are deuterons
that are simulated as 80 MeV protons which would have a
range in water of about 5 cm.
The spectral fluence in water of the delta electrons in the
150 MeV proton beam can be seen in Fig. 5(b). As expected,
the fluence is dominated by low-energy electrons. The maxi-
mum energy transferred to electrons in ionization processes
by 139 MeV protons [compare energy of primary protons in
Fig. 5(a)] is  0.3 MeV.64 Electrons with higher energies are
not produced by protons but by prompt gamma photons from
nuclear reactions. The spectral fluence of these high-energy
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FIG. 3. Results for fQ0 and fQ factors: (a) 1.25 MeV photons and (b) 150 MeV protons. (c) The fQ=fQ0 ratios for 150 MeV protons. The statistical uncertainties
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TABLE VI. fQ=fQ0 ratios for the Monte Carlo codes PENH, FLUKA, and GEANT4/TOPAS using the fQ0 factors calculated with the same Monte Carlo code and using fQ0
determined with EGSNRC. The given statistical uncertainties are one standard deviation.
Monte Carlo code Volume
ratio fQ/fQ0
Difference in %fQ0 from same code fQ0 from EGSNRC
PENH Plane-parallel 1.005  0.001 1.006  0.001 0.09  0.16
Cylindrical 1.013  0.001 1.013  0.001 0.06  0.11
FLUKA Plane-parallel 1.012  0.003 1.009  0.002 0.3  0.3
Cylindrical 1.015  0.003 1.016  0.003 0.1  0.4
GEANT4TOPAS Plane-parallel 1.009  0.002 1.011  0.001 0.2  0.3
Cylindrical 1.012  0.002 1.015  0.001 0.3  0.2
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electrons is considerably larger for GEANT4/TOPAS than for PENH
and FLUKA.
For all codes, there are no relevant differences between the
individual spectra except for the secondary protons and elec-
trons produced by prompt gamma photons as pointed out.
3.D. Electronic and nuclear buildup, ranges, and
stopping powers
Figure 6(a) shows the integrated depth–dose curve of
150 MeV protons in water. Among all codes, the dose curves
are in a good agreement. In panel (b), a zoom to the Bragg
peak is shown. As can be seen, the dose at the peak calcu-
lated with FLUKA is about  1.5% smaller compared to the
doses calculated with PENH and GEANT4/TOPAS. Furthermore,
the ranges of all codes agree within  0.1 mm which is the
resolution of the scored dose curves. In panel (c), a zoom to
the first 95 mm is shown. In this region, the secondary pro-
ton buildup takes place. Small discrepancies between the
codes can be seen at small depths of  5 mm (1.3% differ-
ence in dose) and at greater depth of  70 mm and
 90 mm (1.5% difference in dose). These differences are
statistically significant. The best agreement between the
codes is at depths of 20–40 mm supporting the IAEA refer-
ence depth for monoenergetic protons of 3 g cm.2 Note that
these dose curves were produced with a pencil beam and the
dose was laterally integrated. Hence, the absolute doses differ
from the ones presented in Fig. 2(b).
In Fig. 6(d), the first 2 mm of the Bragg curve is shown
while the dose values are normalized to the dose value at a
depth of 1 mm. As already mentioned, this region provides
an excellent test of the electromagnetic interaction models
implemented in the different Monte Carlo codes. Within the
first millimeters of the depth–dose curve, the buildup is dom-
inated by the creation of delta electrons with energies up to
0.33 MeV.64 The range of these electrons is about 1 mm.
Accordingly, an equilibrium is reached and the electron
buildup is completed at this depth [see Fig. 6(d)]. The elec-
tron buildup is reproduced by all three Monte Carlo codes
identically, indicating that the underlying electromagnetic
interaction models are similar in these codes [also compare
Fig. 5(b)]. The completion of the electronic buildup at a
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depth of 1 mm is the reason why the depth–dose curves are
normalized to the dose at this depth.
To ensure that the stopping powers are the same for the
different Monte Carlo codes for the given mean ionization
potentials of water Iw = 78 eV and air Iair = 85.7 eV, we
compared the stopping powers of water and air for protons
and electrons. In Fig. 7, the electronic mass-stopping powers
of (a) water and (b) air for protons for the Monte Carlo codes
PENH, FLUKA, and GEANT4/TOPAS are shown. As reference, the
ICRU90 data17 are shown. For energies between 0.3 MeV
and 1000 MeV, there are no significant differences between
the codes and the ICRU90 data. Only for energies below
0.3 MeV, differences can be seen. The stopping powers of
water and air for electrons agreed almost perfectly among the
Monte Carlo codes and with the reference data from the
ICRU90 in the energy range from 10 keV to 900 MeV (not
shown).
4. DISCUSSION
Simulations of the absorbed dose in simple water- and
air-filled geometries and the calculation of fQ factors as well
as fQ=fQ0 ratios were carried out with different Monte Carlo
codes for different beam qualities and particle types.
Although the absorbed dose to medium per primary particle
does not always agree for all Monte Carlo codes, these dif-
ferences tend to cancel out in the fQ factors and the fQ=fQ0
ratios. The fQ=fQ0 ratios agree within 0.7% for protons for
the Monte Carlo codes PENH, FLUKA, and GEANT4/TOPAS. Since
these ratios are the only part of kQ;Q0 factors that can be
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determined with the Monte Carlo method and since it was
shown, that PENH can be used to calculate kQ;Q0 factors in
clinical proton beams,15 we conclude that FLUKA and GEANT4/
TOPAS can also be used to calculate kQ;Q0 factors in clinical
proton beams.
When mixing the codes in a way that the fQ factor is taken
from a code capable of transporting protons and fQ0 is derived
using EGSNRC, the differences in the fQ=fQ0 ratios are not sig-
nificant compared to the case when both fQ and fQ0 are calcu-
lated within the same code. Although no significant
differences were seen, it is commonly advised to always use
the same code to calculate the fQ as well as the fQ0 factor to
avoid a mixing of physical models and to enhance the chance
that code-internal systematic uncertainties are canceled out in
the Dw=Dair ratios, that is, in the fQ factors, as well as the
fQ=fQ0 ratios.
The fQ0 factors for 1.25 MeV photons for the air-filled
volumes are in the range of 1.120–1.125 and the fQ factors
for 150 MeV protons for the air-filled volumes are in the
range of 1.130–1.138. These factors correspond approxi-
mately to the Spencer–Attix water to air mass stopping
power ratio sw;air. For a 60Co beam, this mass stopping
power ratio is  1.12765,66, and for a 150 MeV proton
beam, it is 1.130.67 The fQ0 and fQ factors calculated in
this study agree with these values within a few permille.
Differences are due to the fact that the stopping power
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ratio is defined on the fluence in water, whereas in this
work, we scored the fluence in air.
In order to try to explain differences in the particle
transport and the physics models used in the Monte Carlo
codes, we presented spectral fluences in water of the pri-
mary particles and secondary electrons. In spite of possible
differences due to the use of different approaches and mod-
els, we found remarkable agreements between the codes:
For the photons and secondary electrons in the 1.25 MeV
photon field, the spectra agree almost perfectly. For the
spectral fluence of protons and electrons in the 150 MeV
proton field, the spectra also agree reasonably well, except
for the secondary protons and high-energy electrons pro-
duced by prompt gamma photons. For the secondary pro-
tons, we observed differences between the spectra
generated with the different Monte Carlo codes for energies
between 125 and 135 MeV. The production of a secondary
proton from an 16O nucleus requires an energy of
 12 MeV,68; therefore, the gap between the primary and
secondary protons visible in the spectra generated with
TOPAS and FLUKA is reasonable. However, this gap cannot
be observed in the spectrum generated with PENH. Anyway,
this difference in the spectral fluence of secondary protons
has only a very small effect on the absorbed dose Dw at a
water depth of 2 cm (where the spectral fluence and the
absorbed dose were calculated), since the fluence of sec-
ondary protons is >3 orders of magnitudes smaller than the
fluence of primary protons.
The spectral fluence of high-energy electrons produced
by prompt gamma photons is considerably larger for GEAN-
T4/TOPAS than for PENH and FLUKA. It was shown by Robert
et al. that in Geant4, many more prompt gamma photons
are produced compared to FLUKA,40 which might be the
explanation for the differences observed in this work.
However, for dosimetry purposes, these differences in the
prompt gamma photon production are negligible since the
fluence of electrons generated by prompt gamma photons
is >2 orders of magnitudes smaller than the fluence of the
delta electrons.
On the one hand, the agreement in the spectra of sec-
ondary electrons shows that the different electromagnetic
interaction models yield similar results. On the other hand,
the differences in the spectra of secondary protons show that
the more complex nuclear interaction models tend to slight
differences. Accordingly, discrepancies in the proton depth–
dose curves as shown in Fig. 6 due to the different predictions
of the secondary proton production were observed. However,
the impact of these differences at small depths is so low that
the fQ=fQ0 ratios at a water depth of 2 cm calculated with the
different codes agree within 0.7%. Pfuhl et al.27 have com-
pared dose profiles similar to those shown in Fig. 6(d) with
measured dose profiles. FLUKA could reproduce both the elec-
tronic and the nuclear buildup quite well, with a maximum
underestimation of  1% at large depths. In another study by
Yang et al.69, depth–dose curves were calculated with both
FLUKA and Geant4 and compared to measurements. Yang
et al. concluded that FLUKA and Geant4 are “capable of per-
forming dose calculations for therapeutic scanning proton
beams with proper physics settings.”69 Furthermore, Monte
Carlo codes like, for example, FLUKA are already used to gen-
erate basic data for treatment-planning systems and are hence
intensively validated against experimental dose measure-
ments.70,71
We also showed that the ranges of protons in water agree
within  0.1 mm between the codes [see Fig 6(b)]. Since the
range is connected with the stopping power of water, we
investigated the stopping powers of water for protons and
electrons and found good agreements between the codes and
the ICRU90 stopping powers. The only differences for pro-
tons were found for energies below 0.3 MeV. Since the range
in water of protons with an energy of 0.3 MeV is only
 5 lm, these differences in the stopping powers have no
visible effect on the range that we calculated with a resolution
of 0.1 mm.
Finally, a last consideration regarding uncertainties in
Monte Carlo calculations: while type A uncertainties are
easy to calculate and can be reduced by increasing the
number of primary histories, type B uncertainties (due to
uncertainties in the cross sections, nuclear models, particle
transport, geometry, etc.) are more difficult to estimate.
The results of this work could be used to estimate (an
upper limit to) the type B uncertainty in the fQ=fQ0 ratios
calculated with PENH, FLUKA, and GEANT4/TOPAS, due to the
uncertainty in cross-section data, nuclear models, and par-
ticle transport. Figure 3(c) shows that the differences in
fQ=fQ0 ratios are well within three (type A) standard uncer-
tainties of the data points calculated with FLUKA. Thus, it
could be concluded that an upper limit to the type B
uncertainty in the fQ=fQ0 ratios (due to the uncertainty in
cross-section data, nuclear models, and particle transport)
is the type A uncertainty in the fQ=fQ0 ratios calculated
with FLUKA. That is, uB ≤ 0.3%.
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5. CONCLUSION
The Monte Carlo codes PENH , FLUKA, GEANT4/TOPAS, and
EGSNRC were investigated and used to calculate the absorbed
dose in a simple water-filled reference volume and two air-
filled volumes representing simplified ionization chambers
for the irradiation with 1.25 MeV photons representing a
60Co beam and with 150 MeV protons — EGSNRC was used
only for the photon beam calculations. The absorbed doses to
medium (per primary particle) agreed within 1.4% or better
for the photon field among all codes. For the irradiation with
150 MeV protons, the absorbed doses to medium (per pri-
mary particle) agreed within 1.0% or better among the three
codes capable of transporting protons (PENH, FLUKA, and
TOPAS/Geant4). It was shown that by choosing appropriate
transport settings which were reported in detail, the results
for the fQ=fQ0 ratios agreed within 0.7%. In other words,
PENH, FLUKA, and TOPAS/Geant4 are all suitable to calculate
fQ0 , fQ, and kQ;Q0 factors in proton beams.
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APPENDIX A
PHYSICS LIST IN TOPAS FOR PHOTON AND
PROTON FIELDS
As described in Section 2.C, we used the physics list
g4em-standard_opt3 for both the photon and proton simula-
tions for the Monte Carlo code GEANT4/TOPAS. We also tested
the physics list g4em-standard_opt4 for both the photon and
proton simulations. In Fig. 8, the absorbed doses for the three
cavities calculated with PENH and GEANT4/TOPAS for the two
physics lists as well as the deviations relative to PENH are
shown on the left side for photons [panels (a) and (b)]. The
absorbed dose in the water-filled reference volume is  0.5%
smaller and the absorbed dose in the air-filled cavities is
 2% smaller when replacing the physics list g4em-stan-
dard_opt3 by g4em-standard_opt4. Hence, the deviations rel-
ative to PENH are up to 1.5% instead of 0.5%. In Fig. 8 in
panel (c), the resulting fQ0 factors for photons are shown:
when using the physics list g4em-standard_opt4, the fQ0 fac-
tor is  1.141 instead of  1.125 and hence 1.4% greater and
does not agree with the Spencer–Attix water to air mass stop-
ping power ratio sw;air anymore.
In panels (d) and (e), the absorbed doses for the three cavi-
ties calculated with PENH and GEANT4/TOPAS for the two physics
lists as well as the deviations relative to PENH are shown for
protons. The difference in the absorbed dose is <0.1% for the
water-filled reference volume and <0.36% for the air-filled
cavities when replacing the physics list g4em-standard_opt3
by g4em-standard_opt4. For the resulting fQ factors, the differ-
ences are smaller than 0.4% for the different physics lists. The
maximum deviation between PENH and GEANT4/TOPAS rises
from 0.5% for the physics list g4em-standard_opt3 to 0.8%
for the physics list g4em-standard_opt4.
Since the multiple scattering models used in the physics
lists g4em-standard_opt3 and g4em-standard_opt4 are not
the only differences we cannot clarify whether these scatter-
ing models are responsible for the different results.
In conclusion: for the proton simulations, both the physics
lists g4em-standard_opt3 and g4em-standard_opt4 can be
used whereas for the photon simulations, the physics list
g4em-standard_opt4 does not lead to reasonable results.
Additionally, one has to keep in mind that the physics lists
provided by Geant4 may vary with the versions of the code.
Hence, the physics lists used in this work may lead to differ-
ent results in the future when changed in new versions of
Geant4.
APPENDIX B
SCORING THE SPECTRAL FLUENCE IN TOPAS
As mentioned in Section 2.C, we used a self-pro-
grammed scorer in TOPAS to score the spectral fluence in
the water cavity. The reason is that the scorer fluence pro-
vided by TOPAS is not designed to score a spectral flu-
ence. Although the fluence can be binned by energy, this
energy binning is not based on the particle’s energy when
the scoring hit is generated. The scorer fluence bins the
fluence of the particle to the energy the particle had when
the particle was incident on the scoring volume (i.e., when
entering the scoring volume). However, this so-scored
energy-binned fluence does not correspond to the spectral
fluence of a particle. In the case that a particle is pro-
duced within the scoring volume, the difference between
the result of the energy-binned scorer fluence and the
spectral fluence becomes clear: The scorer fluence pro-
vided by TOPAS connects the fluence of this particle cre-
ated within the scoring volume to the energy its
predecessor had when entering the scoring volume and
not to the energy of the scored particle it had when the
hit was generated — as it is the case when scoring the
spectral fluence.
In Fig. 9, the fluences of electrons at 5 cm water depth in
a 1.25 MeV photon beam are shown: In the first scenario, the
fluence is binned by the energy the particle had when enter-
ing the scoring volume (as it is done in the scorer fluence
provided by TOPAS). In the second scenario, the fluence is
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binned by the energy the particle had when generating the
scoring hit (this corresponds to the spectral fluence and is the
scoring method used in this study).
As can be seen, the fluence scored with the scorer flu-
ence provided by TOPAS shows electrons with an energy of
1.25 MeV. These electrons were produced within the scor-
ing volume, and hence, TOPAS bins the fluence of these
electrons by the energy their predecessor (in this case a
1.25 MeV photon) had when entering the scoring volume.
In contrast, the scorer used in this study for the TOPAS sim-
ulations does not show this peak since the fluence is binned
by the energy of the particle itself that was created in the
scoring volume. Correspondingly, differences in the fluence
of low-energy electrons can be seen: Since the scorer flu-
ence provided by TOPAS bins the fluence of low-energy
electrons that are created within the scoring volume by the
energy of their predecessors, the fluence of low-energy elec-
trons is smaller compared to the spectral fluence scored with
the self-programmed scorer which bins the fluence by the
energy of the electron itself that was produced in the scoring
volume. The spectral fluence scored with the self-pro-
grammed scorer was already shown in Fig. 4 and proven to
agree with the results from the Monte Carlo codes PENH,
FLUKA, and EGSNRC.
To avoid confusion when using the scorer fluence pro-
vided by TOPAS, several scoring options are now included in
the new TOPAS version 3.2.
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1. Introduction
The IAEA TRS-398 CoP for reference dosimetry in external radiotherapy beams (Andreo et al 2000) is currently 
being updated. The updated TRS-398 CoP will be based on the new ICRU 90 (Seltzer et al 2016) recommendations 
on key data for ionizing-radiation dosimetry. The RTNORM project (RTNORM 2019) is supporting the IAEA 
with fully Monte Carlo calculated kQ factors for different ionization chambers and various radiotherapy beams 
that will be provided in the updated TRS-398 CoP. Furthermore, kQ factors for monoenergetic proton beams will 
be provided which is not the case in the current TRS-398 CoP. Hence, there is a need for Monte Carlo calculated 
kQ factors in monoenergetic proton beams. Please note that fQ/fQ0 ratios, which are the basis of Monte Carlo 
calculated kQ factors, are the only part of kQ factors that can be calculated using the Monte Carlo method. When 
using the term ‘Monte Carlo calculated kQ factors’ we mean the Monte Carlo calculation of fQ/fQ0 ratios and 
subsequent derivation of kQ factors by using the Wair,Q  values.
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Abstract
To provide Monte Carlo calculated beam quality correction factors (kQ) for monoenergetic proton 
beams using topas, a toolkit based on the Monte Carlo code geant4.
Monte Carlo simulations of six plane-parallel and four cylindrical ionization chambers were 
carried out. The latest ICRU 90 recommendations on key data for ionizing-radiation dosimetry were 
used to calculate the electronic stopping powers and to select the mean energy necessary to create an 
ion pair in air (Wair).
fQ0 factors were calculated for a 
60Co spectrum at a depth of 5 g cm−2. f Q factors and fQ/fQ0 ratios 
as well as kQ factors were calculated at the entrance region of monoenergetic proton beams with 
energies between 60 MeV and 250 MeV.
Additionally, perturbation correction factors for the Exradin A1SL ionization chamber at an 
energy of 250 MeV were calculated.
fQ0 factors agreed within 0.7% or better, f Q factors within 1.7% or better and fQ/fQ0 ratios within 
2.2% or better with Monte Carlo calculated values provided in the literature. Furthermore, kQ factors 
calculated in this work were found to agree within 1% or better with experimentally determined kQ 
factors provided in the literature, with only two exceptions with deviations of 1.4% and 2.4%.
The total perturbation correction factor for the Exradin A1SL chamber was 0.969(7) and hence 
significantly different than unity in contrast to the assumption from the IAEA TRS-398 code of 
practice (CoP).
topas/geant4 can be used to calculate kQ factors in clinical proton beams. kQ factors for 
six plane-parallel and four cylindrical ionization chambers were calculated and provided for the 
upcoming update of the IAEA TRS-398 CoP.
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For ion beams the data of Monte Carlo calculated kQ factors is scarce. Gomà et al (2016) used penh (Salvat 
2013) to calculate kQ factors in monoenergetic proton beams for nine plane-parallel and three cylindrical ioniz-
ation chambers. In the version of penh that was used in that study no proton nuclear interactions were included 
and hence no secondary particles originating from non-elastic nuclear interactions were transported. Therefore, 
gamos (Arce et al 2014) a toolkit based on geant4 (Agostinelli et al 2003) was used to generate a phase space 
file in water directly in front of the ionization chamber while proton nuclear interactions were considered. This 
phase space file was subsequently used in penh to calculate the dose absorbed in water in a reference volume 
and the dose absorbed in air in the sensitive volume of the ionization chambers. The so-calculated kQ factors were 
compared to experimentally determined values from the literature and found to agree within 1%.
In a study by Gomà and Sterpin (2019) penh was used to calculate kQ factors in monoenergetic and modu-
lated proton beams for nine plane-parallel and six cylindrical ionization chambers. In the version of penh 
that was used in that study the simulation of proton nuclear interactions (and prompt-gamma emission) for all 
ICRU 63 (Barschall et al 2000) isotopes was included. The kQ factors agreed with experimentally determined val-
ues on the 1% level. The f Q factors calculated by Gomà and Sterpin (2019) were compared to f Q factors calculated 
by Gomà et al (2016) for three chambers. Especially for high energies the results from both studies differed. Thus, 
the authors concluded that proton nuclear interactions should be included in the Monte Carlo calculation of kQ 
factors, especially for high energies.
To the best of our knowledge, no other Monte Carlo code than penh has been used for the calculation of kQ 
factors in clinical proton beams so far. However, other Monte Carlo codes like topas (Perl et al 2012) a toolkit 
based on geant4 as well as fluka (Ferrari et al 2005, Böhlen et al 2014) have been used for ionization 
chamber calculations in clinical proton beams: Wulff et al (2018) used topas/geant4 to calculate f Q factors 
for the IBA NACP-02 and Farmer NE 2571 ionization chamber in monoenergetic proton beams with energies 
between 70 MeV and 250 MeV. Two different nuclear interaction models were used and compared: binary cas-
cade (BIC) and Bertini cascade (BERT). The f Q factors calculated in that study agreed with those calculated by 
Gomà et al (2016) within 0.6% or better. The difference in f Q factors for the different nuclear interaction models 
was 0.3% at maximum. Lourenço et al (2019) used fluka to calculate perturbation correction factors for 
three different PTW chambers. In the studies by Wulff et al (2018) and Lourenço et al (2019) only clinical proton 
beams and no photon beams (which are needed for the calculation of fQ0 factors) have been investigated.
Hence, in a study by Baumann et al (2019) fQ0 factors, f Q factors and fQ/fQ0 ratios were calculated in a 
1.25 MeV monoenergetic photon and a 150 MeV monoenergetic proton beam for simple air-filled cavities placed 
in a water phantom. The Monte Carlo codes penh, fluka and topas/geant4 were used. The resulting 
fQ/fQ0 ratios agreed within 0.7% or better between the codes. Since Gomà et al (2016) used penh to calculate kQ 
factors in monoenergetic proton beams in agreement with experimental data within 1%, the authors concluded 
that both fluka and topas/geant4 can also be used for the calculation of kQ factors in clinical proton 
beams. However, no kQ factors for ionization chambers were calculated in that study.
Hence, the aim of this study is to calculate kQ factors for six plane-parallel and four cylindrical ionization 
chambers in monoenergetic proton beams using the Monte Carlo code topas/geant4. These kQ factors 
shall be compared to experimentally determined kQ factors provided in the literature. Furthermore, by provid-
ing kQ factors calculated with a Monte Carlo code different than penh we add important value, since for ion 
beams the data of Monte Carlo calculated kQ factors is scarce and all Monte Carlo calculated kQ factors for clinical 
proto n beams provided in the literature have been derived using penh.
Furthermore, the perturbation correction factor p Q of ionization chambers is assumed to be 1 for proton 
beams in the IAEA TRS-398 CoP (Andreo et al 2000). Gomà and Sterpin (2019) calculated f Q factors and water 
to air stopping power ratios sw,air in monoenergetic proton beams and hence were able to derive perturbation 
correction factors. The authors concluded that the perturbation correction factors of some ionization chambers 
might be significantly different than unity for proton beams. Hence, perturbation correction factors for one 
exemplary cylindrical ionization chamber shall be calculated in this study to clarify whether the assumption 
from the IAEA TRS-398 CoP is sufficiently accurate or not.
2. Materials and methods
2.1. Calculation of kQ,Q0  factors
Monte Carlo kQ,Q0 factors were calculated as (Andreo et al 2013):
kQ,Q0 =
fQ
fQ0
Wair,Q
Wair,Q0
=
(Dw/D¯air)Q
(Dw/D¯air)Q0
Wair,Q
Wair,Q0
 (1)
Q denotes the user beam quality and Q0 the reference beam quality. Note that, when 60Co gamma radiation is the 
reference beam quality, the subscript Q0 is typically omitted and kQ is used instead of kQ,Q0. The factor f is both 
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chamber-specific and beam quality-dependent and gives the proportionality between the absorbed dose to water 
at the reference point when the chamber is absent (Dw) and the average absorbed dose to air in the cavity of the 
air-filled ionization chamber (D¯air) (Sempau et al 2004). Wair,Q  is the mean energy necessary to create an ion pair 
in air depending on the beam quality Q.
The dose values Dw and D¯air were calculated using Monte Carlo simulations. The values for Wair,Q  were taken 
from the ICRU 90 (Seltzer et al 2016) (33.97 ± 0.12 eV for electrons, 34.44 ± 0.14 eV for protons).
2.2. Calculation of perturbation correction factors p Q
Exemplary perturbation correction factors were calculated as described by Wulff et al (2008) for the cylindrical 
ionization chamber Exradin A1SL and a monoenergetic proton beam of 250 MeV. We calculated the following 
perturbation factors: pcel that accounts for the central electrode in a cylindrical ionization chamber; pstem that 
takes into account perturbations produced by the chamber stem; pwall  that considers that the material of the wall 
is different than water; the product of pdis · pcav that accounts for the effective point of measurement and the fact 
that the dose deposited in the cavity is an average dose deposited in a finite volume. From these perturbation 
correction factors we calculated the total perturbation correction factor p Q as (Wulff et al 2008):
pQ = pcel · pstem · pwall · pdis · pcav (2)
2.3. Possible influence of the death volume for ionization chambers
In a recent study by Pojtinger et al (2019) it was shown that the collecting volume of ionization chambers is not 
necessarily equal to the cavity of the ionization chamber. If a guard ring is present the resulting electric field lines 
can lead to a death volume in the vicinity of the guard ring inside the cavity. The resulting sensitive volume of the 
chamber is the cavity minus the death volume since charges produced in this death volume are not collected by 
the electrodes.
In this study we calculated the dose in the whole cavity of each chamber disregarding the potential death 
volume. Since the dose deposited in the sensitive volume might be different than the dose deposited in the com-
plete cavity, this might have an effect on the calculated kQ factors. In order to estimate the potential influence of 
this death volume on calculated kQ factors, we calculated the dose deposited in the cavity of the Exradin A1SL 
chamber in a 250 MeV monoenergetic proton beam while the cavity was divided into 10 thin slabs (thickness 
of 0.4445 mm each). By investigating the space-resolved dose deposition we can derive the possible effect of the 
death volume.
2.4. Chamber geometries and materials
We investigated six plane-parallel ionization chambers (PTW Roos, PTW Markus, PTW Advanced Markus, 
IBA NACP-02, IBA PPC-05 and IBA PPC-40) and four cylindrical ionization chambers (NE 2571, PTW 30013, 
IBA FC65-G and Exradin A1SL). In table 1 the geometry and material compositions for the plane-parallel 
ionization chambers are summarized. For graphite the physical density ρg is shown since it varies between the 
manufacturers. The geometries of the cylindrical ionization chambers are too complex to be summarized in a 
table, hence, in figure 1 cross sections of the cylindrical ionization chambers are shown.
In table 2 all materials used in this study and their physical densities as well as the mean ionization potentials 
I used to calculate the electronic stopping powers are shown. For air and water we used the physical densities and 
I-values and for graphite the I-value as given in the ICRU 90.
2.5. Beam qualities and reference conditions
As reference beam quality Q0 we used a 60Co source. We used the energy spectrum as described by Mora et al 
(1999). The beam was uniform and parallel and impinging perpendicular on the water phantom surface. 
The field size was 10 × 10 cm2. The beam was transported through vacuum between the source and the water 
phantom. Typically, a divergent source is used for high-energy photon simulations that develops a rectangular 
field at a certain depth in water at a certain distance to the source (see for instance (Wulff et al 2008, Zink and 
Wulff 2012, Gomà and Sterpin 2019)). However, such a source is not implemented in topas/geant4 by 
default. Hence, we used an uniform and parallel beam.
As proton source we took an uniform and parallel beam of 10 × 10 cm2 impinging perpendicular on the water 
phantom surface. We investigated eight different monoenergetic beams (60, 70, 80, 100, 150, 160, 200 and 250 
MeV). The beam was transported through vacuum between the source and the water phantom.
For the simulations with the 60Co spectrum we followed the IAEA TRS-398 CoP (Andreo et al 2000). That is, 
the reference depth zref  was 5 g cm
−2. For the monoenergetic proton beams we used reference depths zref  of 1 g cm
−2 
for low proton energies (60 and 70 MeV) and 2 g cm−2 for higher energies (E  80 MeV). Beam quality correction 
factors kQ for the cylindrical ionization chambers were only calculated for high energies (E  150 MeV).
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The absorbed dose to water Dw was calculated in a disc of 1 cm of radius and 250 µm of height. This disk was 
centered at zref  in a water phantom of 20 × 20 × 20 cm3 for the photon simulations and 20 × 20 × 5 cm3 for the 
proton simulations. We chose to take a smaller water phantom for the proton simulations in order to reduce com-
puting time and since proton backscatter can be considered negligible (Salvat 2013, Gomà et al 2016).
To calculate the average absorbed dose to air D¯air in the cavity of the ionization chambers, each ionization 
chamber was positioned with its reference point at zref . For plane-parallel chambers, the reference point is at the 
center of the inner surface of the chamber’s entrance window. For cylindrical chambers the reference point cor-
responds to the center of the cavity on the symmetry axis.
2.6. TOPAS/GEANT4
We used topas (TOol for PArticle Simulation) version 3.1.p1 (Perl et al 2012), a toolkit based on the Monte 
Carlo code geant4 (GEometry And Tracking) version geant4-10-03-patch-01 (Agostinelli et al 2003). Since 
topas is based on geant4, it uses the same physics models, processes, and interaction models. topas 
Table 1. Dimensions and materials of the plane-parallel chambers as investigated in this study. ρg denotes the physical density of the 
graphite used in each chamber.
Ionization chamber
Thickness of  
entrance window
Electrode 
spacing (mm)
Radius of sensi-
tive volume (mm)
Thickness of  
collecting electrode
IBA
NACP-02 0.1 mm PET 2 5 50 µm graphite
0.5 mm graphite
(
ρg = 1.82 g cm−3
)(
ρg = 1.82 g cm−3
)
0.25 mm PMMA
PPC-05 0.95 mm C552 0.6 5 50 µm graphite
50 µm graphite
(
ρg = 1.82 g cm−3
)(
ρg = 1.82 g cm−3
)
0.45 mm PPE
PPC-40 0.9 mm PMMA 2 8 0.1 mm graphite
0.1 mm graphite
(
ρg = 0.93 g cm−3
)(
ρg = 0.93 g cm−3
)
1 mm PMMA
PTW
Advanced 0.87 mm PMMA 1 2.5 20 µm graphite
Markus 0.3 mm PE
(
ρg = 0.82 g cm−3
)
Markus 0.87 mm PMMA 2 2.65 20 µm graphite
0.4 mm Air
(
ρg = 1.72 g cm−3
)
30 µm PE
Roos 1.1 mm PMMA 2 7.5 20 µm graphite
20 µm graphite
(
ρg = 0.82 g cm−3
)(
ρg = 0.82 g cm−3
)
Figure 1. Cross sections of the chamber geometries for the cylindrical ionization chambers investigated in this study. The legend on 
the right connects the used colours to the corresponding materials. The chambers are not printed true to scale.
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has been tested extensively against experimental data (Perl et al 2012, Testa et al 2013). topas is capable of 
transporting various kinds of particles including photons, electrons, positrons, neutrons, protons, and heavy 
ions. In geant4, electro-magnetic (EM) interactions of the charged particles are grouped in the condensed 
history (CH) approach. A multiple scattering (MSC) algorithm is used to calculate the angular deflection of all 
soft collisions at the end of a given step. O’Brien et al (2016) and Wulff et al (2018) showed that topas passes the 
Fano test within 0.1% for photons and 0.1%–0.2% for protons (depending on the beam geometry) as long as the 
appropriate physics lists are used and as long as these physics lists are tuned to calculate the radiation transport 
accurately enough. In another study by Simiele and DeWerd (2018) different transport parameters, multiple 
scattering algorithms and versions of geant4 were investigated with the conclusion that depending on the 
multiple scattering algorithm used, the step size has to be limited in order to pass the Fano test within less than 
0.5%. Based on the findings by O’Brien et al (2016) and Wulff et al (2018), Baumann et al (2019) showed that 
TOPAS/GEANT4 can be used to calculate fQ/fQ0 ratios (which are the basis of Monte Carlo calculated kQ factors, 
compare equation (1)) in clinical proton beams for simple air-filled cavities placed in a water phantom. Hence, in 
this study we used the same physics lists and settings as used by Baumann et al (2019). For the photon simulations 
we used the physics list g4em-standard_opt3 that makes use of the G4UrbanMscModel (Urban 2002) to describe 
the multiple scattering of all charged particles. For the proton simulations we used the physics list g4em-
standard_opt4 which makes use of the models WentzelVI (Ivanchenko et al 2010) and Goudsmit–Saunderson 
(Goudsmit and Saunderson 1940a, 1940b) for the multiple scattering of charged particles: for electrons and 
positrons with energies below 100 MeV, the Goudsmit–Saunderson model is used. For electrons and positrons 
with an energy above 100 MeV and for protons with energies below 500 MeV, the WentzelVI model is used. 
The multiple scattering models used in this study are summarized in table 3. Please note that the Goudsmit–
Saunderson model is not implemented by default in the version geant4-10-03-patch-01 which is used in this 
study but has been implemented by us.
We used the physics list g4h-phy_QGSP_BIC_HP to manage the simulation of non-elastic nuclear interac-
tions. The Binary Cascade model (Folger et al 2004) is used in this list for inelastic nucleon-nucleus processes. 
Furthermore, we used the default physics lists g4ion-binarycascade, g4decay, g4h-elastic_HP and g4stopping.
To control the length of a step in the CH, the parameter dRoverR is used in geant4. This parameter describes 
the maximum length of a step in relation to the residual range of the particle. For the photon simulations we set 
dRoverR to 0.003, for the proton simulation to 0.05. While losing energy, the maximum length of a step in the CH 
decreases until it gets smaller than the finalRange, below which the particle is ranged out in a single step. For the 
photon simulations we set finalRange to 1 nm, for the proton simulations to 100 nm. The parameter controlling 
the production of secondaries is given in units of length in geant4. Secondary particles with a continuous slow-
ing down approximation range (RCSDA) lower than this production cut are absorbed on the spot. The default pro-
duction cut in the whole geometry was set to 500 µm, corresponding to  ∼200 keV electrons in water. Within the 
ionization chamber and a surrounding envelope, the production cut was set to 1 µm (corresponding to  <10 keV 
electrons in water). Note that in the study by Baumann et al (2019) a production cut of 0.065 µm was used 
(which corresponds to  ∼1 keV electrons in water). In order to save computing time, we increased this value. We 
checked that this larger production cut has no significant influence on the calculation of fQ0 and f Q factors. This 
Table 2. Mass densities ρ  and mean excitation energies I of the different materials as used in this study in alphabetical order.
Material ρ  (g cm−3) I (eV)
Air 0.0012 85.7
Aluminum 2.70 166.0
Aluminum alloy 2.70 166.4
C552 (shonka) 1.76 86.8
Graphite 0.82–1.82 81.0
Polycarbonate 1.20 73.1
Polyether ether ketone (PEEK) 1.31 74.1
Polyether methacrylate (PMMA) 1.19 74.0
Polyethylene (PE) 0.93 56.5
Polyethylene terephthalate (PET) 1.50 78.7
Polyoxymethylene (POM) 1.43 77.4
Polyphenyl ether (PPE) 1.06 64.0
Polystyrene 1.05 68.7
Polytetrafluoroethylene (PTFE/Teflon) 2.25 99.1
Silicone 1.10 88.0
Steel 8.06 317.7
Water 0.9982 78.0
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has also been investigated for f Q factors in proton beams by Wulff et al (2018) with the same result. To ensure that 
the secondary particle fluence in the ionization chamber is not affected by the higher production cut in the water 
phantom, we used an envelope surrounding the ionization chamber with a thickness equal to the production cut 
applied in the water phantom (500 µm) multiplied by a safety factor of 1.2. The safety factor of 1.2 is applied to 
account for the possibility that an electron may travel a distance larger than RCSDA due to energy-loss straggling 
(Sempau and Andreo 2006). Since the lowest energy geant4 can handle is 990 eV by default, the production 
cut is automatically adapted in materials where the production cut of 1 µm corresponds to an energy  <990 eV. 
For example, the production cut in air is set to 47.2 µm, which is the maximum range of 990 eV electrons in air. 
All production cuts and transport simulation parameters are summarized in table 4.
No variance reduction techniques were used. The statistical uncertainties were estimated by combining the 
uncertainties from independent runs performed with different random seeds as described in Bielajew (2016).
3. Results and discussion
3.1. fQ0 factors for the 
60Co spectrum
In table 5 the Monte Carlo calculated fQ0 factors for the 
60Co spectrum for all ionization chambers investigated 
in this study are shown. The values within parenthesis correspond to one standard uncertainty in the last digit. 
Furthermore, combined data for fQ0 = (sw,air)Q0 · pQ0 as provided by the upcoming revision of the TRS-398 CoP 
(Andreo et al 2019) is shown. The given values are the average of 16 different fQ0 factors all calculated with Monte 
Carlo codes (egsnrc , penh, penelope, and topas/geant4, while the topas/geant4 results 
are those from this study). Chambers were modeled using blue prints or geometries published in former studies.
For all chambers the fQ0 factors calculated in this study agree within one standard uncertainty with the values 
provided by Andreo et al (2019).
In figures 2 and 3 in the upper panels the fQ0 factors for the plane-parallel and cylindrical ionization cham-
bers are shown along with various values published in the literature. In the bottom panel the relative deviations 
between the values from this study and the values from the literature are shown. The values published in the lit-
erature were derived using different Monte Carlo codes and partly different sets of I-values. An overview of these 
characteristics is given in table 6.
For each chamber the deviation between the fQ0 factor calculated in this study using topas/geant4 
and the factors published in the literature is smaller than 0.7% (independently on the choice of I-values). For 
almost each chamber the fQ0 factor calculated in this study agrees with each published value within two standard 
deviations or better. The only exceptions are for the PTW Roos chamber and the results from Zink and Wulff 
(2012) as well as the IBA PPC-40 chamber and the results from Gomà et al (2016). Taking into account the vari-
ance between the fQ0 factors published in the literature using different Monte Carlo codes and sets of I-values, 
topas/geant4 can be used equivalently for the calculation of fQ0 factors for both plane-parallel and cylin-
drical ionization chambers in 60Co beams as long as the physics settings are adapted accordingly. Note that the 
variance between fQ0 factors published in the literature is larger for plane-parallel ionization chambers compared 
to cylindrical chambers.
Table 3. Multiple scattering models used in topas/geant4 for the photon and proton simulations.
Radiation field Multiple scattering model for e+ /e− Multiple scattering model for primaries
60Co spectrum Urban model /
Monoenergetic protons Goudsmit–Saunderson (E  100 MeV)  
Wentzel VI (E  >  100 MeV)
Wentzel VI (E  500 MeV)
Table 4. Production cuts and transport simulation parameters used in topas/geant4 for the photon and proton simulations.
Region Production cut (µm)
dRoverR finalRange (nm)
Photon-sim. | Proton-sim. Photon-sim. | Proton-sim.
Scoring volume and envelope 1 0.003 0.05 1 100
Water phantom 500 0.003 0.05 1 100
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3.2. f Q factors for monoenergetic proton beams
In table 7 the f Q factors for all ionization chambers investigated in this study are shown as a function of the initial 
energy of the monoenergetic proton beams. The depth zref  at which the chambers were positioned is depicted as 
well. The values within parenthesis correspond to one standard uncertainty in the last digit(s).
Furthermore, the water to air stopping power ratios sw,air as calculated by Gomà and Sterpin (2019) are given 
for the different beam qualities in order to estimate perturbation correction factors as done in section 3.3.
Figures 4 and 5 show the f Q factors from this study along with f Q factors published in the literature. Some of 
the values published in the literature were derived using different Monte Carlo codes. An overview of the corre-
sponding characteristics is given in table 8.
For the IBA NACP-02 the f Q factors agree within one standard deviation for energies up to 150 MeV. For 
higher energies the differences are up to 1.2% between this study and Gomà and Sterpin (2019), 0.9% between 
Table 5. Monte Carlo calculated fQ0 factors for 
60Co radiation for different plane-parallel and cylindrical ionization chambers. The values 
within parenthesis correspond to one standard uncertainty in the last digit.
Chamber fQ0 this study fQ0 Andreo et al (2019)
PTW Roos 1.143(3) 1.142(5)
PTW Markus 1.149(4) 1.143(5)
PTW Adv. Markus 1.142(4) 1.143(5)
IBA NACP-02 1.158(3) 1.154(5)
IBA PPC-05 1.144(4) 1.141(5)
IBA PPC-40 1.148(2) 1.142(5)
NE 2571 1.110(3) 1.108(4)
PTW 30013 1.112(3) 1.109(4)
IBA FC65-G 1.111(3) 1.108(4)
Exradin A1SL 1.102(5) 1.103(4)
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Figure 2. In the upper graph Monte Carlo calculated fQ0 factors for 
60Co radiation for different plane-parallel chambers and 
comparison with values from the literature are shown (see table 6 for further explanation). In the bottom graph the relative 
deviations between the values from this study and the values from the literature are shown. For better clarity, the 0% deviation 
is marked with a solid line and the ±1% deviations are marked with dashed lines. The error bars correspond to one standard 
uncertainty.
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this study and Gomà et al (2016) and 0.5% between this study and Wulff et al (2018). The reason for the difference 
in f Q factors between this study and Wulff et al (2018) is that in this study the geometry of the IBA NACP-02 is 
slightly different and a smaller value for dRoverR and finalRange has been taken.
For the PTW Roos chamber the differences between the f Q factors calculated in this study and the values from 
Gomà and Sterpin (2019) are significant for both low and high energies. The maximum deviation is  −1% for an 
energy of 250 MeV while the deviation for low energies is about 0.4%. Differences between the f Q factors calcu-
lated in this study and the values from Lourenço et al (2019) are  ∼0.1% for the energies 60 MeV and 250 MeV 
while the deviation for an energy of 150 MeV is 0.4%.
For all plane-parallel chambers it can be seen that the f Q factors agree within two standard uncertainties or 
better between this study and the studies by Gomà and Sterpin (2019) and Gomà et al (2016) for low energies 
and begin to diverge for higher energies. Only for the PTW Roos chamber as already mentioned and the PTW 
Adv. Markus chamber significant differences in the f Q factors between the studies can be seen for low energies. 
Note that Gomà et al (2016) used a different geometry for the IBA PPC-05 chamber, hence the deviations of the 
f Q factors relative to this study are quite large. The largest deviation of f Q factors between this study and the values 
published in the literature is 1.7% and can be seen for the PTW Markus chamber at an energy of 250 MeV.
For the f Q factors for cylindrical ionization chambers as shown in figure 5 the factors calculated in this 
study agree within  <0.1% with those calculated by Wulff et al (2018) for 150 MeV and 200 MeV. For 250 MeV a 
deviation of  ∼0.5% is visible. In contrast to the calculation of the IBA NACP-02 chamber, the geometry of the 
NE 2571 chamber used in this study is exactly the same as used by Wulff et al (2018). The only remaining differ-
ence between these two studies is that in this study a smaller value for dRoverR and finalRange has been taken.
For all cylindrical chambers the f Q factors calculated in this study agree within one standard uncertainty with 
the factors calculated by Gomà et al (2016). Again, the values calculated by Gomà and Sterpin (2019) agree with 
the factors from this study only for low energies (e.g. 150 MeV) within one standard uncertainty. For higher ener-
gies the values do not agree within two standard uncertainties. The largest deviation of 1.3% can be seen for the 
NE 2571 chamber at an energy of 250 MeV.
In general, the agreement between the values from this study and the values from Gomà et al (2016) is better 
than the agreement between this study and the values from Gomà and Sterpin (2019). The difference between 
these two studies (Gomà and Sterpin (2019) and Gomà et al (2016)) is that in the study from 2019 proton nuclear 
Figure 3. In the upper graph Monte Carlo calculated fQ0 factors for 
60Co radiation for different cylindrical chambers and 
comparison with values from the literature are shown (see table 6 for further explanation). In the bottom graph the relative 
deviations between the values from this study and the values from the literature are shown. For better clarity, the 0% deviation 
is marked with a solid line and the ±1% deviations are marked with dashed lines. The error bars correspond to one standard 
uncertainty.
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Table 6. Description of the values for fQ0 from the literature in chronological order.
Study Monte Carlo code Iw  (eV) Ig (eV) Comments
Gomà and Sterpin (2019) penh 78 81.1 —
Czarnecki et al (2018) egsnrc 78 81.1 Values provided in private communication
Mainegra-Hing and Muir (2018) egsnrc 78 81.1 Values provided in Gomà and Sterpin (2019)
Gomà et al (2016) penh 78 81.1 —
Erazo et al (2014) penelope-2011 75 78 Values provided in Gomà et al (2016)
Andreo et al (2013) egsnrc 78 81.1 —
Zink and Wulff (2012) egsnrc 75 78 Calculated perturbation correction factors pQ0: fQ0 = pQ0 · sw,air (sw,air = 1.133)
Muir et al (2012) egsnrc 75 78 Values provided in Gomà et al (2016)
Muir and Rogers (2010) egsnrc 75 78 Values provided in private communication
Panettieri et al (2008) penelope-2006 75 78 Used three different 60Co sources: we used the weighted mean of the corresponding fQ0 factors
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Table 8. Description of the values for f Q from the literature in chronological order.
Study Monte Carlo code Iw  (eV) Ig (eV) Comments
Gomà and 
Sterpin 
(2019)
penh 78 81.1 Chamber positioned at same depths as in this study
Lourenço 
et al (2019)
fluka 78 81.1 Calculated perturbation correction factors and stopping power ratios 
Values provided in private communication  
Used a slightly different (∼180 µm) depth  
No transport of electrons
Wulff et al 
(2018)
topas/geant4 78 81.1 We used the values derived using the BIC model  
Values for 70 MeV not considered since a different depth has been used
Gomà et al 
(2016)
penh 78 81.1 Values for 70 MeV not considered since a different depth has been used
interactions have been activated in penh. In the study from 2016 no proton nuclear interactions have been 
included in penh. However, the simulations were combined with simulations performed with gamos (Arce 
et al 2014) a toolkit based on geant4 where nuclear interactions were included, which might explain the bet-
ter agreement between this study and the study by Gomà et al (2016). Furthermore, Gomà and Sterpin (2019) 
discussed that the differences in f Q factors for higher energies might be due to differences in the nuclear inter-
action models. To investigate this statement, we recalculated the f Q values for the IBA NACP-02 and NE 2571 
for an energy of 250 MeV without the use of nuclear interaction models (n.i.m.) by deactivating the physics 
list g4h-phy_QGSP_BIC_HP. The results are shown in figure 6: penh with n.i.m. corresponds to the values 
from Gomà and Sterpin (2019) while penh with n.i.m. from geant4 corresponds to the values from Gomà 
et al (2016). The f Q factors calculated with topas/geant4 increase by roughly 1.5% when deactivating the 
nuclear interaction model. For penh it is the other way round: the f Q factors are larger when nuclear interac-
tion models are activated. Interestingly, the values calculated with topas/geant4 without the activation of 
nuclear interaction models agree with those calculated with penh when these models are activated. However, it 
is not possible to identify the role of nuclear interaction models for the calculation of f Q factors in proton beams 
from these results. This remains an issue to be solved in further investigations.
3.3. Perturbation correction factors for monoenergetic proton beams
From the f Q factors and water to air stopping power ratios sw,air as shown in table 7 the total perturbation 
correction factors p Q can be derived as pQ = fQ/(sw,air)Q. It can be seen that for some chambers and energies 
the perturbation correction factors are significantly different than unity in contrast to the assumption from the 
IAEA TRS-398 CoP (Andreo et al 2000). To investigate which part of the chamber might lead to this difference 
we calculated the perturbation correction factors for the Exradin A1SL chamber at 250 MeV. The results are 
shown in table 9. The perturbation factor with the largest influence is pwall  which accounts for the influence of 
the chamber wall. The total perturbation correction factor p Q is 0.969(7). Hence, it can be concluded that the 
assumption of the IAEA TRS-398 CoP (that all perturbation correction factors in proton beams are 1 for all 
Table 7. Monte Carlo calculated f Q factors for monoenergetic proton beams as a function of initial proton energy and the depth zref  at 
which the chambers were positioned. The values within parenthesis correspond to one standard uncertainty in the last digit(s).
Q 60 MeV 70 MeV 80 MeV 100 MeV 150 MeV 160 MeV 200 MeV 250 MeV
zref  (g cm
−2) 1 1 2 2 2 2 2 2
sw,air 1.130 1.130 1.130 1.130 1.129 1.129 1.129 1.129
PTW Roos 1.1219(5) 1.1237(6) 1.1235(6) 1.1239(7) 1.1242(8) 1.1247(9) 1.1220(11) 1.1177(12)
PTW Markus 1.1344(15) 1.1341(15) 1.1318(14) 1.1353(17) 1.1318(23) 1.1321(21) 1.1291(27) 1.1226(34)
PTW Adv. Markus 1.1365(12) 1.1345(15) 1.1348(15) 1.1343(16) 1.1329(22) 1.1331(23) 1.1315(25) 1.1252(28)
IBA NACP-02 1.1177(7) 1.1198(8) 1.1196(7) 1.1209(10) 1.1213(12) 1.1201(12) 1.1211(14) 1.1141(15)
IBA PPC-05 1.1139(8) 1.1157(10) 1.1162(9) 1.1181(12) 1.1200(14) 1.1169(19) 1.1156(28) 1.1122(20)
IBA PPC-40 1.1210(5) 1.1229(5) 1.1215(5) 1.1225(6) 1.1206(8) 1.1212(9) 1.1196(10) 1.1157(11)
NE 2571 1.1232(9) 1.1225(9) 1.1185(11) 1.1115(12)
PTW 30013 1.1257(9) 1.1244(9) 1.1211(11) 1.1168(11)
IBA FC65-G 1.1237(10) 1.1223(10) 1.1192(11) 1.1137(12)
Exradin A1SL 1.1073(23) 1.1036(26) 1.1035(30) 1.0938(34)
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ionization chambers) might not be sufficiently accurate for all chambers and proton energies—especially in the 
case for the factor pwall .
3.4. kQ factors for monoenergetic proton beams
In table 10 the kQ factors for all ionization chambers investigated in this study are shown as a function of the initial 
energy of the monoenergetic proton beams. The depth zref  at which the chambers were positioned is depicted as 
well. The values within parenthesis correspond to one standard uncertainty in the last digit(s).
To compare the results from this study with Monte Carlo calculated values published in the literature, we 
decided not to compare the kQ factors itself but the fQ/fQ0 ratios which are the basis of Monte Carlo calculated 
kQ factors. In figures 7 and 8 fQ/fQ0 ratios from this study along with fQ/fQ0 ratios published in the literature are 
shown. Note that both Gomà and Sterpin (2019) and Gomà et al (2016) used the same Wair,Q  values as in this 
study.
For the plane-parallel chambers the fQ/fQ0 ratios between this study and Gomà and Sterpin (2019) agree 
within two standard uncertainties or better for low energies, except for the IBA PPC-05. For high energies the 
difference in fQ/fQ0 ratios increases up to 2.2%. The agreement between this study and Gomà et al (2016) is better 
compared to the agreement with Gomà and Sterpin (2019) except for the IBA PPC-05. However, the chamber 
model used by Gomà et al (2016) is different from that used in this study as discussed by Gomà and Sterpin 
(2019).
The same can be seen for the cylindrical chambers: while the maximum difference between this study and 
Gomà and Sterpin (2019) is 1.8% for the NE 2571, the maximum difference between this study and Gomà et al 
(2016) is 0.8%.
Figure 4. Monte Carlo calculated f Q factors for monoenergetic proton beams as a function of initial proton energy for different 
plane-parallel chambers and comparison with values from the literature. The error bars correspond to one standard uncertainty.
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In general, the agreement for low energies is better than for higher energies. The differences for high energies 
might be due to differences in the nuclear interaction models used in the different Monte Carlo codes as discussed 
above and by Gomà et al (2016) and in parts by Baumann et al (2019). Of course, the differences in fQ/fQ0 ratios 
might also be due to slight differences in the geometry of the chamber models and the materials used between 
this study and Gomà and Sterpin (2019) and Gomà et al (2016). Note that Gomà and Sterpin (2019) provided 
the physical densities and mean excitation energies of the materials used in their study which are approximately 
the same values as used in this study, except for small differences in some plastics. Gomà et al (2016) did not 
provide these values. Furthermore, in a study by Baumann et al (2019) fQ/fQ0 ratios were calculated for simple 
Table 9. Perturbation correction factors for the Exradin A1SL chamber at a proton energy of 250 MeV. The values within parenthesis 
correspond to one standard uncertainty in the last digit.
Perturbation correction factor Value
pcel 0.996(4)
pstem 0.995(4)
pwall 0.970(3)
pdis · pcav 1.007(3)
p Q 0.969(7)
Figure 5. Monte Carlo calculated f Q factors for monoenergetic proton beams as a function of initial proton energy for different 
cylindrical chambers and comparison with values from the literature. The error bars correspond to one standard uncertainty.
Figure 6. Monte Carlo calculated f Q factors for the IBA NACP-02 and NE 2571 at an energy of 250 MeV with and without the 
use of nuclear interactions models (n.i.m.) calculated with topas/geant4 and the f Q factors calculated with penh taken 
from Gomà and Sterpin (2019) and Gomà et al (2016). The uncertainties represented by error bars correspond to one standard 
uncertainty.
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air-filled cavities as representatives of plane-parallel and cylindrical ionization chambers with different Monte 
Carlo codes (penh, fluka and topas/geant4). A monoenergetic 150 MeV proton beam has been used 
and the cavities were positioned at a depth of 2 g cm−2. The maximum deviation of the fQ/fQ0 ratios between the 
codes was 0.7%. The maximum difference of fQ/fQ0 ratios found in this study for an energy of 150 MeV for the 
plane-parallel chambers is 1.4%. For the cylindrical chambers and an energy of 150 MeV it is 0.8%. Hence, the 
Figure 7. Monte Carlo calculated fQ/fQ0 ratios for monoenergetic proton beams as a function of initial proton energy for different 
plane-parallel chambers and comparison with values from the literature. The error bars correspond to one standard uncertainty.
Table 10. Monte Carlo calculated kQ factors for monoenergetic proton beams as a function of initial proton energy and the depth zref  at 
which the chambers were positioned. The values within parenthesis correspond to one standard uncertainty in the last digit.
Q 60 MeV 70 MeV 80 MeV 100 MeV 150 MeV 160 MeV 200 MeV 250 MeV
zref  (g cm
−2) 1 1 2 2 2 2 2 2
PTW Roos 0.995(6) 0.997(6) 0.996(6) 0.997(6) 0.997(6) 0.997(6) 0.995(6) 0.991(6)
PTW Markus 1.001(7) 1.000(7) 0.998(7) 1.001(7) 0.998(7) 0.999(7) 0.996(7) 0.990(7)
PTW Adv. Markus 1.009(7) 1.007(7) 1.007(7) 1.007(7) 1.006(7) 1.006(7) 1.004(7) 0.999(7)
IBA NACP-02 0.979(6) 0.980(6) 0.980(6) 0.981(6) 0.982(6) 0.981(6) 0.981(6) 0.975(6)
IBA PPC-05 0.987(6) 0.989(6) 0.989(6) 0.991(6) 0.992(6) 0.990(6) 0.989(6) 0.986(6)
IBA PPC-40 0.990(6) 0.992(6) 0.991(6) 0.991(6) 0.990(6) 0.990(6) 0.989(6) 0.986(6)
NE 2571 1.026(6) 1.025(6) 1.022(6) 1.015(6)
PTW 30013 1.027(6) 1.025(6) 1.022(6) 1.018(6)
IBA FC65-G 1.026(6) 1.024(6) 1.022(6) 1.017(6)
Exradin A1SL 1.019(7) 1.015(7) 1.015(7) 1.006(8)
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deviations of fQ/fQ0 ratios for real ionization chambers are in the order of the deviations for simple air-filled cavi-
ties, although the geometries are more complex.
To validate whether the nuclear interaction models lead to larger deviations between the Monte Carlo codes inde-
pendent on the chamber geometry, we re-calculated the simulations for simple air-filled cavities as done by Baumann 
et al (2019) for an energy of 250 MeV. We used exactly the same geometries, physics lists and source parameters. The 
largest difference between topas/geant4 and penh for an energy of 250 MeV was 0.6% and hence compa-
rable to the differences observed for an energy of 150 MeV. Interestingly, the difference between the codes does not 
increase with energy for simple air-filled cavities as it is the case for the ionization chambers. Hence, it might be that 
differences between the codes occur because of the materials and/or complexity of the chamber geometries.
In order to further validate the kQ factors calculated with topas/geant4 in this study, in table 11 the 
ratios of kQ factors are shown for some of the ionization chambers and compared to experimental data. Palmans 
et al (2001) and Palmans et al (2002) determined experimentally the ratios of kQ factors between different cham-
bers and the NE 2571 as a reference chamber. A non-modulated proton beam with Rres = 2.65 cm has been used. 
Hence, we re-calculated the corresponding chambers (NE 2571, IBA FC65-G, IBA NACP-02, PTW Markus and 
PTW Adv. Markus) in a 70 MeV monoenergetic proton beam (Rres = 4.10 cm) at a depth of 2 g cm−2. In the stud-
ies by Palmans et al (2001) and Palmans et al (2002) the ratios of kQ factors were not reported explicitly but can 
be found in Gomà et al (2016). For all four ratios of kQ factors the deviation between the ratios calculated in this 
study and the experimentally determined values are 1% at maximum.
In table 12 ratios of kQ factors are shown for several ionization chambers that were determined by Gomà et al 
(2015). For the comparison we took the values determined in a non-modulated proton beam with Rres ≈ 6 cm. 
This corresponds to an initial proton energy of 100 MeV and a chamber depth of 2 g cm−2. Hence, we calculated 
the kQ factors for the IBA FC65-G and PTW 30013 in a 100 MeV proton beam at that depth. For the IBA NACP-02, 
Figure 8. Monte Carlo calculated fQ/fQ0 ratios for monoenergetic proton beams as a function of initial proton energy for different 
cylindrical chambers and comparison with values from the literature. The error bars correspond to one standard uncertainty.
Table 11. Ratios of kQ factors in a 70 MeV monoenergetic proton beam, at a reference depth of 2 g cm−2, for different ionization chambers 
studied in this study and comparison with experimental values in the literature for non-modulated beams. The values within parenthesis 
correspond to one standard uncertainty in the last digit. In the right column the relative deviations between the values from this study and 
the values from the literature are given.
Ionization chambers This study Palmans et al (2001) Palmans et al (2002) Deviation (%)
IBA FC65-G/NE 2571 1.000(4) 0.997(3) 0.3
IBA NACP-02/NE 2571 0.920(3) 0.930(3) −1.0
PTW Markus/NE 2571 0.942(4) 0.940(3) 0.2
PTW Roos/NE 2571 0.935(2) 0.937(3) −0.2
Rres (g cm−2) 2.10 2.65 2.65
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PTW Roos and PTW 30013 the deviations of the ratios of kQ factors calculated in this study are smaller than 0.5% 
compared to the experimentally determined ratios. For the PTW Markus chamber the deviation is 1.4% and for 
the PTW Adv. Markus it is 2.4%. Note that the deviation for the ratio of kQ factors including the PTW Markus 
chamber is only 0.2% compared to the experimentally determined ratio of kQ factors from Palmans et al (2002) 
(see table 11).
At last, Medin (2010) experimentally determined the kQ factor for the NE 2571 in a proton beam with 
Rres = 16.5 cm. Correspondingly, we took the kQ factor calculated for an initial energy of 160 MeV at a depth of 
2 g cm−2 (Rres = 15.74 g cm−2). Medin et al (2006) experimentally determined the kQ factors for the NE 2571 and 
the IBA FC65-G and a proton beam with Rres = 14.7 cm. Correspondingly, we took the kQ factors calculated for 
an initial energy of 150 MeV at a depth of 2 g cm−2 (Rres = 13.85 g cm−2). The kQ factors calculated in this study as 
well as the experimentally determined values by Medin (2010) and Medin et al (2006) are shown in table 13. The 
maximum deviation between the kQ factors calculated in this study relative to the kQ factors determined exper-
imentally is 0.7%.
In conclusion, the comparison of kQ factors and ratios of kQ factors calculated in this study using the Monte 
Carlo code topas/geant4 with experimental values shows good agreement on the 1% level with only two 
exceptions for the PTW Adv. Markus chamber (2.4%) and the PTW Markus chamber (1.4%). However, for the 
PTW Markus chamber we also found good agreement (deviation of only 0.2%) when the ratio of kQ factors was 
compared to the experimentally determined values from Palmans et al (2002).
3.5. Possible influence of the death volume for ionization chambers
In figure 9 the dose deposited in the Exradin A1SL chamber irradiated with a 250 MeV monoenergetic proton beam 
is shown. The cavity was divided into the tip and 10 slabs each 0.4445 mm thick. Slab 1 is next to the tip, slab 10 next 
to the chamber stem. In red the dose deposited in the tip and each of the slabs. In green the cumulated dose: the 
cumulated dose for slab i averages the doses deposited in the tip and in the slabs 1 to i. It can be seen that the dose 
deposited in the different slabs varies by up to 0.25% at maximum while the dose increases towards the chamber 
stem. The larger dose deposited in the slabs in the vicinity of the chamber stem might be due to secondary particles 
(e.g. electrons) produced in the stem that are being scattered into the cavity. However, due to the short range of these 
secondary particles, the influence on the dose in the complete cavity is small which is in agreement with the finding 
that the perturbation correction factor for the chamber stem is 0.995(3) and hence roughly 1. The cumulated dose 
is quasi-constant over the complete cavity while the maximum deviation between any two cumulated dose values 
is 0.04%, which is not significant (one standard deviation is  ∼0.05% for each cumulated dose value). Following the 
study by Pojtinger et al (2019), the death volume is located in the vicinity of the guard ring and hence the chamber 
stem. Since the cumulated dose is quasi-constant over the complete cavity, it does not matter how large the sensitive 
volume is: for example, if the sensitive volume is restricted to the tip, the dose measured with the chamber would 
not be significantly different from the dose measured if the sensitive volume was consisting of the tip and any 
number of slabs. Hence, the influence of the death volume on the dose deposited in the cavity is negligible for this 
investigated chamber and does not influence the calculation of kQ factors significantly. Since the other cylindrical 
Table 12. Ratios of kQ factors in a 100 MeV monoenergetic proton beam, at a reference depth of 2 g cm−2, for different ionization chambers 
studied in this study and comparison with experimental values in the literature for non-modulated beams. The values within parenthesis 
correspond to one standard uncertainty in the last digit. In the right column the relative deviations between the values from this study and 
the values from the literature are given.
Ionization chambers This study Gomà et al (2015) Deviation (%)
IBA NACP-02/FC65-G 0.947(4) 0.943(4) 0.4
PTW Adv. Markus/FC65-G 0.972(5) 0.949(4) 2.4
PTW Markus/FC65-G 0.967(5) 0.953(4) 1.4
PTW Roos/FC65-G 0.962(4) 0.960(4) 0.2
PTW 30013/FC65-G 0.999(4) 1.002(4) −0.3
Rres (g cm−2) 5.76 5.93
Table 13. Monte Carlo calculated kQ factors in monoenergetic proton beams for different ionization chambers studied in this study 
and comparison with experimental values in the literature for non-modulated beams. The values within parenthesis correspond to one 
standard uncertainty in the last digit(s). In the right column the relative deviations between the values from this study and the values from 
the literature are given.
Ionization chamber Energy (MeV) This study Medin et al (2006) Medin (2010) Deviation (%)
IBA FC65-G 150 1.026(6) 1.021(7) 0.5
NE 2571 150 1.026(6) 1.021(7) 0.5
NE 2571 160 1.025(6) 1.032(13) −0.7
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ionization chambers investigated in this study have a larger cavity compared to the Exradin A1SL, the results from 
this investigation should be applicable to the other cylindrical chambers, as well.
4. Conclusion
The Monte Carlo code topas/geant4 was used to calculate fQ0 factors in a 60Co spectrum and f Q factors in 
monoenergetic proton beams for six plane-parallel and four cylindrical ionization chambers. From these factors 
kQ factors were derived. The comparison of kQ factors calculated in this study with experimentally determined 
kQ factors and ratios of kQ factors showed good agreement on the 1% level. Hence, topas/geant4 can be 
used to calculate kQ factors for ionization chambers in monoenergetic proton beams. The comparison with other 
Monte Carlo calculated fQ/fQ0 ratios showed that the role of nuclear interaction models has to be investigated 
further for high proton energies.
Additionally, perturbation correction factors for the Exradin A1SL chamber in a 250 MeV monoenergetic 
proton beam were calculated. It can be concluded that the assumption of the IAEA TRS-398 CoP (that all pertur-
bation correction factors in proton beams are 1 for all ionization chambers) might not be sufficiently accurate for 
all chambers and proton energies—especially in the case for the factor pwall .
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